Human immunodeficiency virus neutralizing antibodies

ABSTRACT

The present invention provides novel anti-HIV antibodies with improved therapeutic properties, related pharmaceutical compositions, and methods of use thereof.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. application Ser. No.15/379,157, filed on Dec. 14, 2016, issued as U.S. Pat. No. 10,239,935on Mar. 26, 2019, which claims the benefit of U.S. ProvisionalApplication Ser. No. 62/267,652, filed Dec. 15, 2015, which are herebyincorporated by reference in their entireties.

STATEMENT REGARDING SEQUENCE LISTING

The Sequence Listing associated with this application is provided intext format in lieu of a paper copy, and is hereby incorporated byreference into the specification. The name of the text file containingthe Sequence Listing is GILE_112_01WO_ST25.txt. The text file created onDec. 13, 2016 is about 640 KB and submitted electronically via EFS-Web.

FIELD OF THE INVENTION

This invention relates to antibodies and antigen-binding fragmentsthereof for the treatment and prevention of human immunodeficiency virus(HIV) infection. In particular, the present invention provides novelanti-HIV antibodies and antigen-binding fragments thereof, includingbroadly neutralizing anti-HIV antibodies and antigen-binding fragmentsthereof, pharmaceutical compositions containing such antibodies andfragments thereof, and methods for using these antibodies and fragmentsthereof to reduce HIV replication and in the treatment and prevention ofHIV infection.

BACKGROUND OF THE INVENTION

Human immunodeficiency virus (HIV) infection and related diseases are amajor public health problem worldwide. Most currently approved therapiesfor HIV infection target the viral reverse transcriptase, proteaseenzymes, and integrase but resistance of HIV to these existing drugs,long term toxicity, and lack of patient adherence to daily dosingregimens have proven to be problems associated with these therapies.Therefore, it is important to discover and develop new HIV drugs.

WO2012/030904 describes human anti-HIV antibodies derived from memory Bcells of HIV-infected donors, which are capable of inhibiting infectionby HIV-1 species from a plurality of clades. However, the therapeuticuse of these antibodies is limited due to issues with immunogenicity,pharmacokinetics, antigen specificity, effector function, andmanufacturing. Accordingly, there is a need in the art for novelanti-HIV antibodies with advantageous properties for therapeutic uses.

BRIEF SUMMARY OF THE INVENTION

The present invention provides, inter alia, compositions and methods fortreating or preventing HIV.

In one embodiment, the present invention includes an isolated monoclonalantibody, or an antigen-binding fragment thereof, comprising one or moreof the heavy chain complementary determining regions (CDRs) and one ormore of the light chain CDRs of the PGT121 LO6 antibody (using Kabat,IMGT, Chothia, or Honegger numbering). In some embodiments, thedisclosure provides for an antibody, or an antigen-binding fragmentthereof, comprising the heavy chain complementary determining regions1-3 (CDRs 1-3) set forth in SEQ ID NOs: 362, 364 and 367 and the lightchain CDRs 1-3 set forth in SEQ ID NOs: 395, 396 and 397, wherein theantibody or antigen-binding fragment thereof comprises zero to eight (orzero to four) amino acid substitutions within the CDRs, and wherein theantibody or antigen-binding fragment thereof comprises one or more ofthe following: a IgG1m17 allotype heavy chain; a Lambda2 light chain; aheavy chain constant region comprising one or more of the followingamino acid substitutions: Ala at position 236, Asp at position 239, Leuat position 330, Glu at position 332, Leu at position 428, and Ser atposition 434 (using EU numbering); and a heavy chain variable regioncomprising one or more of: Ser-Ser-Val or Thr-Gly-Val at positions82a-82c, Gln at position 39, Asn at position 60, His at position 68, anyone of Lys, His or Thr at position 105, Leu at position 2, Ala atposition 32, and Ala at position 95 (using Kabat numbering). Inparticular embodiments, the antibody or antigen binding fragment thereofcomprises two or more of the heavy chain complementary determiningregions (CDRs) and two or more of the light chain CDRs of the PGT121 LO6antibody (using Kabat, IMGT, Chothia, or Honegger numbering). Inparticular embodiments, the antibody or antigen binding fragment thereofcomprises all three of the heavy chain complementary determining regions(CDRs) and all three of the light chain CDRs of the PGT121 LO6 antibody(using Kabat, IMGT, Chothia, or Honegger numbering). In particularembodiments, the monoclonal antibody or antigen-binding fragmentthereof, comprises the IgG1m17 allotype heavy chain. In particularembodiments, the heavy chain constant region comprises Lys at position214, Glu at position 356, Met at position 358, and Ala at position 431(using EU numbering). In particular embodiments, the monoclonal antibodycomprises a heavy chain constant region (Fc) of any one of the followingantibodies: PGT121.42, PGT121.43, PGT121.60, PGT121.61, PGT121.54,PGT121.55, PGT121.64, and PGT121.65. In particular embodiments of any ofthe antibodies or antigen-binding fragments thereof described herein,the heavy chain constant region (Fc) is set forth in any of SEQ ID NOs:252, 255, 266, 267, 268, 269, 272, and 273. In particular embodiments,the monoclonal antibody or antigen-binding fragment thereof comprises aLambda2 light chain. In certain embodiments, the light chain comprisesone or more of the following amino acid substitutions (using Kabatnumbering): Arg at position 67b, Pro at position 67c, and Lys atposition 103. In one embodiments, the light chain comprises one or moreof the following amino acid substitutions (using Kabat numbering schemein FIG. 1): Arg at position 67b, Pro at position 67c, and Lys atposition 103. In particular embodiments, the monoclonal antibodycomprises a light chain of any one of the following antibodies:PGT121.42, PGT121.43, PGT121.60, PGT121.61, PGT121.54, PGT121.55,PGT121.64, and PGT121.65. In particular embodiments of any of theantibodies or antigen-binding fragments thereof described herein, thelight chain is set forth in any of SEQ ID NOs: 338, 341, 352, 353, 354,355, 358, and 359. In particular embodiments, the monoclonal antibody orantigen-binding fragment thereof comprises a heavy chain constant regioncomprises one or more of the following amino acid substitutions (usingEU numbering): Ala at position 236, Asp at position 239, Leu at position330, Glu at position 332, Leu at position 428, and Ser at position 434.In particular embodiments, the heavy chain constant region comprises Alaat position 236, Asp at position 239, Leu at position 330, and Glu atposition 332. In particular embodiments, the heavy chain constant regioncomprises Leu at position 428 and Ser at position 434. In certainembodiments, the heavy chain constant region comprises Ala at position236, Asp at position 239, Leu at position 330, Glu at position 332, Leuat position 428, and Ser at position 434 (using EU numbering). Inparticular embodiments, the monoclonal antibody or antigen-bindingfragment thereof, comprises a heavy chain constant region of any one ofthe following antibodies: PGT121.42, PGT121.43, PGT121.60, PGT121.61,PGT121.54, PGT121.55, PGT121.64, and PGT121.65. In certain embodiments,the monoclonal antibody, or antigen-binding fragment thereof, comprisesa heavy chain variable region (Fab) comprising one or more of thefollowing amino acid substitutions: Ser-Ser-Val or Thr-Gly-Val atpositions 82a-82c, Gln at position 39, Asn at position 60, His atposition 68, any one of Lys, His or Thr at position 105, Leu at position2, Ala at position 32, and Ala at position 95 (using Kabat numbering).In particular embodiments, the heavy chain variable region comprisesSer-Ser-Val or Thr-Gly-Val at positions 82a-82c (using Kabat numbering).In particular embodiments, the heavy chain variable region comprises Asnat position 60, His at position 68, and Lys, His or Thr at position 105(using Kabat numbering). In certain embodiments, the heavy chainvariable region (Fab) comprises: Ser-Ser-Val or Thr-Gly-Val at positions82a-82c, Gln at position 39, Asn at position 60, His at position 68, andLys, Thr or His at position 105 (using Kabat numbering). In certainembodiments, the monoclonal antibody or antigen-binding fragment thereofcomprises a heavy chain variable region provided in Table 1. Inparticular embodiments, the monoclonal antibody or antigen-bindingfragment thereof comprises a heavy chain constant region provided inTable 1. In particular embodiments, the monoclonal antibody orantigen-binding fragment thereof comprises a light chain or variableregion thereof provided in Table 1.

In a related embodiment, the present invention includes an isolatedpolynucleotide encoding the monoclonal antibody or antigen-bindingfragment thereof of the invention, or the heavy chain or light chain ofthe monoclonal antibody.

In a further related embodiment, the present invention includes a vectorcomprising a polynucleotide of the invention.

In another embodiment, the present invention includes a cell comprisinga polynucleotide or vector of the invention. In particular embodiments,the cell is a mammalian, bacterial or yeast cell.

In yet another embodiment, the present invention includes apharmaceutical composition comprising a monoclonal antibody or fragmentthereof of the present invention, a polynucleotide of the presentinvention, or a vector of the present invention. In particularembodiments, the pharmaceutical composition comprises a pharmaceuticallyacceptable carrier, excipient or diluent.

In another related embodiment, the present invention includes a methodof treating or preventing human immunodeficiency virus (HIV) in asubject in need thereof, comprising providing to the subject aneffective amount of a pharmaceutical composition of the invention. Inparticular embodiments, a second therapeutic agent is also provided tothe subject. In certain embodiments, the second therapeutic agent is ananti-viral agent.

In a further embodiment, the present invention includes a method ofproducing a monoclonal antibody or antigen-binding fragment thereof ofthe invention, comprising recombinantly expressing the monoclonalantibody or antigen-binding fragment thereof in a cell of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the amino acid sequences of the heavy chain variable domainand light chain variable domain of the PGT-121 LO6 antibody with thecorresponding Kabat numbering annotation shown below each amino acid.Amino acid deletions are indicated with a “−”. Amino acid insertions areindicated with lowercase letters next the amino acid number.

FIG. 2 is a graph showing the Tm of the Fab domain as determined by DSFfor PGT121 WT and selected variants. All variants tested have improvedthermal stability as compared to PGT121 WT, as indicated by a higher Tm.

FIG. 3 is a graph showing paired analysis of unique variants differingonly at the amino acid indicated, revealing mutations that bothstabilize or destabilize the Fab domain. The change in Tm of the variousPGT121 mutants as compared to the Tm of PGT121 WT is shown.

FIG. 4 is a graph showing the Fab melting temperature of the Fab domainsof selected PGT121 variants as determined by DSC.

FIG. 5 is a graph showing the fold change in gp120 ELISA EC50 forselected PGT121 variants as compared to PGT121 LO6 WT. Dotted line at anEC50 ratio of 1 indicates no change in affinity. PGT121 LO6 WT is boxed.Variants with EC50 ratios >1 for a given gp120 strain (gp120BaL orgp120TRO as shown) have improved antigen binding affinity compared toPGT121 WT, while variants with EC50 Ratios <1 for a given gp120 strainhave decreased antigen binding affinity compared to PGT121 WT.

FIG. 6 is a graph showing fold change in gp140 ELISA EC50 for PGT121variants Compared to PGT121 LO6 WT. The dotted line at an EC50 ratio of1 indicates no change in affinity. PGT121 LO6 WT is boxed. Variants withEC50 ratios >1 for a given gp140 strain (gp140 BaL and gp140 SHIVSF162P3 are shown) have improved antigen binding affinity compared toPGT121 LO6 WT, while variants with EC50 Ratios <1 for a given gp120strain have decreased antigen binding affinity compared to PGT121 LO6WT.

FIG. 7 is a graph showing EC50 (nM) values for PGT121 variantsdetermined against recombinant gp120 from 7 unique HIV strains (BaL,pRHPA4259, qh0692, 6535, pCAAN5342, pWITO4160, and AC10.0). In contrastto PGT121 WT, there is no statistically significant difference in gp120binding between the specific variants PGT121.42, PGT121.60, PGT121.61,and PGT121.65.

FIGS. 8A-8H provides graphs showing the results of ELISA using variousrecombinant human FcγR extracellular domains and PGT121 WT and Fc andFab variants (8A, FcγRI; 8B, FcγRIII-176F; 8C, FcγRIII-176V; 8D,FcγRII-167H; 8E, FcγRIIA-167R; 8F, FcγRIIB; 8G, FcγRIIIB-NA1; 8H,FcγRIIIB-NA2). Biotinylated human FcγR extracellular domains werecaptured on neutravidin coated 384 well plates at 0.5 ug/mL. 12 pointELISA titrations were conducting with the indicated antibodies, data fitwith a 4-parameter dose-response curve and EC50 values calculated. Greyline is at the geometric mean of EC50 values determined in multipleunique experiments (each data point represents a unique experimentconducted in duplicate).

FIG. 9 shows that PGT121 WT and Fab variants bind to recombinant HIV Envin transfected human cells. Recombinant HIV Env BaL was transfected inHEK293T cells. The transfected cells were incubated with the indicatedantibodies at different concentrations. After flow cytometry, collectedMFIs were fitted to non-linear regression dose-response curve.

FIG. 10 shows the fold change in recombinant HIV Env binding EC50 forPGT121 variants compared to PGT121 WT. Dotted line at an EC50 ratio of 1indicates no change in affinity. Variants with EC50 ratios >1 for agiven recombinant HIV Env strain (BaL or US657 as shown) have improvedantigen binding affinity compared to PGT121 WT, while variants with EC50ratios <1 for a given recombinant HIV Env strain have decreased antigenbinding affinity compared to PGT121 WT.

FIG. 11 shows pH hold screen results for PGT121 and variants in WT Fcbackground. The change in % monomer as indicated by SEC (where monomeris defined as a single full IgG molecule) after a 1 hour low pH hold atpH 3.5 after elution from protein A resin is plotted for each antibodyin buffers with different NaCl content as indicated. Values below 0%indicate a reduction in antibody monomer and a corresponding increase inaggregate content during the low pH hold screen. The dotted and dashedlines indicate the values for PGT121 WT (boxed) in buffers containing 0mM and 10 mM NaCl, respectively. Variants with improved or decreasedperformance relative to PGT121 LO6 are indicated

FIG. 12 shows pH hold screen on PGT121 variants in DEALLS Fc background.The DEALLS Fc constructs comprise the following amino acid substitutionsas compared to PGT121 L06: G236A, S239D, A330L, 1332E, M428L, and N434S.The change in % monomer as indicated by SEC (where monomer is defined asa single full IgG molecule) after a 1 hour low pH hold at pH 3.5 informulation buffer is plotted for each antibody in buffers withdifferent NaCl content as indicated. Values below 0% indicate areduction in antibody monomer and a corresponding increase in aggregatecontent during the low pH hold screen. The dotted and dashed lineindicates the mean values for PGT121 WT (boxed) in buffers containing 0mM and 40 mM NaCl respectively. PGT121 WT (boxed) with the WT Fc isshown for reference alongside PGT121.56 (which contains the PGT121 WTFab combined with the DEALLS Fc). The other variants tested containvariable domain mutations and show improved low pH stability in thisscreen.

FIG. 13 shows effector cell activation by PGT121 WT and Fc variants,including those having the following amino acid substitution as comparedto PGT121 WT (EU numbering): S239D and I332E (DE); G236A, S239D andI332E (DEA); S239D, A330L and I332E (DEL); G236A, S239D, A330L, andI332E (DEAL); and S239D, H268F, S324T, and I332E (FTDE). Recombinant HIVEnv 92HT593 was transfected in HEK293T cells. The transfected cells wereincubated with the indicated antibodies at different concentrations andengineered Jurkat T cells expressing human FcγRIIIA coupled to a NFATluciferase reporter. The activation of the effector cells by theantibodies was measured as luciferase activity.

FIG. 14 is a graph showing fold change in antibody-dependent effectorcell activation for PGT121 Fc variants compared to PGT121 WT, includingthose shown in FIG. 13 and another comprising the following amino acidsubstitutions as compared to PGT121 WT (EU numbering): G236A, S267E,H268F, S324T, and I332E (EFTEA). The antibody-dependent effector cellactivation was represented by AUC of non-regression dose-response curveshown in FIG. 14. Dotted line at a ratio of 1 indicates no change inantibody activity. Variants with AUC ratios >1 for a given recombinantHIV Env strain (BaL or 92HT593 as shown) have improved activity comparedto PGT121 WT, while a variant with AUC ratio <1 for a given recombinantHIV Env strain has decreased activity compared to PGT121 WT.

FIG. 15 is a graph showing fold change in antibody-dependent effectorcell activation for PGT121 Fab variants with DEAL Fc mutation comparedto PGT121 WT Fab variant with DEAL Fc mutation. The antibody-dependenteffector cell activation was represented by AUC of non-regressiondose-response curve of a given antibody. Dotted line at a ratio of 1indicates no change in antibody activity. Variants with AUC ratios >1for a given recombinant HIV Env strain (US657 or 92HT593 as shown) haveimproved activity compared to PGT121 WT Fab, while variants with AUCratios <1 for a given recombinant HIV Env strain have decreased activitycompared to PGT121 WT Fab variant. Of note, the activity of certainantibodies of the present invention was 10-fold enhanced over that ofthe PGT-121 antibody, when quantified by area under the curve (AUC).

FIG. 16 is a graph showing the fold change in AUC in the effector cellactivation assay using Env HT593 transfected HEK293 cells of thePGT121.60 and PGT121.61 mutants as compared to the PGT121.42 mutant.

FIG. 17 is a graph showing enhanced ADCC of HIV-infected target CD4⁺ Tcells by PGT121.42. Representative dose-response curves for ADCC ofprimary CD4⁺ T cells infected with viral isolate US657 by the effectorenhanced PGT121.42 and the WT PGT121. Assays are performed in thepresence of 10 mg/mL serum IgG.

FIGS. 18A and 18B are graphs showing enhanced monocyte and PBMC-mediatedkilling of HIV-infected target CD4⁺ T cells by PGT121.42 in the presenceof 1 mg/mL serum IgG. Representative dose-response curves of PGT121.42and PGT121 donors CD4⁺ T cells infected in vitro with viral isolateUS657 using either isolated autologous PBMCs (A) or autologous monocytes(B).

FIGS. 19A and 19B are graphs showing neutralization activity of PGT121and variants against a panel of isolates with dual and/or mixed tropism(DM and X4 isolates, 19A) or R5 tropism (R5 isolates; 19B) using theMonogram PhenoSense neutralization assay. For each antibody variant,activity against any given isolate is expressed relative to PGT121 (IC50of variant/IC50 PGT121). Each dot represents a single isolate. Barsrepresent median IC50 for the isolates with interquartile range.

FIG. 20 is a graph showing neutralization activity of variants against alarge panel of clinical isolates using the Monogram PhenoSenseneutralization assay. Each circle represents a single isolate. For eachantibody, activity against a given isolate is shown relative to PGT121(IC95 PGT121/IC95 variant).

FIG. 21 is a graph showing neutralization of PGT121 variants against apanel of 5 HIV-1 isolates using the CEM-NKr-CCR5-Luc reporter cell linebased assay. Horizontal line indicates geometric mean IC50s for each the5 isolates. Specific variants were observed to have improvedneutralization potency over PGT121 (up to 2-fold) against severalisolates but not necessarily all isolates tested.

FIG. 22 is a graph showing whole molecule immunogenicity assessment ofPGT121 WT and selected variants tested on primary cells from a panel of50 donors. VRCO1 is an anti-HIV antibody, and A33 is a positive controlthat showed anti-drug-antibody responses in phase I trials (Welt et al.2003. Clin Cancer Res. 9: 1338-1346).

FIGS. 23A and 23B are graphs showing FcRn ELISA pH 6.0 EC50 values forPGT121 WT (23B) and select variants (23A and 23B).

FIG. 24 is a graph showing serum concentration-time profiles forPGT121.1 (triangle) and PGT121.42 (circle) following 1 mg/kg IV bolusdosing to Naïve cynomolgus monkeys (n=2). Each symbol is the measuredconcentration from each individual animal and the line represents meanof two subjects.

FIG. 25 is a graph showing serum concentration-time profiles forPGT121.1 (triangle), PGT121.42 (circle), PGT121 LS (open circle), andPGT121.60 (open square) following 10 mg/kg IV dosing to naïve cynomolgusmonkeys (n=3). Each symbol is the measured concentration from eachindividual animal and the line represents mean of three subjects.

FIG. 26 is a graph showing effector cell activation by PGT121 (opencircle) and the mutant PGT121.60 (closed circle) in the effector cellactivation assay using Env HT593 transfected HEK293 cells.

FIG. 27 is a graph showing ADCC activity of HIV-infected target CD4⁺ Tcells by a select set of PGT121 variants. Representative ADCCdose-response curves are shown for killing of primary CD4⁺ T cellsinfected with viral isolate US657 by the effector enhanced PGT121variants.

FIG. 28 is a graph showing enhanced ADCC activity of the PGT121 variantPGT121.60 in comparison to PGT121 in the presence of 5 mg/mL competinghuman serum IgG. Killing of the CEM.NKr.CCR5.Luc CD4 reporter cell lineinfected with HIV-1 isolate US657 as shown using primary human NK cellsfrom two healthy donors.

FIGS. 29A and 29B show the increased potency of PGT121 variants againstR5, X4 and D/M viruses. FIG. 29A: fold increase in potency of individualPGT121 Fab variants versus PGT121 WT for R5 viruses and X4 & D/Mviruses. FIG. 29B: fold more potent or fold change (IC50) of PGT121variants over PGT121 WT against R4 viruses or R5 viruses. R5viruses=R5-tropic viruses, preferentially uses CCR5 receptor;X4=R4-tropic viruses, preferentially uses CXCR4 receptor; D/Mviruses=Dual/Mixed, showing both R5 and X4 tropism.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is based, in part, on the identification of novelneutralizing anti-HIV antibodies with advantageous properties fortherapeutic use. The present invention provides these antibodies, andantigen-binding fragments thereof, as well as related pharmaceuticalcompositions and methods of use thereof, e.g., for the treatment andprevention of HIV and related diseases and disorders.

Definitions and Abbreviations

The words “a” and “an” denote one or more, unless specifically noted.

By “about” is meant a quantity, level, value, number, frequency,percentage, dimension, size, amount, weight or length that varies by asmuch as 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1% to a referencequantity, level, value, number, frequency, percentage, dimension, size,amount, weight or length. In any embodiment discussed in the context ofa numerical value used in conjunction with the term “about,” it isspecifically contemplated that the term about can be omitted.

Unless the context requires otherwise, throughout the presentspecification and claims, the word “comprise” and variations thereof,such as, “comprises” and “comprising” are to be construed in an open,inclusive sense, that is as “including, but not limited to”. Where theterms “comprise” or “comprising” are used herein, it is understood thatthe invention further includes embodiments wherein these terms arereplaced with “consist of” or “consist essentially of” or “consistingof” or “consisting essentially of.”

By “consisting of” is meant including, and limited to, whatever followsthe phrase “consisting of” Thus, the phrase “consisting of” indicatesthat the listed elements are required or mandatory, and that no otherelements may be present.

By “consisting essentially of” is meant including any elements listedafter the phrase, and limited to other elements that do not interferewith or contribute to the activity or action specified in the disclosurefor the listed elements. Thus, the phrase “consisting essentially of”indicates that the listed elements are required or mandatory, but thatother elements are optional and may or may not be present depending uponwhether or not they affect the activity or action of the listedelements.

Reference throughout this specification to “one embodiment” or “anembodiment” means that a particular feature, structure or characteristicdescribed in connection with the embodiment is included in at least oneembodiment of the present invention. Thus, the appearances of thephrases “in one embodiment” or “in an embodiment” in various placesthroughout this specification are not necessarily all referring to thesame embodiment. Furthermore, the particular features, structures, orcharacteristics may be combined in any suitable manner in one or moreembodiments.

An “increased” or “enhanced” amount is typically a “statisticallysignificant” amount, and may include an increase that is 1.1, 1.2, 1.3,1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10,15, 20, 30, 40, or 50 or more times (e.g., 100, 500, 1000 times)(including all integers and decimal points in between and above 1, e.g.,2.1, 2.2, 2.3, 2.4, etc.) an amount or level described herein. It mayalso include an increase of at least 10%, at least 20%, at least 30%, atleast 40%, at least 50%, at least 60%, at least 70%, at least 80%, atleast 90%, at least 100%, at least 150%, at least 200%, at least 500%,or at least 1000% of an amount or level described herein.

A “decreased” or “reduced” or “lesser” amount is typically a“statistically significant” amount, and may include a decrease that isabout 1.1, 1.2, 1.3, 1.4, 1.5, 1.6 1.7, 1.8, 1.9, 2, 2.5, 3, 3.5, 4,4.5, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, or 50 or more times (e.g., 100,500, 1000 times) (including all integers and decimal points in betweenand above 1, e.g., 1.5, 1.6, 1.7. 1.8, etc.) an amount or leveldescribed herein. It may also include a decrease of at least 10%, atleast 20%, at least 30%, at least 40%, at least 50%, at least 60%, atleast 70%, at least 80%, or at least 90%, at least 100%, at least 150%,at least 200%, at least 500%, or at least 1000% of an amount or leveldescribed herein.

A “composition” can comprise an active agent, e.g., a contrast agent anda carrier, inert or active, e.g., a pharmaceutically acceptable carrier,diluent or excipient. A composition may be a pharmaceutical composition.In particular embodiments, the compositions are sterile, substantiallyfree of endotoxins or non-toxic to recipients at the dosage orconcentration employed.

“Pharmaceutically acceptable carrier, diluent or excipient” includeswithout limitation any adjuvant, carrier, excipient, glidant, sweeteningagent, diluent, preservative, dye/colorant, flavor enhancer, surfactant,wetting agent, dispersing agent, suspending agent, stabilizer, isotonicagent, solvent or emulsifier which has been approved by the UnitedStates Food and Drug Administration as being acceptable for use inhumans or domestic animals.

The terms “mammal” and “subject” includes human and non-human mammals,such as, e.g., a human, mouse, rat, rabbit, monkey, cow, hog, sheep,horse, dog, and cat.

The term “buffer” as used herein denotes a pharmaceutically acceptableexcipient, which stabilizes the pH of a pharmaceutical preparation.Suitable buffers are well known in the art. Suitable pharmaceuticallyacceptable buffers include but are not limited to acetate-buffers,histidine-buffers, citrate-buffers, succinate-buffers, tris-buffers andphosphate-buffers. In certain embodiments, the concentration of thebuffer is from about 0.01 mM to about 1000 mM, about 0.1 mM to about1000 mM, about 0.1 mM to about 500 mM, about 0.1 to about 200 mM, about0.1 to about 100 mM, about 1 mM to about 1000 mM, about 1 mM to about500 mM, about 1 mM to about 200 mM, about 1 mM to about 100 mM, about 1mM to about 50 mM, about 2 mM to about 60 mM, about 4 mM to about 60 mM,or about 4 mM to about 40 mM, about 5 mM to about 20 mM, or about 5 mMto about 25 mM.

“Optional” or “optionally” means that the subsequently described eventof circumstances may or may not occur, and that the description includesinstances where said event or circumstance occurs and instances in whichit does not.

“Pharmaceutical composition” refers to a formulation of a compound and amedium generally accepted in the art for the delivery of thebiologically active compound to mammals, e.g., humans. Such a medium mayinclude any pharmaceutically acceptable carriers, diluents or excipientstherefore.

“Effective amount” or “therapeutically effective amount” refers to thatamount of an antibody or antigen-binding fragment thereof of theinvention that, when administered alone or in combination with anothertherapeutic agent to a cell, tissue, or subject is sufficient to effecttreatment or a beneficial result in the subject. The amount whichconstitutes an “effective amount” will vary depending on the antibody orantigen-binding fragment thereof and its specific use, and potentiallyalso the condition and its severity, the manner of administration, andthe age of the subject to be treated, but can be determined routinely byone of ordinary skill in the art having regard to his own knowledge andto this disclosure. A therapeutically effective dose further refers tothat amount of the antibody or antigen-binding fragment thereofsufficient to treat, prevent or ameliorate an infection or diseasecondition or the progression of an infection or disease, and that amountsufficient to effect an increase in rate of treatment, healing,prevention or amelioration of such conditions. When applied to anindividual antibody or antigen-binding fragment thereof administeredalone, a therapeutically effective dose refers to that active ingredientalone. When applied to a combination, a therapeutically effective doserefers to combined amounts of the active ingredients that result in thetherapeutic effect, whether administered in combination, serially orsimultaneously.

“Treat,” “treating” or “treatment” as used herein covers the treatmentof the disease, injury, or condition of interest, e.g., HIV-1 infection,in a subject, e.g., a mammal, such as a human, having the disease orcondition of interest, and includes: (i) inhibiting progression of thedisease, injury, or condition, i.e., arresting its development; (ii)reducing or relieving the disease, injury, or condition, i.e., causingregression of the disease or condition; or (iii) relieving the symptomsresulting from the disease, injury, or condition. As used herein, theterms “disease,” “disorder,” and “condition” may be usedinterchangeably. As used herein, “inhibition,” “treatment,” “treating,”and “ameliorating” are used interchangeably and refer to, e.g., stasisof symptoms, prolongation of survival, partial or full amelioration ofsymptoms, and partial or full eradication of a condition, disease ordisorder.

As used herein, ‘prevent” or “prevention” includes (i) preventing orinhibiting the disease, injury, or condition from occurring in asubject, in particular, when such subject is predisposed to thecondition but has not yet been diagnosed as having it; or (ii) reducingthe likelihood that the disease, injury, or condition will occur in thesubject.

As used herein, the term “antibody” means an isolated or recombinantbinding agent that comprises the necessary variable region sequences tospecifically bind an antigenic epitope. Therefore, an antibody is anyform of antibody or fragment thereof that exhibits the desiredbiological activity, e.g., binding the specific target antigen. Thus, itis used in the broadest sense and specifically covers monoclonalantibodies (including full-length monoclonal antibodies), polyclonalantibodies, human antibodies, humanized antibodies, chimeric antibodies,nanobodies, diabodies, multispecific antibodies (e.g., bispecificantibodies), and antibody fragments including but not limited to scFv,Fab, and Fab₂, so long as they exhibit the desired biological activity.

The term “human antibody” refers to antibodies containing sequences ofhuman origin, except for possible non-human CDR regions, and does notimply that the full structure of an Ig molecule be present, only thatthe antibody has minimal immunogenic effect in a human.

“Antibody fragments” comprise a portion of an intact antibody, forexample, the antigen-binding or variable region of the intact antibody.Examples of antibody fragments include Fab, Fab′, F(ab′)₂, and Fvfragments; diabodies; linear antibodies (e.g., Zapata et al., ProteinEng. 8(10): 1057-1062 (1995)); single-chain antibody molecules (e.g.,scFv); and multispecific antibodies formed from antibody fragments.Papain digestion of antibodies produces two identical antigen-bindingfragments, called “Fab” fragments, each with a single antigen-bindingsite, and a residual “Fc” fragment, a designation reflecting the abilityto crystallize readily. Pepsin treatment yields an F(ab′)₂ fragment thathas two antigen combining sites and is still capable of cross-linkingantigen.

“Fv” is the minimum antibody fragment which contains a completeantigen-recognition and -binding site. This region consists of a dimerof one heavy- and one light-chain variable domain in tight, non-covalentassociation. It is in this configuration that the three CDRS of eachvariable domain typically interact to define an antigen-binding site onthe surface of the V_(H)-V_(L) dimer. Generally, the six CDRscollectively confer antigen-binding specificity to the antibody,although there are examples of antigen-binding specificity beingmaintained when one or more of the six CDRs are deleted or modified,e.g., by altering the amino acid sequence of the one or more CDRs, e.g.,by amino acid insertion, deletion or substitution. In addition, even asingle variable domain (or half of an Fv comprising only three CDRsspecific for an antigen) has the ability to recognize and bind antigen,although at a lower affinity than the entire binding site. Residuesother than those present in the CDRs may also be important for or play arole in antigen binding and/or specificity as shown for PGT121 andclosely related somatic variants which interact with the gp120 antigenusing residues in light chain framework 3 (Julien et al. Science342:1477-83 (2013); Julien et al. PLOS Pathog. 9: e1003342 (2013)) Theseresidues in part arise from an unusual three amino acid insertion whichextends an otherwise short surface loop in PGT121 and related somaticvariants (e.g. PGT122, PGT123, PGT124, PGT133, PGT134) that contactsboth the N332 linked glycan and protein residues on HIV Env, effectivelyforming an additional (e.g. a fourth) complementarity determining region(CDR) loop in the PGT121 light chain between LC CDRs 2 and 3.

The term “hypervariable region” refers to the amino acid residues of anantibody that are typically responsible for antigen-binding. Thehypervariable region generally comprises amino acid residues from a“complementarity determining region” or “CDR” (e.g., around aboutresidues 24-34 (L1), 50-56 (L2) and 89-97 (L3) in the V_(L), and aroundabout 31-35 (H1), 50-65 (H2) and 95-102 (H3) in the V_(H) when numberedin accordance with the Kabat numbering system; Kabat et al., Sequencesof Proteins of Immunological Interest, 5th Ed. Public Health Service,National Institutes of Health, Bethesda, Md. (1991)); and/or thoseresidues from a “hypervariable loop” (e.g., residues 24-34 (L1), 50-56(L2) and 89-97 (L3) in the V_(L), and 26-32 (H1), 52-56 (H2) and 95-101(H3) in the V_(H) when numbered in accordance with the Chothia numberingsystem; Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987)); and/orthose residues from a “hypervariable loop” VCDR (e.g., residues 27-38(L1), 56-65 (L2) and 105-120 (L3) in the V_(L), and 27-38 (H1), 56-65(H2) and 105-120 (H3) in the V_(H) when numbered in accordance with theIMGT numbering system; Lefranc, M. P. et al. Nucl. Acids Res. 27:209-212(1999), Ruiz, M. e al. Nucl. Acids Res. 28:219-221 (2000)). Optionally,the antibody has symmetrical insertions at one or more of the followingpoints 28, 36 (L1), 63, 74-75 (L2) and 123 (L3) in the V_(L), and 28, 36(H1), 63, 74-75 (H2) and 123 (H3) in the V_(H) when numbered inaccordance with AHo; Honneger, A. and Plunkthun, A. J. Mol. Biol.309:657-670 (2001)).

The “Fab” fragment is a region on an antibody that binds to antigens. Itis composed of one constant and one variable domain of each of the heavyand light chain. These domains shape the paratope—the antigen-bindingsite—at the amino terminal end of the monomer. The two variable domainsbind the epitope on their specific antigens. Fab fragments differ fromFab′ fragments by the addition of a few residues at the carboxy terminusof the heavy chain CH₁ domain including one or more cysteines from theantibody hinge region. Fab′-SH is the designation herein for Fab′ inwhich the cysteine residue(s) of the constant domains bear a free thiolgroup. F(ab′)₂ antibody fragments originally were produced as pairs ofFab′ fragments which have hinge cysteines between them. Other chemicalcouplings of antibody fragments are also known.

The “light chains” of antibodies (immunoglobulins) from any vertebratespecies can be assigned to one of two clearly distinct types, calledkappa and lambda, based on the amino acid sequences of their variable orconstant domains. Depending on the amino acid sequence of the constantdomain of their heavy chains, immunoglobulins can be assigned todifferent classes. There are five major classes of immunoglobulins: IgA,IgD, IgE, IgG, and IgM, and several of these may be further divided intosubclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA, and IgA2.

“Single-chain Fv” or “scFv” or “sFv” antibody fragments comprise theV_(H) and V_(L) domains of antibody, wherein these domains are presentin a single polypeptide chain. In some embodiments, the Fv polypeptidefurther comprises a polypeptide linker between the V_(H) and V_(L)domains, which enables the sFv to form the desired structure forantigen-binding.

The term “diabodies” refers to small antibody fragments with twoantigen-binding sites, which fragments comprise a heavy-chain variabledomain (V_(H)) connected to a light-chain variable domain (V_(L)) in thesame polypeptide chain (V_(H)-V_(L)). By using a linker that is tooshort to allow pairing between the two domains on the same chain, thedomains are forced to pair with the complementary domains of anotherchain and create two antigen-binding sites. Diabodies are described morefully in, for example, EP 404,097; WO 93/11161; and Hollinger et al,Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993).

An “isolated” antibody or antigen-binding fragment thereof is one thathas been identified and separated and/or recovered from a component ofits natural environment. Contaminant components of its naturalenvironment are materials that would interfere with diagnostic ortherapeutic uses for the antibody, and may include enzymes, hormones,and other proteinaceous or nonproteinaceous solutes. In someembodiments, the antibody will be purified (1) to greater than 95% byweight of antibody as determined by the Lowry method, for example, morethan 99% by weight, (2) to a degree sufficient to obtain at least 15residues of N-terminal or internal amino acid sequence by use of aspinning cup sequenator, or (3) to homogeneity by SDS-PAGE underreducing or nonreducing conditions using Coomassie blue or silver stain.Isolated antibody includes the antibody in situ within recombinant cellssince at least one component of the antibody's natural environment willnot be present. Ordinarily, however, isolated antibody will be preparedby at least one purification step.

An antibody or antigen-binding fragment thereof that “specifically bindsto” or is “specific for” a particular polypeptide or an epitope on aparticular polypeptide is one that binds to that particular polypeptideor epitope on a particular polypeptide without substantially binding toany other polypeptide or polypeptide epitope. In some embodiments, theantibody of the present disclosure specifically binds to an antigen,e.g., an HIV-1 gp120 polypeptide, with dissociation constant K_(d) equalto or lower than 100 nM, optionally lower than 10 nM, optionally lowerthan 1 nM, optionally lower than 0.5 nM, optionally lower than 0.1 nM,optionally lower than 0.01 nM, or optionally lower than 0.005 nM, in theform of monoclonal antibody, scFv, Fab, or other form of antibodymeasured at a temperature of about 4° C., 25° C., 37° C., or 42° C.Affinities of antibodies can be readily determined using conventionaltechniques, for example, those described by Scatchard et al. (Ann. N. Y.Acad. Sci. USA 51: 660 (1949), ELISA assays, biolayer interferometry(BLI) assays, and surface plasmon resonance (SPR) assays). Bindingproperties of an antibody to antigens, cells or tissues thereof maygenerally be determined and assessed using immunodetection methodsincluding, for example, immunofluorescence-based assays, such asimmuno-histochemistry (IHC) and/or fluorescence-activated cell sorting(FACS).

As used herein, an antibody that “internalizes” is one that is taken upby {i.e., enters) the cell upon binding to an antigen on a mammaliancell {e.g., a cell surface polypeptide or receptor). The internalizingantibody will of course include antibody fragments, human or chimericantibody, and antibody conjugates. For certain therapeutic applications,internalization in vivo is contemplated. The number of antibodymolecules internalized will be sufficient or adequate to kill a cell orinhibit its growth, especially an infected cell. Depending on thepotency of the antibody or antibody conjugate, in some instances, theuptake of a single antibody molecule into the cell is sufficient to killthe target cell to which the antibody binds. For example, certain toxinsare highly potent in killing such that internalization of one moleculeof the toxin conjugated to the antibody is sufficient to kill theinfected cell.

The term “antagonist” antibody is used in the broadest sense, andincludes an antibody that partially or fully blocks, inhibits, orneutralizes a biological activity of an epitope, polypeptide, or cellthat it specifically binds. Methods for identifying antagonistantibodies may comprise contacting a polypeptide or cell specificallybound by a candidate antagonist antibody with the candidate antagonistantibody and measuring a detectable change in one or more biologicalactivities normally associated with the polypeptide or cell.

An “antibody that inhibits the growth of infected cells” or a “growthinhibitory” antibody is one that binds to and results in measurablegrowth inhibition of infected cells expressing or capable of expressingan HIV1 epitope bound by an antibody. Preferred growth inhibitoryantibodies inhibit growth of infected cells by greater than 20%,preferably from about 20% to about 50%, and even more preferably, bygreater than 50% (e.g., from about 50% to about 100%) as compared to theappropriate control, the control typically being infected cells nottreated with the antibody being tested. Growth inhibition can bemeasured at an antibody concentration of about 0.1 to about 30 μg/ml orabout 0.5 nM to about 200 nM in cell culture, where the growthinhibition is determined 1-10 days after exposure of the infected cellsto the antibody. Growth inhibition of infected cells in vivo can bedetermined in various ways known in the art. The antibody is growthinhibitory in vivo if administration of the antibody at about 1 μg/kg toabout 100 mg/kg body weight results in reduction the percent of infectedcells or total number of infected cells within about 5 days to 3 monthsfrom the first administration of the antibody, preferably within about 5to 30 days.

An antibody that “induces apoptosis” is one which induces programmedcell death as determined by binding of annexin V, fragmentation of DNA,cell shrinkage, dilation of endoplasmic reticulum, cell fragmentation,and/or formation of membrane vesicles (called apoptotic bodies).Preferably the cell is an infected cell. Various methods are availablefor evaluating the cellular events associated with apoptosis. Forexample, phosphatidyl serine (PS) translocation can be measured byannexin binding; DNA fragmentation can be evaluated through DNAladdering; and nuclear/chromatin condensation along with DNAfragmentation can be evaluated by any increase in hypodiploid cells.Preferably, the antibody that induces apoptosis is one that results inabout 2 to 50 fold, preferably about 5 to 50 fold, and most preferablyabout 10 to 50 fold, induction of annexin binding relative to untreatedcell in an annexin binding assay.

Antibody “effector functions” refer to those biological activitiesattributable to the Fc region (a native sequence Fc region or amino acidsequence variant Fc region) of an antibody, and vary with the antibodyisotype. Examples of antibody effector functions include: Clq bindingand complement dependent cytotoxicity; Fc receptor binding;antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis(e.g., antibody-dependent cell-mediated phagocytosis (ADCP)); downregulation of cell surface receptors (e.g., B cell receptor); and B cellactivation.

“Antibody-dependent cell-mediated cytotoxicity” or “ADCC” refers to aform of cytotoxicity in which secreted or exogenously administered Igbound to Fc receptors (FcRs) present on certain cytotoxic cells (e.g.,Natural Killer (NK) cells, neutrophils, and macrophages) enable thesecytotoxic effector cells to bind specifically to an antigen-bearingtarget cell and subsequently kill the target cell with cytotoxins. Theantibodies “arm” the cytotoxic cells and are required for such killing.The primary cells for mediating ADCC, NK cells, express FcγRIII only,whereas monocytes express FcγRI, FcγRII and FcγRIII. FcR expression onhematopoietic cells is summarized in Table 4 on page 464 of Ravetch andKinet, Annu. Rev. Immunol 9:457-92 (1991). To assess ADCC activity of amolecule of interest, an in vitro ADCC assay, such as that described inU.S. Pat. No. 5,500,362 or 5,821,337 may be performed. Useful effectorcells for such assays include peripheral blood mononuclear cells (PBMC)and Natural Killer (NK) cells. Alternatively, or additionally, ADCCactivity of the antibody or antigen-binding fragment thereof may beassessed in vivo, e.g., in an animal model such as that disclosed inClynes et al., Proc. Natl. Acad. Sci. (USA) 95:652-656 (1998).

“Fc receptor” or “FcR” describes a receptor that binds to the Fc regionof an antibody. In certain embodiments, the FcR is a native sequencehuman FcR. Moreover, a preferred FcR is one that binds an IgG antibody(a gamma receptor) and includes receptors of the FcγRI, FcγRII, andFcγRIII subclasses, including allelic variants and alternatively splicedforms of these receptors. FCγRII receptors include FcγRIIA (an“activating receptor”) and FcγRIIB (an “inhibiting receptor”), whichhave similar amino acid sequences that differ primarily in thecytoplasmic domains thereof, and FcγRIIC, which includes the FcγRIIBextracellular domain fused to an activating cytoplasmic region.Activating receptor FcγRIIA contains an immunoreceptor tyrosine-basedactivation motif (ITAM) in its cytoplasmic domain. Inhibiting receptorFcγRIIB contains an immunoreceptor tyrosine-based inhibition motif(ITIM) in its cytoplasmic domain (see review M. in Daeron, Annu. Rev.Immunol. 15:203-234 (1997)). FcRs are reviewed in Ravetch and Kinet,Annu. Rev. Immunol 9:457-92 (1991); Capel et al, Immunomethods 4:25-34(1994); and de Haas et al, J. Lab. Clin. Med. 126:330-41 (1995). OtherFcRs, including those to be identified in the future, are encompassed bythe term “FcR” herein. The term also includes the neonatal receptor,FcRn, which is responsible for the transfer of maternal IgGs to thefetus (Guyer et al, J. Immunol. 117:587 (1976) and Kim et al, J.Immunol. 24:249 (1994)), and which plays a role in salvaging IgG fromlysosomal degradation by FcRn dependent recycling following endocytosis.FcRn binding following pinocytosis in endothelial cells has been shownto be important for sustaining the prolonged pharmacokinetic half-lifeof antibodies. Assessment of pH dependent human FcRn binding ofantibodies in vitro may be performed to provide a prediction ofpotential for favorable clinical pharmacokinetics (Datta-Mannan andWroblewski, Drug Metab. Dispos. 42:1867-1872 (2014)).

“Human effector cells” are leukocytes that express one or more FcRs andperform effector functions. Preferably, the cells express at leastFcγRIII and perform ADCC effector function. Examples of human leukocytesthat mediate ADCC include PBMC, NK cells, monocytes, cytotoxic T cellsand neutrophils; with PBMCs and NK cells being preferred. The effectorcells may be isolated from a native source, e.g., from blood.

“Complement dependent cytotoxicity” or “CDC” refers to the lysis of atarget cell in the presence of complement. Activation of the classicalcomplement pathway is initiated by the binding of the first component ofthe complement system (Clq) to antibodies (of the appropriate subclass)that are bound to their cognate antigen. To assess complementactivation, a CDC assay, e.g., as described in Gazzano-Santoro et al, J.Immunol. Methods 202: 163 (1996), may be performed.

A “mammal” for purposes of treating an infection, refers to any mammal,including humans, domestic and farm animals, research animals, such asmice, rats, and primates, and zoo, sports, or pet animals, such as dogs,cats, cattle, horses, sheep, pigs, goats, rabbits, etc. In particularembodiments, the mammal is human.

A “neutralizing antibody” is one that can neutralize the ability of thatpathogen to initiate and/or perpetuate an infection in a host and/or intarget cells in vitro. The invention provides neutralizing monoclonalhuman antibodies and antigen-binding fragments thereof, wherein theantibody recognizes an antigen from HIV, e.g., a gp120 polypeptide. Incertain embodiments, a “neutralizing antibody” may inhibit the entry ofHIV-1 virus, e.g., SF162 and/or JR-CSF, with a neutralization index >1.5or >2.0 (Kostrikis L G et al./Virol. 1996; 70(1): 445-458). By “broadlyneutralizing antibodies” are meant antibodies that neutralize more thanone HIV-1 virus species (from diverse clades and different strainswithin a clade) in a neutralization assay. A broad neutralizing antibodymay neutralize at least 2, 3, 4, 5, 6, 7, 8, 9 or more different strainsof HIV-1, the strains belonging to the same or different clades. Inparticular embodiments, a broad neutralizing antibody may neutralizemultiple HIV-1 species belonging to at least 2, 3, 4, 5, or 6 differentclades. In certain embodiments, the inhibitory concentration of themonoclonal antibody may be less than about 0.0001 μg/ml, less than about0.001 μg/ml, less than about 0.01 μg/ml, less than about 0.1 μg/ml, lessthan about 0.5 μg/ml, less than about 1.0 μg/ml, less than about 5μg/ml, less than about 10 μg/ml, less than about 25 μg/ml, less thanabout 50 μg/ml, or less than about 100 μg/ml to neutralize about 50% ofthe input virus in the neutralization assay.

HIV viruses are divided into specific groups, M, N, O and P, of which Mis the “major” group and responsible for majority of HIV/AIDS globally.Based on their genetic sequence, Group M is further subdivided intosubtypes (also called clades) with prevalence in distinct geographicallocations.

A Group M “subtype” or “clade” is a subtype of HIV-1 group M defined bygenetic sequence data. Examples of Group M subtypes include SubtypesA-K. Some of the subtypes are known to be more virulent or are resistantto different medications. There are also “circulating recombinant forms”or CRFs derived from recombination between viruses of differentsubtypes, which are each given a number. CRF12_BF, for example, is arecombination between subtypes B and F. Subtype A is common in WestAfrica. Subtype B is the dominant form in Europe, the Americas, Japan,Thailand, and Australia. Subtype C is the dominant form in SouthernAfrica, Eastern Africa, India, Nepal, and parts of China. Subtype D isgenerally only seen in Eastern and central Africa. Subtype E has neverbeen identified as a nonrecombinant, only recombined with subtype A asCRFO1_AE. Subtype F has been found in central Africa, South America andEastern Europe. Subtype G (and the CRFO2_AG) have been found in Africaand central Europe. Subtype H is limited to central Africa. Subtype Iwas originally used to describe a strain that is now accounted for asCRFO4_cpx, with the cpx for a “complex” recombination of severalsubtypes. Subtype J is primarily found in North, Central and WestAfrica, and the Caribbean Subtype K is limited to the DemocraticRepublic of Congo and Cameroon. These subtypes are sometimes furthersplit into sub-subtypes such as A1 and A2 or F, 1 and F2. In 2015, thestrain CRF19, a recombinant of subtype A, subtype D and subtype G, witha subtype D protease was found to be strongly associated with rapidprogression to AIDS in Cuba.

“HIV tropism” refers to the specificity of an HIV virus for a particularhost cell, determined in part by the interaction of viral surfacestructures with receptors present on the surface of the host cell. HIVtropism of a patient's virus may be measured by the Trofile assay.

HIV can infect a variety of cells such as CD4+ helper T cells andmacrophages that express the CD4 molecule on their surface. HIV-1 entryto macrophages and T helper cells is mediated not only throughinteraction of the virion envelope glycoprotein, (e.g., gp120) with theCD4 molecule on the target cells but also with its chemokinecoreceptors. Macrophage (M-tropic) strains of HIV-1, ornon-syncitia-inducing strains (NSI) use the beta-chemokine receptor CCR5for entry and are thus able to replicate in macrophages and CD4+T-cells. These strains are called R5 viruses. This CCR5 coreceptor isused by almost all primary HIV-1 isolates regardless of viral geneticsubtype. T-tropic isolates, or syncitia-inducing (SI) strains replicatein primary CD4+ T-cells as well as in macrophages and use thealpha-chemokine receptor, CSCR4, for entry. These strains are called X4viruses. Viruses that use only the CCR5 receptor are termed R5, thosethat only use CXCR4 are termed X4, and those that use both, X4R5 ordual/mixed-tropism. However, the use of a coreceptor alone does notexplain viral tropism, as not all R5 viruses are able to use CCR5 onmacrophages for a productive infection.

The present invention also relates to “non-neutralizing antibodies,”which in certain embodiments are antibodies that bind to one or morestrains of virus but do not neutralize the virus. However, in terms ofFc-mediated killing, the non-neutralizing antibody could still eliminatecells expressing viral antigens that are bound but not neutralized bythe antibody. Thus, in certain embodiments, an antibody of the inventioncan bind a viral antigen and eliminate virally infected cells withoutneutralizing the virus.

The term “nucleic acid molecule” refers to a polymeric form ofnucleotides and includes both sense and anti-sense strands of RNA, cDNA,genomic DNA, and synthetic forms and mixed polymers of the above. Inparticular embodiments, a nucleotide refers to a ribonucleotide,deoxynucleotide or a modified form of either type of nucleotide, andcombinations thereof. The terms also include, but is not limited to,single- and double-stranded forms of DNA. In addition, a polynucleotide,e.g., a cDNA or mRNA, may include either or both naturally occurring andmodified nucleotides linked together by naturally occurring and/ornon-naturally occurring nucleotide linkages. The nucleic acid moleculesmay be modified chemically or biochemically or may contain non-naturalor derivatized nucleotide bases, as will be readily appreciated by thoseof skill in the art. Such modifications include, for example, labels,methylation, substitution of one or more of the naturally occurringnucleotides with an analogue, internucleotide modifications such asuncharged linkages (e.g., methyl phosphonates, phosphotriesters,phosphoramidates, carbamates, etc.), charged linkages (e.g.,phosphorothioates, phosphorodithioates, etc.), pendent moieties (e.g.,polypeptides), intercalators (e.g., acridine, psoralen, etc.),chelators, alkylators, and modified linkages (e.g., alpha anomericnucleic acids, etc.). The above term is also intended to include anytopological conformation, including single-stranded, double-stranded,partially duplexed, triplex, hairpinned, circular and padlockedconformations. A reference to a nucleic acid sequence encompasses itscomplement unless otherwise specified. Thus, a reference to a nucleicacid molecule having a particular sequence should be understood toencompass its complementary strand, with its complementary sequence. Theterm also includes codon-optimized nucleic acids.

The term “operably linked” refers to two or more nucleic acid sequenceelements that are usually physically linked and are in a functionalrelationship with each other. For instance, a promoter is operablylinked to a coding sequence if the promoter is able to initiate orregulate the transcription or expression of a coding sequence, in whichcase, the coding sequence should be understood as being “under thecontrol of” the promoter.

A “substitution,” as used herein, denotes the replacement of one or moreamino acids or nucleotides by different amino acids or nucleotides,respectively.

An “isolated” nucleic acid refers to a nucleic acid molecule that hasbeen separated from a component of its natural environment. An isolatednucleic acid includes a nucleic acid molecule contained in cells thatordinarily contain the nucleic acid molecule, but the nucleic acidmolecule is present extrachromosomally or at a chromosomal location thatis different from its natural chromosomal location.

“Isolated nucleic acid encoding an antibody or fragment thereof” refersto one or more nucleic acid molecules encoding antibody heavy and lightchains (or fragments thereof), including such nucleic acid molecule(s)in a single vector or separate vectors, and such nucleic acidmolecule(s) present at one or more locations in a host cell.

The term “vector,” as used herein, refers to a nucleic acid moleculecapable of propagating another nucleic acid to which it is linked. Theterm includes the vector as a self-replicating nucleic acid structure aswell as the vector incorporated into the genome of a host cell intowhich it has been introduced. Certain vectors are capable of directingthe expression of nucleic acids to which they are operatively linked.Such vectors are referred to herein as “expression vectors.”

The terms “host cell,” “host cell line,” and “host cell culture” areused interchangeably and refer to cells into which exogenous nucleicacid has been introduced, including the progeny of such cells. Hostcells include “transformants” and “transformed cells,” which include theprimary transformed cell and progeny derived therefrom without regard tothe number of passages. Progeny may not be completely identical innucleic acid content to a parent cell, but may contain mutations. Mutantprogeny that have the same function or biological activity as screenedor selected for in the originally transformed cell are included herein.

A polynucleotide “variant,” as the term is used herein, is apolynucleotide that typically differs from a polynucleotide specificallydisclosed herein in one or more substitutions, deletions, additionsand/or insertions. Such variants may be naturally occurring or may besynthetically generated, for example, by modifying one or more of thepolynucleotide sequences of the invention and evaluating one or morebiological activities of the encoded polypeptide as described hereinand/or using any of a number of techniques well known in the art.

A polypeptide “variant,” as the term is used herein, is a polypeptidethat typically differs from a polypeptide specifically disclosed hereinin one or more substitutions, deletions, additions and/or insertions.Such variants may be naturally occurring or may be syntheticallygenerated, for example, by modifying one or more of the abovepolypeptide sequences of the invention and evaluating one or morebiological activities of the polypeptide as described herein and/orusing any of a number of techniques well known in the art.

The term “variant” may also refer to any naturally occurring orengineered molecule comprising one or more nucleotide or amino acidmutations. In one embodiment, the molecule is an antibody. For example,somatic variants may encompass all related naturally occurringantibodies that are part of or derived from the same B-cell lineage.Engineered variants may encompass all single mutations or combinatorialmutations made to an antibody.

The terms “PGT121,” “PGT-121,” “PGT121 WT,” “PGT-121 WT,” “PGT121-WT,”“PGT121.WT,” “PGT121.1,” “PGT121 L06,” “PGT121 L06,” “PGT121 L06 WT,”“PGT121 LO6 WT” or the like are used interchangeably herein and refer toan antibody comprising a heavy chain and a light chain, wherein theheavy chain having an amino acid sequence as set forth in SEQ ID NO:190, and the light chain having an amino acid sequence as set forth inSEQ ID NO: 276 Modifications may be made in the structure of thepolynucleotides and polypeptides of the present invention and stillobtain a functional molecule that encodes a variant or derivativepolypeptide with desirable characteristics. When it is desired to alterthe amino acid sequence of a polypeptide to create an equivalent, oreven an improved, variant or portion of a polypeptide of the invention,one skilled in the art will typically change one or more of the codonsof the encoding DNA sequence.

For example, certain amino acids may be substituted for other aminoacids in a protein structure without appreciable loss of its ability tobind other polypeptides (e.g., antigens) or cells. Since it is thebinding capacity and nature of a protein that defines that protein'sbiological functional activity, certain amino acid sequencesubstitutions can be made in a protein sequence, and, of course, itsunderlying DNA coding sequence, and nevertheless obtain a protein withlike properties. It is thus contemplated that various changes may bemade in the polypeptide sequences of the disclosed antibodies andantigen-binding fragments thereof, or corresponding DNA sequences thatencode said polypeptides without appreciable loss of their biologicalutility or activity.

In many instances, a polypeptide variant will contain one or moreconservative substitutions. A “conservative substitution” is one inwhich an amino acid is substituted for another amino acid that hassimilar properties, such that one skilled in the art of peptidechemistry would expect the secondary structure and hydropathic nature ofthe polypeptide to be substantially unchanged.

When comparing polynucleotide and polypeptide sequences, two sequencesare said to be “identical” if the sequence of nucleotides or amino acidsin the two sequences is the same when aligned for maximumcorrespondence, as described below. Comparisons between two sequencesare typically performed by comparing the sequences over a comparisonwindow to identify and compare local regions of sequence similarity. A“comparison window” as used herein, refers to a segment of at leastabout 20 contiguous positions, usually 30 to about 75, 40 to about 50,in which a sequence may be compared to a reference sequence of the samenumber of contiguous positions after the two sequences are optimallyaligned.

Optimal alignment of sequences for comparison may be conducted using theMegalign program in the Lasergene suite of bioinformatics software(DNASTAR, Inc., Madison, Wis.), using default parameters. This programembodies several alignment schemes described in the followingreferences: Dayhoff, M. O. (1978) A model of evolutionary change inproteins—Matrices for detecting distant relationships. In Dayhoff, M. O.(ed.) Atlas of Protein Sequence and Structure, National BiomedicalResearch Foundation, Washington D.C. Vol. 5, Suppl. 3, pp. 345-358; HeinJ. (1990) Unified Approach to Alignment and Phylogenes pp. 626-645Methods in Enzymology vol. 183, Academic Press, Inc., San Diego, Calif.;Higgins, D. G. and Sharp, P. M. (1989) CABIOS 5: 151-153; Myers, E. W.and Muller W. (1988) CABIOS 4:11-17; Robinson, E. D. (1971) Comb. Theor77: 105; Santou, N. Nes, M. (1987) Mol. Biol. Evol. 4:406-425; Sneath,P. H. A. and Sokal, R. R. (1973) Numerical Taxonomy—the Principles andPractice of Numerical Taxonomy, Freeman Press, San Francisco, Calif.;Wilbur, W. J. and Lipman, D. J. (1983) Proc. Natl. Acad., Sci. USA80:726-730.

Alternatively, optimal alignment of sequences for comparison may beconducted by the local identity algorithm of Smith and Waterman (1981)Add. APL. Math 2:482, by the identity alignment algorithm of Needlemanand Wunsch (1970) J. Mol. Biol. 48:443, by the search for similaritymethods of Pearson and Lipman (1988) Proc. Natl. Acad. Sci. USA 85:2444, by computerized implementations of these algorithms (GAP, BESTFIT,BLAST, FASTA, and TFASTA in the Wisconsin Genetics Software Package,Genetics Computer Group (GCG), 575 Science Dr., Madison, Wis.), or byinspection.

One example of algorithms that are suitable for determining percentsequence identity and sequence similarity are the BLAST and BLAST 2.0algorithms, which are described in Altschul et al. (1977) Nucl. AcidsRes. 25:3389-3402 and Altschul et al. (1990) J. Mol. Biol. 215:403-410,respectively. BLAST and BLAST 2.0 can be used, for example with theparameters described herein, to determine percent sequence identity forthe polynucleotides and polypeptides of the invention. Software forperforming BLAST analyses is publicly available through the NationalCenter for Biotechnology Information.

In one illustrative example, cumulative scores can be calculated using,for nucleotide sequences, the parameters M (reward score for a pair ofmatching residues; always >0) and N (penalty score for mismatchingresidues; always <0). Extension of the word hits in each direction arehalted when: the cumulative alignment score falls off by the quantity Xfrom its maximum achieved value; the cumulative score goes to zero orbelow, due to the accumulation of one or more negative-scoring residuealignments; or the end of either sequence is reached. The BLASTalgorithm parameters W, T and X determine the sensitivity and speed ofthe alignment. The BLASTN program (for nucleotide sequences) uses asdefaults a word length (W) of 11, and expectation (E) of 10, and theBLOSUM62 scoring matrix (see Henikoff and Henikoff (1989) Proc. Natl.Acad. Sci. USA 89: 10915) alignments, (B) of 50, expectation (E) of 10,M=5, N=−4 and a comparison of both strands.

For amino acid sequences, a scoring matrix can be used to calculate thecumulative score. Extension of the word hits in each direction arehalted when: the cumulative alignment score falls off by the quantity Xfrom its maximum achieved value; the cumulative score goes to zero orbelow, due to the accumulation of one or more negative-scoring residuealignments; or the end of either sequence is reached. The BLASTalgorithm parameters W, T and X determine the sensitivity and speed ofthe alignment.

In one approach, the “percentage of sequence identity” is determined bycomparing two optimally aligned sequences over a window of comparison ofat least 20 positions, wherein the portion of the polynucleotide orpolypeptide sequence in the comparison window may comprise additions ordeletions (i.e., gaps) of 20 percent or less, usually 5 to 15 percent,or 10 to 12 percent, as compared to the reference sequences (which doesnot comprise additions or deletions) for optimal alignment of the twosequences. The percentage is calculated by determining the number ofpositions at which the identical nucleic acid bases or amino acidresidues occur in both sequences to yield the number of matchedpositions, dividing the number of matched positions by the total numberof positions in the reference sequence (i.e., the window size) andmultiplying the results by 100 to yield the percentage of sequenceidentity.

“Homology” refers to the percentage of residues in the polynucleotide orpolypeptide sequence variant that are identical to the non-variantsequence after aligning the sequences and introducing gaps, ifnecessary, to achieve the maximum percent homology.

“Developability” refers to the intrinsic chemical and biophysicalproperties of an antibody that make it suitable for commercialmanufacturing and therapeutic use. These properties may include thermalstability (e.g. melting temperature), low pH stability (e.g. duringviral inactivation procedures required during GMP production),solubility, viscosity, product homogeneity and chemical stability (e.g.oxidation, deamidation, isomerization, cleavage, glycosylation,glycation, hydroxylation).

“Binding affinity” may refer to a binding dissociate constant (Kd) or anapparent affinity (e.g., EC50) value.

“Percent aggregation” may refer to a percent loss of soluble proteinmonomer as determined by SEC. Thus, a percent change in monomer contentwith a negative value would indicate a loss of monomer and an increasein aggregation, while a percent change in monomer content with apositive value would indicate an increase in monomer and a correspondingdecrease in aggregation.

Antibodies and Antigen-Binding Fragments Thereof, Nucleic Acids, Vectorsand Host Cells

The present invention includes novel antibodies and antigen-bindingfragments thereof. In certain embodiments, these antibodies andantigen-binding fragments thereof bind to and neutralize HIV-1, e.g.,cell-free HIV-1 virus. In certain embodiments, these antibodies andantigen-binding fragments thereof bind to HIV-1 antigens expressed on acell surface and eliminate or kill the cell. In various embodiments, theantibodies activate effector cells, e.g., T cells expressing FcγRIIA. Incertain embodiments, the Fc domain of the antibodies binds FCγRsexpressed on innate immune cells. In particular embodiments, they inducenatural killer (NK) cell-mediated antibody-dependent cell killing ofHIV-1 infected cells, e.g., via antibody dependent cellular cytotoxicity(ADCC). In particular embodiments, they induce monocyte- and peripheralblood mononuclear cell (PBMC)-mediated antibody-dependent cell killing,e.g., via antibody-dependent cellular phagocytosis (ADCP) and/orgranzyme- and perforin-mediated cytotoxicity or ADCC.

In particular embodiments, antibodies and antigen-binding fragmentsthereof of the present invention are related to the antibody previouslydescribed as PGT-121 LO6 in PCT Application Publication No.WO2012/030904. In certain embodiments, the antibodies andantigen-binding fragments thereof comprise the six CDRs present in thePGT-121 LO6 antibody, as defined by one or more of the Kabat, IMGT, orChothia antibody numbering schemes. In certain embodiments, theantibodies and antigen-binding fragments thereof comprise at least one,at least two, at least three, at least four, or at least five of theCDRs present in the PGT-121 LO6 antibody. The PGT-121 LO6 CDRs areprovided in Table 1. In particular embodiments, the present inventionincludes a light chain (or antigen-binding fragment thereof) or a heavychain (or antigen-binding fragment thereof) of an antibody of thepresent invention. In particular embodiments, an antibody of the presentinvention or antigen-binding fragment thereof is not the PGT-121 LO6antibody or an antigen-binding fragment thereof.

In particular embodiments, antibodies and antigen-binding fragmentsthereof of the present invention are related to any of the variants orderivatives of PGT-121 LO6 described herein, e.g., having sequencesshown in Table 1. In certain embodiments, the antibodies andantigen-binding fragments thereof comprise six CDRs present in any ofthe antibodies shown in Table 1, as defined by one or more of the Kabat,IMGT, or Chothia antibody numbering schemes. In certain embodiments, theantibodies and antigen-binding fragments thereof comprise at least one,at least two, at least three, at least four, or at least five of theCDRs present in any of the antibodies provided in Table 1.

In particular embodiments, the antibodies and antigen-binding fragmentsthereof comprise a CDR, heavy chain and/or a light chain comprising oneor more amino acid modification, e.g., insertion, deletion orsubstitution, as compared to PGT-121 L06. In various embodiments, theone or more amino acid modification imparts one or more improvedproperties, (e.g., therapeutic properties) to the antibody orantigen-binding fragment thereof as compared to the PGT-121 LO6antibody. Without limitation, particular embodiments of the one or moreamino acid modifications provide the antibody or antigen-bindingfragment thereof with superior pharmacokinetic properties, increasedserum stability (e.g., increased serum half-life), increased C_(max),increased binding affinity, increased effector function, increasedneutralization of HIV-1, reduced immunogenicity, and/or increasedefficiency or ease of manufacture, as compared to PGT-121 L06. Invarious embodiments, the one or more amino acid modifications impartimproved developability (e.g., increased Tm, increased stability duringlow pH viral inactivation procedures, and/or removal of heterogeneousN-linked glycans). In various embodiments, the one or more amino acidmodifications impart reduced immunogenicity (e.g., reduction in ex vivoT-cell activation donor response rate) through removal (e.g., throughsite directed mutagenesis) of experimentally identified T-cell epitopes.Without limitation, particular embodiments of the one or more amino acidmodifications provide the antibody or antigen-binding fragment thereofwith superior pharmacokinetic properties, increased serum stability(e.g., increased serum half-life), increased C_(max), increased bindingaffinity, increased effector function, increased neutralization ofHIV-1, reduced immunogenicity, and/or increased efficiency or ease ofmanufacture, as compared to PGT-121 L06. In various embodiments themutations introduced to enhance any of the properties listed above(e.g., reduced immunogenicity, enhanced therapeutic properties and/orantigen binding, or enhanced developability properties) may lie in theCDR regions, the framework regions or in framework regions predicted tointeract directly with antigen (e.g., framework regions that arefunctionally equivalent to CDRs).

Crystal structure and experimental analysis of an antibody highlyrelated to the PGT-121 LO6 antibody (i.e., PGT-122) revealed that itutilizes amino acid residues outside of the CDRs to bind antigen(together with the CDRs). For example, this antibody appears to haveadditional regions in the framework region that contact antigens (see,e.g., Experimental Validation for PGT121 and related antibodies: Sok etal. 2013. PLOS Pathogens 9, e1003754). High resolution structures ofPGT122 bound to the Env viral antigen have been determined (see, e.g.,Julien, J. P. et al, 2013, Science 342, 14777-14783 and Pancera, M. etal., 2014, Nature 514, 455-461). The structure of PGT121 is described inJulien J P et al. 2013, PLOS Pathogens 9, e1003342 and Mouquet H et al.2012, PNAS 109, E3268-E3277. The structure of PGT122 is described inJulien J P et al. 2013. PLOS Pathogens 9, e1003342. PDB ID 4JY5; and thestructure of PGT123 is described in Julien J P et al. 2013, PLOSPathogens 9, e1003342. The PGT122 and PGT123 antibodies are closelyrelated to the PGT121 antibody, so the PGT122/Env structure, togetherwith knowledge of the PGT121, PGT122 and PGT123 structures, can be usedto model the structure of PGT121 bound to Env very accurately andpredict with high confidence the residues of PGT121 involved in bindingto Env. The predicted PGT121 contact residues based on similarity toPGT122 and the PGT122/Env structure (Kabat numbering) are provided belowwith framework residues shown in bold:

HC (Kabat #): 33, 56, 58, 99, 100, 100A, 100B, 100C, 100D, 100E, 100G,100I, 100J, 100K, 100L; and

LC (Kabat #): 28, 29, 30, 50, 51, 52, 66, 67, 67A, 67C, 91, 92, 93, 94,95, 95A, 95B.

In addition, the PGT-121 LO6 antibody has been shown to bind to manydifferent variants of antigen, e.g., different viral strains, which maycontact the antibody at unknown amino acid positions in addition tothose listed above. Different viral strains have different Env (i.e.,antigen) sequences and different glycosylation patterns, and even asingle Env sequence can have heterogeneous glycosylation patterns,requiring a broadly binding or neutralizing antibody to recognize Envproteins of different HIV-1 variants or even different glycosylationpatterns on the same Env protein. For example, the epitope of PGT121 iscomprised of the Env V3 loop, in particular an N-linked glycan atposition N332. The V3 loop is the major determinant of cellular tropismand viral clade. Among 117 CCR5-tropic viruses of multiple clades, thepresence of a potential N-linked glycosylation (PNG) motif in the viralDNA sequence encoding for the N332 glycan was statisticallysignificantly associated with susceptibility to neutralization by PGT121amongst viruses of clades B, G, A, AC and AE. Among 50 clade B Envsequences isolated from patients participating in Gilead-sponsoredclinical trials, 94% of CCR5-tropic Envs harboring the N332 PNG motifwere susceptible to neutralization by PGT121 compared to only 26% ofviruses that were not CCR5-tropic, N332 PNG positive (P<0.0001). Thus,genetic determination of Env clade, tropism and presence of the N332 PNGmotif is highly predictive of neutralization susceptibility by PGT121and may be useful as a marker to predict viral susceptibility toneutralization by PGT121 and its derivatives.

Nevertheless, given the diversity in the amino acid sequences of thedifferent antigen variants, it may be difficult to predict which aminoacid residues in the antibody variable regions are required for bindingto the various antigen variants, and may also, therefore, be difficultor impossible to predict a priori exactly which amino acid residues ofthe antibody could be altered to impart improved properties to theantibody, e.g., reduced glycosylation, reduced immunogenicity, reducedisomerization, enhanced effector function, enhanced neutralizingactivity, or enhanced recombinant production. The present inventionrelates to the identification of particular amino acid modifications,and combinations thereof, that effectively enhance the therapeuticproperties of the claimed antibodies and antigen-binding fragmentsthereof, without substantially impacting their ability to bind multipleantigen variants and, in certain embodiments, their related broadlyneutralizing properties. In certain embodiments, antibodies of thepresent invention are neutralizing antibodies, e.g., broadlyneutralizing antibodies, while in other embodiments, antibodies of thepresent invention are non-neutralizing antibodies capable of eliminatingcells expressing viral antigens that are bound but not neutralized bythe antibodies.

In particular embodiments, an antibody or antigen-binding fragment ofthe present invention has better serum pharmacokinetics (e.g., increasedserum half-life) as compared to the PGT-121 LO6 antibody, e.g.,following administration to a mammal. In other embodiments, an antibodyor antigen-binding fragment of the present invention has comparableserum pharmacokinetics (e.g., increased serum half-life) as compared tothe PGT-121 LO6 antibody. In particular embodiments of the currentinvention, the serum pharmacokinetics (e.g., area underconcentration-time curve (AUC), clearance (CL), volume (V), half-life(t_(1/2)), maximum concentration (C_(max)), or minimum concentration(C_(min))) are determined from the measured serum levels of the antibodyat various time points following administration to test subjects. Assaysto measure serum antibody levels and methods to calculate the resultingpharmacokinetics are known in the art. Amounts of the antibody presentin the serum may be determined by standard techniques, such as LC-MS/MS,ELISA, SPR, BLI, ECL (MSD), alpha-LISA or HTRF, e.g., ELISA usingrecombinant gp120 protein as described in Example 3 of PCT ApplicationPublication No. WO2012/040904. In certain embodiments the antibody serumconcentrations may be determined by capturing using recombinant BALgp120 or SHIV gp140 and detected with an anti-human IgG₁ conjugateemploying electrochemilluminescence (ECL) detection with the Meso ScaleDiscovery (MSD) platform. Pharmacokinetics can be determined usingstandard non- or multi-compartmental pharmacokinetic analysis from theresulting antibody serum concentration-time profiles. In certainembodiments, an antibody or antigen-binding fragment of the presentinvention has unchanged, or improved pharmacokinetics, as compared tothe PGT121 LO6 antibody following administration to mammals (e.g.,humans, rats or monkeys). Improved pharmacokinetics is defined by eitherincreased exposure (AUC), reduced clearance, and increased half-life,increased C_(max), or increased C_(min). In certain embodiments, thepharmacokinetics are improved by at least 0%, 10%, at least 20%, atleast 30%, at least 40%, at least 50%, at least 60%, at least 70%, atleast 80%, at least 90%, at least 100%, at least 150%, at least 200%, atleast 300%, at least 400%, at least 500%, or at least 1000%.

In certain embodiments, an antibody or antigen-binding fragment of thepresent invention has increased serum stability (e.g., increased serumhalf-life) as compared to the PGT-121 LO6 antibody, e.g., followingadministration to a mammal. Assays to measure serum stability orantibody half-life are known in the art. In one embodiments, serumstability or serum half-life may be determined by measuring serum levelsof the antibody at various time points following administration to asubject, e.g., a human or test animal. Amounts of the antibody presentin the serum may be determined by standard techniques, such as LC-MS/MS,ELISA, SPR, BLI, ECL (MSD), alpha-LISA or HTRF, e.g., ELISA usingrecombinant gp120 protein as described in WO 2012/040904. In someembodiments, the serum stability or serum half-life may be increased byat least 10%, at least 20%, at least 30%, at least 40%, at least 50%, atleast 60%, at least 70%, at least 80%, at least 90%, at least 100%, atleast 150%, at least 200%, at least 300%, at least 400%, at least 500%,or at least 1000%. In certain embodiments, the antibodies orantigen-binding fragments thereof of the present invention have a serumhalf-life of at least 30 min, at least 1 hour, at least 4 hours, atleast 8 hours, at least 12 hours, at least 16 hours, at least 24 hours,at least 2 days, at least 3 days, at least 4 days, at least 5 days, atleast one week, at least two weeks, at least three weeks, at least fourweeks, or at least two months. In some embodiments, the antibodies orantigen-binding fragments thereof of the present invention may haveincreased serum stability as compared to the PGT-121 LO6 antibody atabout 4° C., at about 5° C., at about 10° C., at about 15° C., at about20° C., at about 25° C., at about 30° C., at about 37° C., or more.

In certain embodiments, an antibody or antigen-binding fragment of thepresent invention has equal or increased or greater antigen bindingaffinity as compared to the PGT-121 LO6 antibody, e.g., to at least onestrain of HIV. In particular embodiments, the antigen is the completemembrane bound HIV Env trimer expressed on either a cellular surface orviral envelope, the soluble gp140 fragment of Env, the soluble gp120fragment of Env, or any smaller sub-domain or engineered portion of Envcontaining all necessary epitope determining residues and structuresneeded for PGT121 binding, from any of the HIV-1 strains describedherein. Binding affinity may be readily determined using an assay knownand available in the art, such as ELISA, SPR, BLI or flow cytometry.

In particular embodiments, apparent binding affinity is determined bystandard techniques, such as ELISA, e.g., using recombinant gp120 orgp140 protein as described in Example 3 of PCT Application PublicationNo. WO2012/030904, or as described herein. In certain embodiments, thebinding affinity to at least one HIV strain is increased, e.g., by atleast 0%, 10%, at least 20%, at least 30%, at least 40%, at least 50%,at least 60%, at least 70%, at least 80%, at least 90%, at least 100%,at least 150%, at least 200%, at least 300%, at least 400%, at least500%, at least 1000%, at least 1500%, at least 2000%, at least 2500%, atleast 3000%, at least 5000%, or at least 10,000%. In certainembodiments, the one or more strain includes BaL, TRO, SHIV, SF162 P3,pRHPA4259, qh0692, 6535, pCAAN5342, pWITO4160, AC10.0, US92HT593, orU92US657. In some embodiments, the one or more strain includes BaL, TRO,SHIV SF162 P3, pRHPA4259, qh0692, 6535, pCAAN5342, pWITO4160, AC10.0,US92HT593, or U92US657. In particular embodiments, antibodies andfragments thereof of the present invention bind to HIV gp120 BaL with anEC50 of <20.0 nM, <10 nM, or <1 nM as determined in direct ELISA assayas described herein. In certain embodiments, antibodies and fragmentsthereof of the present invention bind to HIV gp120 BaL, gp140 BaL, gp140SHIV SF162P3, or gp120 TRO with ELISA EC50 values lower, e.g., 2-fold,1.6-fold, 1.4-fold, 1.2-fold, 1-fold, 0.8-fold, 0.6-fold lower thanPGT121 L06. In certain embodiments, antibodies and fragments thereof ofthe present invention bind to HIV gp120 BaL, gp120 pRHPA4259, gp120qh0692, gp120 6535, gp120 pCAAN5342, gp120 pWITO4160, or gp120 AC10.0with ELISA EC50 values 3-fold, 2.5-fold, 2-fold, 1.5-fold, 1-fold, or0.5-fold lower than for PGT121 L06.

In other embodiments, binding affinity is determined by FACS using humancell lines expressing recombinant HIV Env. The one or more strainincludes BaL, US657, HT593 or SHIV SF162 P3. In particular embodiments,the binding affinity to at least one strain is increased, e.g., by atleast 10%, at least 20%, at least 30%, at least 40%, at least 50%, atleast 60%, at least 70%, at least 80%, at least 90%, at least 100%, atleast 150%, at least 200%, at least 300%, at least 400%, at least 500%,at least 1000%, at least 1500%, at least 2000%, at least 2500%, at least3000%, at least 5000%, or at least 10,000%. In certain embodiments,antibodies and fragments thereof of the present invention bind to an HIVEnv of at least one strain with an IC50 of <1.0 nM or <0.8 nM asdetermined by ELISA. In certain embodiments, antibodies and fragmentsthereof of the present invention bind to an HIV Env of at least onestrain with an IC50 as determined by ELISA of about 0.1 uM to about 10nM or about 0.1 uM to about 20 nM. In certain embodiments, antibodiesand fragments thereof of the present invention bind to an HIV gp120(BaL) of at least one strain with an EC50 of <20 nM, <10 nM, <5 nM, <2nM, <1 nM, <0.5 nM, <0.2 nM or <0.1 nM. In particular embodiments, theat least one strain comprises two or more, three or more, four or more,or five or more strains, e.g., any of those described herein.

In particular embodiments, an antibody or antigen binding fragment ofthe present invention has increased binding affinity to FcγR as comparedto the PGT-121 LO6 antibody. Binding affinity may be readily determinedusing an assay known and available in the art, such as ELISA, SPR orBLI. In particular embodiments, binding affinity is determined bystandard techniques, such as ELISA, e.g., as described herein. Inparticular embodiments, the binding affinity is increased, e.g., by atleast 10%, at least 20%, at least 30%, at least 40%, at least 50%, atleast 60%, at least 70%, at least 80%, at least 90%, at least 100%, atleast 150%, at least 200%, at least 300%, at least 400%, at least 500%,at least 1000%, at least 20-fold, at least 30-fold, at least 50-fold, atleast 100-fold, or at least 1000-fold. In certain embodiments,antibodies or fragments thereof of the present invention bind to any ofhuman FcγRI, human FcγRIIA-167H, human FcγRIIA-167R, human FcγRIIB,human FcγRIIIA-176V, human FcγRIII-176F, human FcγRIIIB-NA1, humanFcγRIIIB-NA2, human FcRn at pH 7.0, or human FcRn at pH 6.0 with any ofthe following EC50s as determined by ELISA: <0.1 nM, <0.2 nM, <0.3 nM,<0.5 nM, <1.0 nM, <1.5 nM, <2.0 nM, <2.5 nM, <3.0 nM, <3.5 nM, <5 nM,<10 nM, <20 nM, <25 nM, <30 nM, >40 nM, <50 nM, <100 nM, <200 nM, <250nM, <500 nM, <1 μM, <2<5 or greater than or equal to 10 μM. Inparticular embodiments, antibodies or fragments thereof of the presentinvention bind to human FcγRI with an EC50 between 0.1 and 1 μM. Inparticular embodiments, antibodies or fragments thereof of the presentinvention bind to human FcγRIIIA-176F with an EC50 between 0.1 and 10nM. In particular embodiments, antibodies or fragments thereof of thepresent invention bind to human FcγRIIIA-176V with an EC50 between 1 and0.1 nM. In particular embodiments, antibodies or fragments thereof ofthe present invention bind to human FcγRIIA-167H with an EC50 between100 and 1 nM. In particular embodiments, antibodies or fragments thereofof the present invention bind to human FcγRIIA-167R with an EC50 between50 and 1 nM. In particular embodiments, antibodies or fragments thereofof the present invention bind to human FcγRIIB with an EC50 between 1 μMand 10 nM. In particular embodiments, antibodies or fragments thereof ofthe present invention bind to human FcγRIIIB-NA1 with an EC50 between 1nM and 50 nM. In particular embodiments, antibodies or fragments thereofof the present invention bind to human FcγRIIIB-NA2 with an EC50 between1 nM and 50 nM. In certain embodiments, antibodies or fragments thereofof the present invention bind to human FcγRI with an EC50 between0.5-fold and 1.5 fold of the EC50 determined for PGT121 L06. Inparticular embodiments, antibodies or fragments thereof of the presentinvention bind to human FcγRI with an EC50 that is unchanged compared toPGT121 L06. In certain embodiments, antibodies or fragments thereof ofthe present invention bind to human FcγRIIIA-176F with an EC50 0.5-fold,2-fold, 4-fold, 10-fold, 15-fold, 20-fold, 50-fold, or 100-fold lowerthan that determined for PGT121 L06. In particular embodiments,antibodies or fragments thereof of the present invention bind to humanFcγRIIIA-176F with an ELISA EC50 that is between 10- and 20-fold lowerthan PGT121 L06.

In particular embodiments, an antibody or antigen binding fragment ofthe present invention has increased binding affinity to FcRn at pH 6.0when compared to the PGT-121 LO6 antibody. In certain embodiments, anantibody or antigen binding fragment of the present invention hasincreased binding affinity to FcRn at pH 6.0 and decreased or similarbinding at pH 7.4 or pH 7.0 when compared to the PGT-121 LO6 antibody.Binding affinity may be readily determined using an assay known andavailable in the art, such as ELISA, SPR or BLI. In particularembodiments, binding affinity is determined by standard techniques, suchas ELISA, e.g., as described herein. In particular embodiments, thebinding affinity to FcRn is increased, e.g., by at least 10%, at least20%, at least 30%, at least 40%, at least 50%, at least 60%, at least70%, at least 80%, at least 90%, at least 100%, at least 150%, at least200%, at least 300%, at least 400%, at least 500%, at least 1000%, atleast 20-fold, at least 30-fold, at least 50-fold, at least 100-fold, orat least 1000-fold. In certain embodiments, antibodies or fragmentsthereof of the present invention bind to human FcRn pH 6.0: <10 nM, <2.0nM or <1.0 nM. In certain embodiments, antibodies or fragments thereofof the present invention bind to human FcRn at pH 7.0 with any of thefollowing EC50s as determined by ELISA: <0.1 nM, <0.2 nM, <0.3 nM, <0.5nM, <1.0 nM, <1.5 nM, <2.0 nM, <2.5 nM, <3.0 nM, <3.5 nM, <5 nM, <10 nM,<20 nM, <25 nM, <30 nM, <40 nM, <50 nM, <100 nM, <200 nM, <250 nM, <500nM, <1 μM, <2 μM, <5 μM, <10 μM, <50 μM, <100 μM, or greater than orequal to 100 μM.

The manufacturing process for biotherapeutics requires a viralinactivation (VI) procedure, designed as a safety measure to remove anypotential viral contaminants that could be present in the cell cultureprocess used to produce the antibody. This VI procedure is typicallyaccomplished by holding the purified antibody solution at a low pH(often at or near a pH of 3.5) for an extended time (often 1-3 hours).Certain antibodies are known to form either soluble or insolubleaggregates during this process (10-20% or greater aggregate content),making them unfit for manufacturing. Thus, the stability of an antibodyat low pH (e.g., pH 3.5) is a critical manufacturing attribute, andimprovement of low pH stability can enable manufacturing and productionof certain antibodies for therapeutic use.

In certain embodiments, an antibody or antigen binding fragment of thepresent invention has increased stability at low pH as measured by %aggregation, i.e., it shows reduced aggregation when stored at a low pH,e.g., pH 3.5 in various antibody storage and elution buffers whencompared to PGT121 L06. In particular embodiments, it shows less than80%, less than 50%, less than 10% aggregation when held at pH 3.5 for 1h. In particular embodiments, it shows less than 10%, less than 5%, lessthan 2%, or less than 1%, or 0% measurable aggregation when held at pH3.5 for 1 hour. In particular embodiments it shows an improvement inmonomer content (ie a reduction in aggregate content) of 1%, 2%, 5% or10% when held at pH 3.5 for 1 h.

In certain embodiments, an antibody or antigen-binding fragment of thepresent invention has increased or greater effector function as comparedto the PGT-121 LO6 antibody. In particular embodiments, the effectorfunction is increased, e.g., by at least 1%, at least 2%, at least 3%,at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, atleast 50%, at least 60%, at least 70%, at least 80%, at least 90%, atleast 100%, at least 150%, at least 200%, at least 300%, at least 400%,at least 500%, at least 1000%, at least 1.5-fold, at least 2-fold, atleast 3-fold, at least 5-fold, at least 10-fold, at least 20-fold, atleast 30-fold, at least 50-fold, at least 100-fold, at least 1000-fold,or at least 10,000-fold. In particular embodiments, the effectorfunction is ADCC, while in other embodiments, the effector function isADCP. In particular embodiments, effector function of an antibody orantigen-binding fragment of the present invention ranges from noresponse (below limit of detection) observed at 100 μg/ml (˜667 nM) to apotency in the 0.1 nM-1 μM range or the 0.1 nM-1 nM range.

Effector function may be measured using assays known or available in theart, including, e.g., those described in the accompanying Examples. Incertain embodiments, ADCC is measured in an ex vivo ADCC reporter assayusing engineered cells, such as donor cell infected with various strainsof HIV; and ADCP is measure in an ex vivo ADCP assay using donor cellsinfected with various strains of HIV. In certain embodiments, ADCC ismeasured in an in vitro ADCCassay using primary NK effector cells fromhealthy donors and engineered CD4+ luciferase reporter T cell lineinfected with various strains of HIV; and ADCP is measure in an in vitroADCP assay using donor cells infected with various strains of HIV. Incertain embodiments, antibody-dependent effector cell activation isdetermined using cells, e.g., T cells, expressing human FcγRIIIA coupledto an NFAT-linked reporter gene Env expressing cells. In certainembodiments, antibody-dependent effector cell activation is determinedusing engineered cells, e.g., T cells, expressing human FcγRIIIA coupledto an NFAT-linked reporter gene co-cultured with HIV Env expressingcells. In particular embodiments, ADCC is determined in a cell-basedassay using HIV-1-infected primary CD4+ T cells and autologous effectorNK cells from healthy donors, which express FcγRIIIA and mediateantibody-mediated killing of infected cells via granzyme- andperforin-mediated cytotoxicity (ADCC), e.g., as described in theaccompanying Examples. On certain embodiments, monocyte- andPBMC-mediated antibody-dependent cell killing is determined usingHIV-1-infected CD4+ T cells as target cells and primary autologous PBMCsor isolated monocytes as effector cells, e.g., as described in theaccompanying Examples,

In certain embodiments, an antibody or antigen-binding fragment of thepresent invention shows increased or greater neutralization of HIV-1 ascompared to the PGT-121 LO6 antibody. Neutralization may be determinedusing techniques known in the art. In particular embodiments, the HIV-1is one particular strain, e.g., any of the strains described herein,e.g., an HIV subtype B isolate. In particular embodiments,neutralization is determined for a plurality of different strains, e.g.,as an average over several or many different strains. For example,neutralization activity may be determined against a virus or a panel ofviruses using the CEM-NKr-CCR5-LucR (modified CD4 T-cell line) or theJC53-BL (also called TZM-b1, modified HeLa cell-line) luciferasereporter cell-based infectivity assays (Li et al, 2005 JVir, 79(16),10108-25). The assays may be run as single or multicycle viralreplication assays depending on the virus used (pseudotyped orreplication competent virus). Alternately neutralization activity may bedetermined using the U87.CCR5.CXCR4 cell line (modified CD4 T cell line)based infectivity assay using recombinant luciferase reporter virusespseudotyped with patient HIV envelope proteins (Richman et al, 2003PNAS, 100 (7), 4144-9). Examples of viruses that may be used include,but are not limited to, the lab adapted HIV-1 BaL strain and subtype Bclinical isolates 93HT593, 92US657, 92US712 and 92US727 (NIH AIDSReagent Program). In certain embodiments, neutralization is measured asdescribed in Example 4 of PCT Application Publication No. WO2012/030904,or as described in the accompanying Examples. In particular embodiments,the neutralization of any particular strain, or the averageneutralization of a plurality of different strains, is increased, e.g.,by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%,at least 60%, at least 70%, at least 80%, at least 90%, at least 100%,at least 150%, at least 200%, at least 300%, at least 400%, at least500%, at least 1000%, at least 20-fold, at least 30-fold, at least50-fold, at least 100-fold, or at least 1000-fold, or at least10,000-fold. In certain embodiments, neutralization is increased for oneor several strains, but there is no significant improvement of averageneutralization for the plurality of strains tested In particularembodiments, antibodies or fragments thereof have an IC50 forneutralizing BaL of <0.02 or <0.015; HT593 of <0.2 or <0.16; US657 of<0.1; US712 of <0.25 or <0.20; and/or US727 of <0.1 or <0.02 or <0.015.In one embodiments, antibodies or fragments thereof may have an IC₅₀ forneutralizing BaL of <0.02 μg/ml or <0.015 μg/ml; HT593 of <0.2 μg/ml or<0.16 μg/ml; US657 of <0.1 μg/ml; US712 of <0.25 μg/ml or <0.20 μg/ml;and/or US727 of <0.1 μg/ml or <0.02 μg/ml or <0.015 μg/ml. In certainembodiments, the antibodies or antigen-binding fragments thereof mayhave a neutralization IC50 range of 0.0005 μg/mL to 10 μg/mL for subtypeB isolates. In some embodiments, the antibodies or antigen-bindingfragments thereof may have a neutralization IC50 range of 0.001 μg/mL to3.3 μg/mL for subtype B DM and X4 isolates.

In certain embodiments, an antibody or antigen-binding fragment of thepresent invention has reduced or less immunogenicity as compared to thePGT-121 LO6 antibody. In certain embodiments, immunogenicity isdetermined using an assay known and available in the art or described inthe accompanying Examples. In particular embodiments the location ofT-cell epitopes is determined using EpiScreen™ T-cell epitope mapping,which involves a 50 donor ex-vivo peptide scanning T-cell activationassay as described (Baker et al. 2007. Drug Discovery Development 10(2):219-227). In particular embodiments, the relative immunogenicity ofengineered antibody variants is determined using a 50 donor ex-vivowhole molecule T-cell activation and cytokine release assays, which maybe predictive of clinical immunogenicity as described (Jaber et al.2007. J Pharm Biomed Anal. 43(4): 1256-1261). In particular embodiments,the donor response rate is reduced, e.g., by at least 5%, at least 10%,at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, atleast 70%, or at least 80%, as compared to the PGT-121 LO6 antibody. Inparticular embodiments the EpiScreen donor response is <10%, <15%, <20%,<25%, <30%, or <35%.

In particular embodiments, binding of the antibodies and fragmentsthereof of the present invention to the Env protein is predicted toinvolve regions of Env in or around the following residues (HIV Env HXB2numbering): V3 loop (324-328, 330) and associated N332 glycan and aportion of the V1-loop (135-137) and associated N137 glycan, residues415-417. Antibody paratope for Env binding is predicted to involveresidues in the following regions that make direct contact with theantigen in the PGT-122-Env crystal structure (Kabat numbering): CDRH1(33), CDRH2 (50, 56, 58), CDRH3 (99, 100, 100A-E, 100G, 100I, 100L),CDRL1 (28-30), CDRL2 (50-52), LFR3 (66, 67 67A-C) and CDRL3 (93, 94,95A-95B).

In some aspect, the antibodies provided herein may be conjugated orlinked to therapeutic and/or imaging/detectable moieties. Methods forconjugating or linking antibodies are well known in the art.Associations between antibodies and labels include any means known inthe art including, but not limited to, covalent and non-covalentinteractions. In one non-limiting embodiment, antibodies can beassociated with a toxin, a radionuclide, an iron-related compound, adye, an imaging reagent, a fluorescent label or a chemotherapeutic agentthat would be toxic when delivered to a cancer cell. Alternatively, theantibodies can be associated with detectable label, such as aradionuclide, iron-related compound, a dye, an imaging agent or afluorescent agent for immunodetection of target antigens. Non-limitingexamples of radiolabels include, for example, 32P, 33P, 43K, 52Fe, 57Co,64Cu, 67Ga, 67Cu, 68Ga, 71Ge, 75Br, 76Br, 77Br, 77As, 77Br, 81Rb/81MKr,87MSr, 90Y, 97Ru, 99Tc, 100Pd, 101Rh, 103Pb, 105Rh, 109Pd, 111Ag, 111In,113In, 119Sb, 121Sn, 123I, 125I, 127Cs, 128Ba, 129Cs, 131I, 131Cs,143Pr, 153Sm, 161Tb, 166Ho, 169Eu, 177Lu, 186Re, 188Re, 189Re, 1910s,193Pt, 194Ir, 197Hg, 199Au, 203Pb, 211At, 212Pb, 212Bi and 213Bi.Non-limiting examples of toxins include, for example, diphtheria Achain, nonbinding active fragments of diphtheria toxin, exotoxin A chain(from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin Achain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins,Phytolaca americana proteins (PAPI, PAPII, and PAP-S), Momordicacharantia inhibitor, curcin, crotin, Sapaonaria officinalis inhibitor,gelonin, mitogellin, restrictocin, phenomycin, enomycin, tricothecenes,Clostridium perfringens phospholipase C (PLC), bovine pancreaticribonuclease (BPR), antiviral protein (PAP), abrin, cobra venom factor(CVF), gelonin (GEL), saporin (SAP) viscumin. Non-limiting examples ofiron-related compounds include, for example, magnetic iron-oxideparticles, ferric or ferrous particles, Fe203 and Fe304. Iron-relatedcompounds and methods of labeling polypeptides, proteins and peptidescan be found, for example, in U.S. Pat. Nos. 4,101,435 and 4,452,773,and U.S. published applications 20020064502 and 20020136693, all ofwhich are hereby incorporated by reference in their entirety. In certainembodiments, the subject antibodies can be covalently or non-covalentlycoupled to a cytotoxin or other cell proliferation inhibiting compound,in order to localize delivery of that agent to a tumor cell. Forinstance, the agent can be selected from the group consisting agents,enzyme inhibitors, proliferation inhibitors, lytic agents, DNA or RNAsynthesis inhibitors, membrane permeability modifiers, DNA metabolites,dichloroethylsulfide derivatives, protein production inhibitors,ribosome inhibitors, inducers of apoptosis, and neurotoxins. In certainembodiments, the subject antibodies can be coupled with an agent usefulin imaging tumors. Such agents include: metals; metal chelators;lanthanides; lanthanide chelators; radiometals; radiometal chelators;positron-emitting nuclei; microbubbles (for ultrasound); liposomes;molecules microencapsulated in liposomes or nanosphere; monocrystallineiron oxide nanocompounds; magnetic resonance imaging contrast agents;light absorbing, reflecting and/or scattering agents; colloidalparticles; fluorophores, such as near-infrared fluorophores. In manyembodiments, such secondary functionality/moiety will be relativelylarge, e.g., at least 25 amu in size, and in many instances can be atleast 50,100 or 250 amu in size. In certain embodiments, the secondaryfunctionality is a chelate moiety for chelating a metal, e.g., achelator for a radiometal or paramagnetic ion. In additionalembodiments, it is a chelator for a radionuclide useful for radiotherapyor imaging procedures. Radionuclides useful within the present inventioninclude gamma-emitters, positron-emitters, Auger electron-emitters,X-ray emitters and fluorescence-emitters, with beta- or alpha-emitterspreferred for therapeutic use. Examples of radionuclides useful astoxins in radiation therapy include: 32P, 33P, 43K, 52Fe, 57Co, 64Cu,67Ga, 67Cu, 68Ga, 71Ge, 75Br, 76Br, 77Br, 77As, 77Br, 81Rb/81MKr, 87MSr,90Y, 97Ru, 99Tc, 100Pd, 101Rh, 103Pb, 105Rh, 109Pd, 111Ag, 111In, 113In,119Sb, 121Sn, 123I, 125I, 127Cs, 128Ba, 129Cs, 131I, 131Cs, 143Pr,153Sm, 161Tb, 166Ho, 169Eu, 177Lu, 186Re, 188Re, 189Re, 1910s, 193Pt,194Ir, 197Hg, 199Au, 203Pb, 211At, 212Pb, 212Bi and 213Bi. Preferredtherapeutic radionuclides include 188Re, 186Re, 203Pb, 212Pb, 212Bi,109Pd, 64Cu, 67Cu, 90Y, 125I, 131I, 77Br, 211At, 97Ru, 105Rh, 198Au and199Ag, 166Ho or 177Lu. Conditions under which a chelator will coordinatea metal are described, for example, by Gasnow et al. U.S. Pat. Nos.4,831,175, 4,454,106 and 4,472,509, each of which is incorporated hereinby reference. Within the present invention, “radionuclide” and“radiolabel” are interchangeable. 99Tc is a particularly attractiveradioisotope for diagnostic applications, as it is readily available toall nuclear medicine departments, is inexpensive, gives minimal patientradiation doses, and has ideal nuclear imaging properties. It has ahalf-life of six hours which means that rapid targeting of atechnetium-labeled antibody is desirable. Accordingly, in certainpreferred embodiments, the modified antibodies include a chelating agentfor technium. In still other embodiments, the secondary functionalitycan be a radiosensitizing agent, e.g., a moiety that increases thesensitivity of cells to radiation. Examples of radiosensitizing agentsinclude nitroimidazoles, metronidazole and misonidazole (see: DeVita, V.T. in Harrison's Principles of Internal Medicine, p. 68, McGraw-HillBook Co., NY, 1983, which is incorporated herein by reference). Themodified antibodies that comprise a radiosensitizing agent as the activemoiety are administered and localize at the target cell. Upon exposureof the individual to radiation, the radiosensitizing agent is “excited”and causes the death of the cell.

Antibody Sequences

Antibodies of the present invention comprise one or more polypeptidesequences of gamma heavy chains and lambda light chains of variousantibodies described herein, and variants and antigen-binding fragmentsthereof. In certain embodiments, antibodies of the present invention(and variants thereof and antigen-binding fragments thereof) comprise aheavy chain variable region and/or light chain variable region of any ofthe various antibodies described herein. In particular embodiments,antibodies, variable regions thereof, and antigen-binding fragmentsthereof of the present invention include one or more amino acid sequencemodifications as compared to the wild type PGT-121 LO6 antibody. Table 1provides the following amino acid sequences for PGT121 LO6 andillustrative antibodies of the present invention: heavy chain, heavychain CDRs 1-3 (Kabat, IMGT, Chothia and Honegger), light chain, lightchain CDRs 1-3 (Kabat, IMGT, Chothia and Honegger). The PGT121 variantantibodies shown in Table 1 are identified by a PGT number, such as,e.g., PGT121.15 and/or by description of modifications as compared toPGT L06. PGT121 LO6 may also be referred to as PGT121 WT (wild-type).Table 1 also provides amino acid sequences for illustrative PGT122antibodies of the present invention: heavy chain, heavy chain CDRs 1-3(Kabat, IMGT, Chothia and Honegger), light chain, light chain CDRs 1-3(Kabat, IMGT, Chothia and Honegger). Table 1 also provides amino acidsequences for illustrative PGT123 antibodies of the present invention:heavy chain, heavy chain CDRs 1-3 (Kabat, IMGT, Chothia and Honegger),light chain, light chain CDRs 1-3 (Kabat, IMGT, Chothia and Honegger).In some embodiments, any of the antibodies or antigen-binding fragmentsthereof of the present disclosure are modified to comprise one or moretags. In certain embodiments, the one or more tags comprise an avidintag.

In particular embodiments, any of the heavy chains or light chainsdescribed herein further comprises a signal peptide at the N-terminus.In various embodiments, the signal peptide used is “native” (derivedfrom an antibody), endogenous (i.e., used by naturally secretedproteins, e.g. albumins) or engineered (e.g., designed in silico forencoding secretion for protein In particular embodiments, the signalpeptide has any of the following sequences: MDPKGSLSWRILLFLSLAFELSYG(SEQ ID NO: 1) or MSVPTQVLGLLLLWLTDARC (SEQ ID NO: 2). In particularembodiments, the heavy chain includes the signal sequence:MDPKGSLSWRILLFLSLAFELSYG (SEQ ID NO: 1), and the light chain includesthe signal sequence: MSVPTQVLGLLLLWLTDARC (SEQ ID NO: 2).

In particular embodiments, any of the antibodies or antigen-bindingfragments thereof of the present invention are glycosylated. Inparticular embodiments, the glycosylation is a native glycosylationpresent in the PGT-121 LO6 antibody. In other embodiments, theglycosylation is a modified glycosylation, which, e.g., may beintroduced post-translationally or through genetic engineering. Inparticular embodiments, the antibody of antigen-binding fragment thereofis afucosylated, e.g., at a glycosylation site present in the antibodyor antigen-binding fragment thereof. Most approved monoclonal antibodiesare of the IgG1 isotype, where two N-linked biantennary complex-typeoligosaccharides are bound to the Fc region. The Fc region exercises theeffector function of ADCC through its interaction with leukocytereceptors of the FcγR family. Afucosylated monoclonal antibodies aremonoclonal antibodies engineered so that the oligosaccharides in the Fcregion of the antibody do not have any fucose sugar units. Whenantibodies are afucosylated, they may have improved FcγIIIa binding andincreased antibody-dependent cellular cytotoxicity (ADCC). In particularembodiments, antibodies and antigen-binding fragments thereof areafucosylated and comprise the DEAL modifications (i.e., S239D, 1332E,G236A, and A330L by EU numbering) in their Fc regions.

The PGT-121 LO6 antibody comprises a gamma heavy chain having the aminoacid sequence shown in Table 1. The variable region of the gamma heavychain of the PGT-121 LO6 antibody is underlined in Table 1. The constantregion of the heavy chain (Fc) constitutes the non-underlined sequenceas shown in Table 1 for PGT-121 L06. The gamma heavy chain CDRs ofPGT-121 LO6 and illustrative antibodies and antigen-binding fragmentsthereof of the present invention are also provided in Table 1. Thevariable regions of the heavy and light chains of all illustrativeantibodies and antigen-binding fragments thereof provided in Table 1 areunderlined. The constant regions of the heavy and light chains of allillustrative antibodies and antigen-binding fragments thereof providedin Table 1 constitute the non-underlined sequences in particularembodiments, antibodies and antigen binding fragments of the presentinvention comprise one or more PGT-121 LO6 gamma heavy chain CDRs asdefined by any of the Kabat, IMGT, Chothia or Honegger antibodynumbering schemes. In particular embodiments, antibodies and antigenbinding fragments of the present invention comprise two or more, or allthree of these gamma heavy chain CDRs. In particular embodiments,antibodies and antigen binding fragments of the present inventioncomprise all three of these gamma heavy chain CDRs, wherein the CDRscollectively comprise one or more, e.g., one, two, three, four, five,six, seven or eight amino acid modifications, e.g., amino acidsubstitutions, deletions or insertions (as compared to the correspondingsequence of PGT121 L06). In further embodiments, antibodies and antigenbinding fragments of the present invention comprise one or more PGT-122gamma heavy chain CDRs as defined by any of the Kabat, IMGT, Chothia orHonegger antibody numbering schemes. In yet further embodiments,antibodies and antigen binding fragments of the present inventioncomprise one or more PGT-123 gamma heavy chain CDRs as defined by any ofthe Kabat, IMGT, Chothia or Honegger antibody numbering schemes. Incertain embodiments, an antibody or antigen binding fragment thereof ofthe present invention comprises a heavy chain, heavy chain variableregion, or heavy chain constant region having the sequence of any of theantibodies shown in Table 1, or having at least 90%, at least 95%, atleast 98%, or at least 99% sequence identity or homology thereto.

The coding sequence of the polynucleotide sequence encoding the gammaheavy chain of PGT-121 LO6 is shown below:

(SEQ ID NO: 3) ATGAAACACCTGTGGTTCTTCCTTCTCCTGGTGGCAGCTCCCAGATGGGTCCTGTCACAGATGCAGTTACAGGAGTCGGGCCCCGGACTGGTGAAGCCTTCGGAAACCCTGTCCCTCACGTGCAGTGTGTCTGGTGCCTCCATAAGTGACAGTTACTGGAGCTGGATCCGGCGGTCCCCAGGGAAGGGACTTGAGTGGATTGGGTATGTCCACAAAAGCGGCGACACAAATTACAGCCCCTCCCTCAAGAGTCGAGTCAACTTGTCGTTAGACACGTCCAAAAATCAGGTGTCCCTGAGCCTTGTGGCCGCGACCGCTGCGGACTCGGGCAAATATTATTGCGCGAGAACACTGCACGGGAGGAGAATTTATGGAATCGTTGCCTTCAATGAGTGGTTCACCTACTTCTACATGGACGTCTGGGGCAATGGGACTCAGGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGA.

The coding region of the polynucleotide encoding the gamma heavy chainvariable region of PGT-121 LO6 is shown below:

(SEQ ID NO: 4) CAGATGCAGTTACAGGAGTCGGGCCCCGGACTGGTGAAGCCTTCGGAAACCCTGTCCCTCACGTGCAGTGTGTCTGGTGCCTCCATAAGTGACAGTTACTGGAGCTGGATCCGGCGGTCCCCAGGGAAGGGACTTGAGTGGATTGGGTATGTCCACAAAAGCGGCGACACAAATTACAGCCCCTCCCTCAAGAGTCGAGTCAACTTGTCGTTAGACACGTCCAAAAATCAGGTGTCCCTGAGCCTTGTGGCCGCGACCGCTGCGGACTCGGGCAAATATTATTGCGCGAGAACACTGCACGGGAGGAGAATTTATGGAATCGTTGCCTTCAATGAGTGGTTCACCTACTTCTACATGGACGTCTGGGGCAATGGGACTCAGGTCACCGTCTCCTCA.

The PGT-121 LO6 antibody comprises a lambda light chain having the aminoacid sequence shown in Table 1. The PGT-121 LO6 antibody lambda lightchain variable region amino acid sequence is shaded in Table 1. Thevariable regions of the other antibodies in Table 1 may be determined bycomparison. The lambda light chain Kabat CDRs of PGT-121 LO6 andillustrative antibodies and antigen-binding fragments thereof of thepresent invention are shown in Table 1. In particular embodiments,antibodies and antigen binding fragments of the present inventioncomprise one or more PGT-121 LO6 lambda light chain CDRs as defined byany of the Kabat, IMGT, Chothia or Honegger antibody numbering schemes.In particular embodiments, antibodies and antigen binding fragments ofthe present invention comprise two or more, or all three of these lightchain CDRs. In particular embodiments, antibodies and antigen bindingfragments of the present invention comprise all three of these lightchain CDRs, wherein the CDRs collectively comprise one or more, e.g.,one, two, three, four, five, six, seven or eight amino acidmodifications, e.g., amino acid substitutions, deletions or insertions(as compared to the corresponding sequence of PGT121 L06. In furtherembodiments, antibodies and antigen binding fragments of the presentinvention comprise one or more PGT-122 light chain CDRs as defined byany of the Kabat, IMGT, Chothia or Honegger antibody numbering schemes.In yet further embodiments, antibodies and antigen binding fragments ofthe present invention comprise one or more PGT-123 light chain CDRs asdefined by any of the Kabat, IMGT, Chothia or Honegger antibodynumbering schemes. In certain embodiments, an antibody or antigenbinding fragment thereof of the present invention comprises a lightchain or light chain variable region having the sequence of any of theantibodies shown in Table 1, or having at least 90%, at least 95%, atleast 98%, or at least 99% sequence identity or homology thereto.

The coding region of the polynucleotide encoding the lambda light chainof PGT-121 LO6 is shown below:

(SEQ ID NO: 19) ATGGCCTGGACCTTTCTCCTCCTCGGCCTCCTCTCTCACTGCACAGCCTCTGTGACCTCCGATATATCTGTGGCCCCAGGAGAGACGGCCAGGATTTCCTGTGGGGAAAAGAGCCTTGGAAGTAGAGCTGTACAATGGTATCAACACAGGGCCGGCCAGGCCCCCTCTTTAATCATATATAATAATCAGGACCGGCCCTCAGGGATCCCTGAGCGATTCTCTGGCTCCCCTGACTCCCCTTTTGGGACCACGGCCACCCTGACCATCACCAGTGTCGAAGCCGGGGATGAGGCCGACTATTACTGTCATATATGGGATAGTAGAGTTCCCACCAAATGGGTCTTCGGCGGAGGGACCACGCTGACCGTGTTAGGTCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCCAGCAGCTACCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAAAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTACAGAATGTTCATAG.

The coding region of the polynucleotide encoding the lambda light chainvariable region of PGT-121 LO6 is shown below:

(SEQ ID NO: 20) TCCGATATATCTGTGGCCCCAGGAGAGACGGCCAGGATTTCCTGTGGGGAAAAGAGCCTTGGAAGTAGAGCTGTACAATGGTATCAACACAGGGCCGGCCAGGCCCCCTCTTTAATCATATATAATAATCAGGACCGGCCCTCAGGGATCCCTGAGCGATTCTCTGGCTCCCCTGACTCCCCTTTTGGGACCACGGCCACCCTGACCATCACCAGTGTCGAAGCCGGGGATGAGGCCGACTATTACTGTCATATATGGGATAGTAGAGTTCCCACCAAATGGGTCTTCGGCGGAGGGACC ACGCTGACCGTGTTA.

In certain embodiments, an antibody or fragment thereof of the presentinvention comprises one or more, two or more, three or more, four ormore, five or more, or all six of the CDRs present in the PGT-121 LO6antibody, as defined by any of the Kabat, IMGT, Chothia or Honeggernumbering schemes. In particular embodiments, antibodies and antigenbinding fragments of the present invention comprise all six of theseCDRs, wherein the CDRs collectively comprise one or more, e.g., one,two, three, four, five, six, seven or eight amino acid modifications,e.g., amino acid substitutions, deletions or insertions. In certainembodiments, an antibody or fragment thereof of the present inventioncomprises one or more, two or more, three or more, four or more, five ormore, or all six of the CDRs present in any of the antibodies shown inTable 1. In other embodiments, one or more of the PGT-121 LO6 CDRs isreplaced, e.g., by one or more corresponding CDRs of another anti-HIVantibody. In particular embodiments, one or more of the PGT-121 LO6 CDRsis replaced by one or more corresponding CDRs from the PGT-122, PGT-123,PGT-124, PGT-133, or PGT-134 antibodies described in PCT PublicationWO2012/030904. Corresponding CDRs are CDRs at the same position in theother antibody, such as heavy chain CDRs 1, 2, and 3, and light chainCDRs 1, 2 and 3, so a replacement with a corresponding CDR indicatesreplacement of a heavy chain CDR1 with a different heavy chain CDR1,replacement of a light chain CDR1 with a different CDR1, etc. The CDRsequences of these antibodies are provided below:

TABLE 2 CDRs of PGT antibodies Ab HC CDR1 HC CDR2 HC CDR3 LC CDR1LC CDR2 LC CDR3 PGT- DNYWS YHDSGDTNYN TKHGRRIYGV GEESLGSRSVI NNNDRPSHIWDSRRPT 122 (SEQ ID PSLKS VAFKEWFTYF (Kabat) (Kabat) NWV NO: 5)(Kabat) YMDV (SEQ ID (SEQ ID (Kabat) (Kabat) (SEQ ID (Kabat) NO: 29)NO: 34) (SEQ ID GTLVDR NO: 13) (SEQ ID GEESLGSRSVI NNNDRPS NO: 37)(Chothia) YVHDSGDTN NO: 23) (Chothia) (Chothia) HIWDSRRPT (SEQ ID(Chothia) TKHGRRIYGV (SEQ ID (SEQ ID NWV NO: 6) (SEQ ID VAFKEWFTYFNO: 29) NO: 34) (Chothia) NO: 14) YMDV (SEQ ID (Chothia) NO: 37) (SEQ IDNO: 23) PGT- DAYWS YVHHSGDTNY ALHGKRIYGIV GKESIGSRAV NNQDRPA HIYDARGGT123 (Kabat) NPSLKR ALGELFTYFY Q (Kabat) (Kabat) NWV (SEQ ID (Kabat)MDV (Kabat) (SEQ ID (SEQ ID (Kabat) NO: 7) (SEQ ID (SEQ ID NO: 30)NO: 35) (SEQ ID GASIND NO: 15) NO: 24) GKESIGSRAV NNQDRPA NO: 38)(Chothia) YVHHSGDTN ALHGKRIYGIV Q (Chothia) HIYDARGGT (SEQ ID (Chothia)ALGELFTYFY (Chothia) (SEQ ID NWV NO: 8) (SEQ ID MDV (SEQ ID NO: 35)(Chothia) NO: 16) (Chothia) NO: 30) (SEQ ID (SEQ ID NO: 38) NO: 24) PGT-NYYWT YISDRETTTYN ARRGQRIYGV GRQALGSRAV NNQDRPS HMWDSRSG 124 (Kabat)PSLNS VSFGEFFYYY Q (Kabat) (Kabat) FSWS (SEQ ID (Kabat)  YMDV (SEQ ID(SEQ ID (Kabat) NO: 9) (SEQ ID (Kabat) NO: 31) NO: 36) (SEQ ID GGSISNNO: 17) (SEQ ID GRQALGSRAV NNQDRPS NO: 39) (Chothia) YISDRETTT NO: 25) Q(Chothia) HMWDSRSG (SEQ ID (Chothia) ARRGQRIYGV (Chothia) (SEQ ID FSWSNO: 10) (SEQ ID VSFGEFFYYY (SEQ ID NO: 36) (Chothia) NO: 18) YMDVNO: 31) (SEQ ID (Chothia) NO: 39) (SEQ ID NO: 25) PGT- GRFWS YFSDTDRSEYAQQGKRIYGI GERSRGSRAV NNQDRPA HYWDSRSPI 133 (Kabat) NPSLRS GSFGEFFYYYA (Kabat) (Kabat) SWI (SEQ ID (Kabat) YMDA (SEQ ID (SEQ ID (Kabat)NO: 11) (SEQ ID (Kabat) NO: 32) NO: 35) (SEQ ID NGSVSG NO: 21) (SEQ IDGERSRGSRAV NNQDRPA NO: 40) (Chothia) YFSDTDRSE NO: 26) Q  (Chothia)HYWDSRSPI (SEQ ID (Chothia) AQQGKRIYGI (Chothia) (SEQ ID SWI NO: 12)(SEQ ID VSFGEFFYYY (SEQ ID NO: 35) (Chothia) NO: 22) YMDA NO: 33)(SEQ ID (Chothia) NO: 40) (SEQ ID NO: 27) PGT- GRFWS YFSDTDRSEYAQQGKRIYGI GERSRGSRAV NNQDRPA HYWDSRSPI 134 (Kabat) NPSLRS VSFGELFYYYQ (Kabat) (Kabat) SWI (SEQ ID (Kabat) YMDA (SEQ ID (SEQ ID (Kabat)NO: 11) (SEQ ID (Kabat) NO: 33) NO: 35) (SEQ ID NGSVSG NO: 21) (SEQ IDGERSRGSRAV NNQDRPA NO: 40) (Chothia) YFSDTDRSE NO: 28) Q (Chothia)HYWDSRSPI (SEQ ID (Chothia) AQQGKRIYGI (Chothia) (SEQ ID SWI NO: 12)(SEQ ID VSFGELFYYY (SEQ ID NO: 35) (Chothia) NO: 22) YMDA NO: 33)(SEQ ID (Chothia) NO: 40) (SEQ ID NO: 28)

Antibodies of the present invention and antigen-binding fragmentsthereof comprise one or more amino acid modifications as compared toPGT-121 L06. These may include any of a variety of different types ofmodifications, including, e.g., allotype modification, Fc modifications,Fab modifications, and modification of selected residues, such asglycosylation sites. Non-limiting examples of modifications present incertain embodiments of antibodies and antigen-binding fragments thereofof the present invention are described herein and shown in the sequencesset forth in Table 1.

i. Allotype Modifications

IgG antibodies exist in various allotypes and isoallotypes. Inparticular embodiments, antibodies and antigen-binding fragments thereofof the present invention include an IgG1 heavy chain having an allotypeof Glm1; nGlm2; Glm3; Glm17,1; Glm17,1,2; Glm3,1; or Glm17. Each ofthese allotypes or isoallotypes is characterized by the following aminoacid residues at the indicated positions within the IgG1 heavy chainconstant region (Fc)(EU numbering):

-   -   Glm1: D356, L358;    -   nGlm1: E356, M358;    -   Glm3: R214, E356, M358, A431;    -   Glm17,1: K214, D356, L358, A431;    -   Glm17,1,2: K214, D356, L358, G431;    -   Glm3,1: R214, D356, L358, A431; and    -   Glm17: K214, E356, M358, A431.

The PGT-121 LO6 antibody comprises the IgG1m3 allotype. In particularembodiments, the antibodies and antigen-binding fragments thereof of thepresent invention comprise the IgG1m3 allotype, whereas in otherembodiments, the allotype is modified as compared to the PGT-121 LO6antibody. In particular embodiments, the allotype is nGlm1, Glm3;Glm17,1; Glm17,1,2; Glm3,1; or Glm17. In certain embodiments, theallotype is Glm17. In particular embodiments, an antibody ofantigen-binding fragment thereof comprises an IgG1 heavy chain constantregion comprising one of the following amino acid sequences, in whichrepresentative allotype-determining residues are indicated in bold:

IgG1m3: (SEQ ID NO: 41)ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK; IgG1m17, 1: (SEQ ID NO: 42)ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK; IgG1m17, 1, 2: (SEQ ID NO: 43)ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEGLHNHYTQKSLSLSPGK; IgG1m3, 1: (SEQ ID NO: 44)ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK; or IgG1m17: (SEQ ID NO: 45)ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK.

In certain embodiments, an antibody or an antigen-binding fragmentthereof of the present invention comprises an IgG1 heavy chaincomprising the following amino acid sequence of allotype IgG1m17:

(SEQ ID NO: 46) QMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPGK.

In particular embodiments, antibodies and antigen-binding fragmentsthereof of the present invention comprise a kappa light chain having anallotype selected from Km1; Km1,2; or Km3. Each of these allotypes ischaracterized by the following amino acid residues at the indicatedpositions within the IgG1 light chain (EU numbering):

-   -   Km1: V153, L191;    -   Km1,2: A153, L191; and    -   Km3: A153, V191.

In particular embodiments, an antibody of antigen-binding fragmentthereof comprises an IgG1 kappa light chain comprising one of thefollowing amino acid sequences, in which representativeallotype-determining residues are indicated in bold:

Km1: (SEQ ID NO: 47) TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNVLQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKLYACEVTHQGLSSPVTKS FNRGEC; Km1, 2:(SEQ ID NO: 48) TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKLYACEVTHQGLSSPVTKS FNRGEC; or Km3:(SEQ ID NO: 49) TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKS FNRGEC.

Each individual human includes between seven and eleven different lambdalight chain genes, which encode light chains selected from Lambda1,Lambda2, Lambda3, Lambda4, Lambda5, Lambda6, and Lambda7. In particularembodiments, antibodies and antigen-binding fragments thereof of thepresent invention comprise a lambda light chain selected from Lambda1,Lambda2, Lambda3, Lambda4, Lambda5, Lambda6, and Lambda7. In particularembodiments, antibodies and antigen-binding fragments thereof of thepresent invention comprise a lambda light chain selected from Lambda1,Lambda2, Lambda3, and Lambda 7. In particular embodiments, an antibodyof antigen-binding fragment thereof comprises an IgG1 lambda light chaincomprising one of the following amino acid sequences, in whichrepresentative lambda-determining residues are indicated in bold:

IGLC1: (SEQ ID NO: 50)GQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTV APTECS; IGLC2:(SEQ ID NO: 51) GQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTV APTECS; IGLC3:(SEQ ID NO: 52) GQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPAKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEKTV APTECS; or IGLC7:(SEQ ID NO: 53) GQPKAAPSVTLFPPSSEELQANKATLVCLVSDFYPGAVTVAWKADGSPVKVGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCRVTHEGSTVEKTV APAECS.

In particular embodiments, the light chain comprises the amino acidsequence:

(SEQ ID NO: 54) SDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGST VEKTVAPTECS.

In particular embodiments, an antibody or antibody binding fragmentthereof of the present invention comprises any of the light chainsequences set forth in Table 1 or sequences having at least 90%, atleast 95%, at least 98%, or at least 99% identity thereto.

In particular embodiments, an antibody or antigen-binding fragmentthereof comprises an IgG1 heavy chain having the IgG1m17 allotype and aLambda2 light chain.

In certain embodiments, the light chain comprises one or more of thefollowing amino acid substitutions (as compared to PGT121 LO6 usingKabat numbering scheme in FIG. 1): Arg at position 67b, Pro at position67c, and Lys at position 103. In certain embodiments, the light chaincomprises the following amino acid substitutions (as compared to PGT121LO6 using Kabat numbering scheme in FIG. 1): Arg at position 67b and Proat position 67c.

ii. Fc Modifications

In certain embodiments, antibodies and antigen-binding fragments thereofinclude one or more amino acid sequence modifications in the heavy chainconstant region (Fc) as compared to the PGT-121 LO6 antibody. Inparticular embodiments, these modifications increase stability orincrease binding affinity of the modified antibody or antigen-bindingfragment thereof as compared to the PGT-121 LO6 antibody. In particularembodiments, certain of these modifications, or combinations thereof,surprisingly increase antibody effector function or neutralizationactivity. The sequence of certain illustrative heavy chain sequencescomprising one or more Fc modifications, and antibodies comprising suchmodified heavy chain sequences, are shown in Table 1.

In certain embodiments, the one or more modifications are selected fromthe following Fc amino acid substitutions (as compared to PGT121 L06; EUnumbering) or combinations thereof: L234F; L235E; G236A; S239D; F243L;D265E; S267E; H268F; R292P; N297Q; S298A; S324T; 1332E; S239D; A330L;L234F; L235E; P331S; F243L; Y300L; V3051; P396L; S298A; E333A; K334A;E345R; L235V; F243L; R292P; Y300L; P396L; M428L; E430G; N434S; G236A,S267E, H268F, S324T, and 1332E; G236A, S239D, and 1332E; S239D, A330L,1332E; L234F, L235E, and P331S; F243L, R292P, Y300L, V3051, and P396L;G236A, H268F, S324T, and 1332E; S239D, H268F, S324T, and 1332E; S298A,E333A, and K334A; L235V, F243L, R292P, Y300L, and P396L; S239D, 1332E;S239D, S298A, and 1332E; G236A, S239D, 1332E, M428L, and N434S; G236A,S239D, A330L, 1332E, M428L, and N434S; S239D, 1332E, G236A and A330L;M428L and N4343S; M428L, N434S; G236A, S239D, A330L, and 1332E; andG236A and 1332E.

In particular embodiments, the antibodies and antigen-binding fragmentscomprise two or more, three or more, four or more, five or more, or sixor more modified Fc amino acid residues. In certain embodiments, theantibodies and antigen-binding fragments thereof comprise the S239D,1332E, G236A and A330L mutations, which are collectively referred to asDEAL. In certain embodiments, the antibodies and antigen-bindingfragments thereof comprise the M428L and N434S mutations, which arecollectively referred to as LS. In certain embodiments, the antibodiesand antigen-binding fragments thereof comprise the S239D, 1332E, G236A,A330L, M428L and N434S mutations (DEALLS). In particular embodiments,antibodies and antigen-binding fragments thereof of the presentinvention comprise one of the heavy chain constant region sequencespresent in any of the antibodies set forth in Table 1 of a variantthereof having at least 90%, at least 95%, at least 98%, or at least 99%sequence identity or homology thereto.

In particular embodiments, the antibodies and antigen-binding fragmentsare afucosylated. In some embodiments, the antibodies andantigen-binding fragments comprise one or more tags. In certainembodiments, the one or more tags comprise an avidin tag.

iii. Fab Modifications

In certain embodiments, antibodies and antigen-binding fragments thereofinclude one or more amino acid sequence modifications in a heavy chainvariable region or a light chain variable region (Fab) as compared tothe PGT-121 LO6 antibody. In particular embodiments, these modificationsincrease stability or increase binding affinity of the modified antibodyor antigen-binding fragment thereof as compared to the PGT-121 LO6antibody. In certain embodiments, these modifications reduceimmunogenicity, isomerization, glycosylation or oxidation of theantibodies or antigen-binding fragments thereof. In particularembodiments, the modification results in the removal of a potential siteof isomerization, glycosylation or oxidation from the antibodies orantigen-binding fragments thereof. In certain embodiments, the aminoacid substitutions result in increased translation of the antibodies orantigen-binding fragments thereof. In certain embodiments, thesemodifications increase the % recovery of monomeric IgG from a low pHviral inactivation procedure. In certain embodiments, thesemodifications increase the HIV neutralization potency of the antibodiesor antigen-binding fragments thereof as compared to the PGT-121 LO6antibody when measured against either a single HIV strain, or a sub-setof related HIV strains.

In particular embodiments, the modification comprises an amino acidsubstitution within one or more potential glycosylation sites located inthe PGT-121 LO6 antibody. N-linked glycosylation sites may comprise thesequence NX(S/T) where X is any amino acid residue except proline, andwherein the N is glycosylated. In particular embodiments, theglycosylation sites are located at residues 58, 68 and 105 (Kabatnumbering) of the PGT-121 L06 heavy chain variable region sequence. Inparticular embodiments, an antibody or antigen-binding fragment thereofof the present invention comprises one or more amino acid substitutionswithin residues 58-60, 68-70 and 105-107 (Kabat numbering) of the heavychain Fab as compared to PGT-121 L06, which eliminates the NX(S/T)glycosylation consensus sequence. In certain embodiments, the one ormore amino acid substitutions occur at positions 60, 68 or 105 (Kabatnumbering). In particular embodiments, the amino acid substitutionsremove or destroy the glycosylation site at the modified position. Incertain embodiments, the antibodies or antigen-binding fragments thereofof the present invention comprise two or more or three or more aminoacid substitutions at these glycosylation sites. In one embodiment, theycomprise amino acid substitutions that remove or destroy all three ofthese glycosylation sites.

In particular embodiments, the modification comprises an amino acidsubstitution within one or more potentially immunogenic regions locatedin the PGT-121 LO6 antibody. In particular embodiments, the potentialimmunogenic regions are located at residues 82a-82c of the PGT-121 LO6heavy chain variable region. In particular embodiments, an antibody orantigen-binding fragment thereof of the present invention comprises oneor more amino acid substitutions within residues 82a-82c (Kabatnumbering) of the heavy chain Fab as compared to PGT-121 L06. In certainembodiments, the one or more amino acid substitutions occur at positions82a-82c (Kabat numbering) of the heavy chain Fab as compared to PGT-121L06. In particular embodiments, the amino acid substitutions reduce theimmunogenicity of the antibodies or antigen-binding fragments thereof.In certain embodiments, the antibodies or antigen-binding fragmentsthereof of the present invention comprise two or more or three or moreamino acid substitutions in this immunogenic region. In one embodiment,they comprise amino acid substitutions of three residues in thisimmunogenic region, e.g., the substitution of the VAA present in PGT-121L06, e.g., with SSV, TSV or TGV. In certain embodiments, an antibody orantigen-binding fragment thereof of the present invention comprises oneor more amino acid substitutions that remove a glycosylation site and inwhich the immunogenicity is less than or equal to that of PGT-121 L06.In certain embodiments, the antibodies comprise one or more amino acidmodifications, e.g., substitutions, within a determined or predictedimmunogenic region corresponding to any of the regions of PGT-121 LO6shown in any of Tables 14-16.

In particular embodiments, the antibodies comprise modification in anycombination at heavy chain residues 2, 32, 60, 68, 82a-82c, 95, or 105and/or light chain residues 67b, 67c, or 103 resulting in reduced donorresponse in a whole molecule T-cell activation assay described herein.

In certain embodiments, the antibodies or antigen-binding fragmentsthereof include one or more amino acid modification, e.g.,substitutions, to enhance translation. For example, the substitution maybe of an amino acid encoded by a rare codon, or for which there is onlya limited amount of corresponding tRNA present in the cells in which theprotein is expressed. In certain embodiments, antibodies orantigen-binding fragments thereof of the present invention comprise oneor more such modifications, or amino acid substitutions, e.g., ascompared to PGT-121 L06. In particular embodiments, the antibodies orantigen-binding fragments thereof comprise an amino acid substitution ofone or more of M2, A28, R39, N68, S81, V82a, A82b, A82c or N105 (Kabatnumbering) in the PGT-121 LO6 antibody's heavy chain variable region. Incertain embodiments, R39 of PGT-121 LO6 is substituted, e.g., by a Q.

In certain embodiments, the antibodies or antigen-binding fragmentsthereof include one or more amino acid substitutions to enhancestability of the Fab domain as measured by melting temperature. Inparticular embodiments, the antibodies or antigen-binding fragmentsthereof comprise one or more of the following amino acid substitutionsin a heavy chain: R39Q, S60N and VAA(82a-82c)SSV (Kabat numbering). Asshown in the accompanying Examples, antibodies of the present inventionshow enhanced thermal stability as compared to PTG-121 L06, as measuredby an increase in Fab domain Tm determined by DSF. In particularembodiments, the antibodies or antigen-binding fragments thereofcomprise an amino acid substitution of in a heavy chain of R39Q, S60Nand VAA(82a-82c)TGV (Kabat numbering). In particular embodiments, theantibodies or antigen-binding fragments thereof comprise the amino acidsubstitution in a heavy chain of VAA(82a-82c)SSV (Kabat numbering). Inparticular embodiments, the antibodies or antigen-binding fragmentsthereof comprise an amino acid substitution of in a heavy chain ofVAA(82a-82c)TGV (Kabat numbering).

In certain embodiments, the antibodies or antigen-binding fragmentsthereof include one or more amino acid substitutions to enhancestability of the Fab domain at low pH, preventing aggregation during alow “pH hold” procedure used to inactivate potential viruses derivedfrom mammalian cell culture during purification of antibodies such asPGT-121 L06. In particular embodiments, the antibodies orantigen-binding fragments thereof comprise an amino acid substitution ofone or more of the following heavy chain mutations: Q1E, M2V, M2L, A27G,S32A, R39Q, S60N, N68T, N68H, S81K, VAA(82a-82c)SSV, VAA(82a-82c)TSV,VAA(82a-82c)TGV, K89T, T95A, N105K, N105H, N105Q, N105T; light chainmutations K95cN or S45V; or the combination of heavy chain mutation R39Qplus light chain mutation H38Q. In particular embodiments, theantibodies or antigen-binding fragments thereof comprise addition ofeither SYVLTQP or SSVTSYV to the N-terminus of the light chain, as wellas the combination of these additions with any of the aforementionedsubstitutions. As described in the accompanying Examples, antibodies ofthe present invention show enhanced stability at low pH as compared toPGT-121 L06, which enables GMP production of these molecules. This maybe found in WHO Technical Report, Series No. 924, 2004; Jacob and Frech.2004. Scale up of antibody purification: from laboratory scale toproduction, p. 101-132. In G. Subramanian (ed.), Antibodies, vol. 1.Production and Purification. Kluwer Academic/Plenum Publishers, NewYork, N.Y.

In certain embodiments, the antibodies or antigen-binding fragmentsthereof include one or more amino acid substitutions to enhance HIVneutralization potency and breadth. As shown in the accompanyingExamples, certain antibodies of the present invention show astatistically significant improvement in both breadth and neutralizationpotency (˜2-3 fold) as compared to PGT-121 LO6 or other antibodies.

In certain embodiments, the one or more modifications are selected fromthe following heavy chain Fab mutations (Kabat numbering) orcombinations thereof (as compared to PGT121 L06): Q1E; M2V; M2L; A27G;S32A; R39Q; S60N; N68T; N68H; S81K; V82aT; V82aS; A82bG; A82bS; A82cV;K89T; T95A; W100jA; W100jL; N105K; N105Q; N105T; N105H; S60A; N68A;N105A; N105H; N105T; S60N, N68T and N105K; S32A, S60N, N68T and N105K;S60N, N68T and N105K; V82aS; A82bS; A82cV; V82aT, A82bG; and A82cV. Incertain embodiments, the heavy chain Fab comprises the followingmutations (Kabat numbering): S60N, N68H, VAA82a-cTGV, and N105T. Incertain embodiments, the heavy chain Fab comprises the followingmutations (Kabat numbering): S60N, N68H, VAA82a-cSSV, and N105K. Incertain embodiments, the heavy chain Fab comprises the followingmutations (Kabat numbering): S60N, N68H, VAA82a-cSSV, and N105H. Incertain embodiments, the heavy chain Fab comprises the followingmutations (Kabat numbering): M2L, S32A, S60N, N68H, VAA82a-cTGV, T95Aand N105T. In certain embodiments, the heavy chain Fab comprises thefollowing mutations (Kabat numbering): R39Q, S60N, N68H, VAA82a-cSSV,and N105K.

In particular embodiments, the antibodies and antigen-binding fragmentsthereof of the present invention comprise one or more, two or more,three or more, or four or more amino acid substitutions in the heavychain Fab, wherein the amino acid substitution are selected from thefollowing combinations of substitutions (EU numbering): V82aS A82bS,A82cV, and N105K; N68H, V82aS, A82bS, and A82cV; N68H, V82aS A82bS,A82cV, and N105K; S60N, V82aS A82bS, and A82cV; S60N, N105K; S60N, andN68H; S60N, N68H, and N105K; R39Q; R39Q, N68H, and N105K; R39Q and N68H;R39Q and N105K; R39Q and S60N; R39Q, S60N, and N105K; R39Q, S60N, andN68H; R39Q, S60N, N68H, and N105K; V82aS, A82bS, and A82cV; S60N, N68H,VAA82a-cTGV, and N105T; S60N, N68H, VAA82a-cSSV, and N105K; S60N, N68H,VAA82a-cSSV, and N105H; M2L, S32A, S60N, N68H, VAA82a-cTGV, T95A andN105T; and R39Q, S60N, N68H, VAA82a-cSSV, and N105K. In someembodiments, the antibodies and antigen-binding fragments thereof of thepresent invention comprise one or more, two or more, three or more, fouror more, five or more, or six or more amino acid substitutions in theheavy chain Fab, wherein the amino acid substitution are selected fromthe following combinations of substitutions (EU numbering): V82aS A82bS,A82cV, and N105K; N68H, V82aS, A82bS, and A82cV; N68H, V82aS A82bS,A82cV, and N105K; S60N, V82aS A82bS, and A82cV; S60N, N105K; S60N, andN68H; S60N, N68H, and N105K; R39Q; R39Q, N68H, and N105K; R39Q and N68H;R39Q and N105K; R39Q and S60N; R39Q, S60N, and N105K; R39Q, S60N, andN68H; R39Q, S60N, N68H, and N105K; V82aS, A82bS, and A82cV; S60N, N68H,VAA82a-cTGV, and N105T; S60N, N68H, VAA82a-cSSV, and N105K; S60N, N68H,VAA82a-cSSV, and N105H; M2L, S32A, S60N, N68H, VAA82a-cTGV, T95A andN105T; and R39Q, S60N, N68H, VAA82a-cSSV, and N105K. In particularembodiments, any of these antibodies or antigen-binding fragmentsthereof further comprise one or more, two or more, three or more, fouror more, or five or more of the following Fc mutations (EU numbering):G236A, S239D, A330L, I332E, M428L, and N434S. In particular embodiments,they comprise four, five, six, or seven of these amino acidsubstitutions in the heavy chain Fab. In particular embodiments, theyfurther comprise all of the following Fc mutations (EU numbering):G236A, S239D, A330L, I332E, M428L, and N434S. In particular embodiments,they further comprise the Glm17 allotype. In some embodiments, theantibodies and antigen-binding fragments thereof of the presentinvention comprise six heavy chain variable domain mutations. In otherembodiments, the antibodies and antigen-binding fragments thereof of thepresent invention comprise two light chain variable domain mutations. Incertain embodiments, the antibodies and antigen-binding fragmentsthereof of the present invention comprise six heavy chain variabledomain mutations and two light chain variable domain mutations.Embodiments of the present invention include any combinatorial variantderived from any of the mutations described herein.

In particular embodiments, an antibody or antigen-binding fragmentthereof of the present invention comprises one or more amino acidmodifications in the light chain as compared to PGT121 L06. Inparticular embodiments, the one or more modification are selected fromthe following light chain mutations: P67bR, F67 cP and T103K (Kabatnumbering). In one embodiments, the one or more modification areselected from the following light chain amino acid substitutions: P67bR,F67 cP and T103K (Kabat numbering). In particular embodiments, theantibody or antigen binding fragment thereof comprises the followinglight chain mutations: P67bR, F67 cP and T103K. In certain embodiments,the one or more modifications are selected from the following lightchain Fab mutations (Kabat numbering) or combinations thereof: SYVLTQPat N-terminus; SSVTSYV at N-terminus; S45T; or K95cN. In certainembodiments, the one or more modifications are selected from thefollowing light chain Fab mutations (Kabat numbering) or combinationsthereof: SYVLTQP at N-terminus; SSVTSYV at N-terminus; S45T; or K95cN.

In certain embodiments, an antibody or antigen-binding fragment thereofcomprises one or more modifications selected from the followingcombination of heavy chain Fab mutations and light chain Fab mutations(Kabat numbering): HC: R39Q and LC: H38Q; HC: S60N, N68T and N105K andLC: SYVLTPQ at N-terminus; HC: S60N, N68H, VAA82a-cTGV, N105T and LC:P67bR and F67 cP; HC: S60N, N68H, VAA82a-cTGV, N105T and LC: P67bR, F67cP and T103K; HC: M2L, S32A, S60N, N68H, VAA82a-cTGV, N105T and LC:P67bR and F67 cP; or HC: M2L, S32A, S60N, N68H, VAA82a-cTGV, N105T andLC: P67bR, F67 cP and T103K. In one embodiments, an antibody orantigen-binding fragment thereof comprises one or more modificationsselected from the following combination of heavy chain Fab mutations andlight chain Fab mutations (Kabat numbering): HC: R39Q and LC: H38Q; HC:S60N, N68T and N105K and LC: SYVLTPQ at N-terminus; HC: S60N, N68H,VAA82a-cTGV, N105T and LC: P67bR and F67 cP; HC: S60N, N68H,VAA82a-cTGV, N105T and LC: P67bR, F67 cP and T103K; HC: M2L, S32A, S60N,N68H, VAA82a-cTGV, N105T and LC: P67bR and F67 cP; HC: M2L, S32A, S60N,N68H, VAA82a-cTGV, N105T and LC: P67bR, F67 cP and T103K; HC: S60N,N68H, VAA82a-cSSV, N105K and LC: P67bR and F67 cP. In particularembodiments, the antibody or antigen-binding fragment thereof hassequence identity of at least 80%, at least 85%, at least 90%, at least95%, at least 98%, or at least 99% to the corresponding region of thePGT121 LO6 antibody. In further embodiments, it comprises all six CDRspresent in the PTG121 LO6 antibody by Kabat numbering.

In particular embodiments, the antibodies and antigen-binding fragmentscomprise two or more, three or more, four or more, five or more, or sixor more of any of the Fab mutations described herein or shown in any ofthe PGT121 LO6 mutant sequences provided in Table 1. In certainembodiments, any of these antibodies and antigen-binding fragmentsthereof further comprise one or more of the following heavy chainconstant region mutations: S239D, 1332E, G236A and A330L (EU numbering).In certain embodiments, any of these antibodies and antigen-bindingfragments thereof comprise the M428L and N434S mutations. In certainembodiments, any of the antibodies and antigen-binding fragments thereofcomprise the S239D, 1332E, G236A, A330L, M428L and N434S mutations.

In particular embodiments, an antibody or fragment thereof of thepresent invention comprises any of the heavy chain sequences, constantregions thereof, or variable regions thereof, or light chain sequences,constant regions thereof, or variable regions thereof, shown in Table 1,or a variant having at least 90%, at least 95%, at least 98%, or atleast 99% sequence identity thereto. In particular embodiments,antibodies and antigen-binding fragments thereof of the presentinvention comprise one of the heavy chain Fab or variable domainsequences indicated by underlining in Table 1. In particularembodiments, antibodies and antigen-binding fragments thereof of thepresent invention comprise any of the heavy chains shown in Table 1. Incertain embodiments, an antibody or fragment thereof of the presentinvention comprises both the heavy chain sequence and the light chainsequence present in any of the antibodies shown in Table 1, i.e., thecombination present in any of the clone designations. In particularembodiments, an antibody or antigen-binding fragment of the presentinvention comprises a heavy chain having a sequence shown in Table 1 (orfragment thereof), and a light chain having a sequence shown in Table 1(or fragment thereof), wherein the heavy chain and light chain are notpresent in the same antibody in Table 1. Any of the heavy chains shownin Table 1 (or fragments thereof) may be combined with any of the lightchains shown in Table 1 (or fragments thereof).

In particular embodiments, an antibody or fragment thereof of thepresent invention comprises one or modifications in the light chainvariable region as compared to PGT-121 L06. In certain embodiments, themodification is selected from the following amino acid substitutions:P67bR, F67 cP, or T103K.

In particular embodiments, an antibody or fragment thereof of thepresent invention comprises one of the light chain variable regionsshown in underlining in Table 1 or shown below:

(SEQ ID NO: 55) SDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGT TLTVLG;(SEQ ID NO: 56) SDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGT KLTVLG;(SEQ ID NO: 57) SDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSRPGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGT TLTVLG; or(SEQ ID NO: 58) SDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSRPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGG TKLTVLG.

In certain embodiments, the invention includes antigen-binding fragmentsof antibodies. In certain circumstances there are advantages of usingantibody fragments, rather than whole antibodies. For example, thesmaller size of the fragments allows for rapid clearance, and may leadto improved access to certain tissues, such as solid tumors. Examples ofantibody fragments include: Fab, Fab′, F(ab′)₂ and Fv fragments;diabodies; linear antibodies; single-chain antibodies; nanobodies, andmultispecific antibodies formed from antibody fragments.

In other embodiments, the antibody of choice is a single chain Fvfragment (scFv). See WO 93/16185; U.S. Pat. Nos. 5,571,894; and5,587,458. Fv and sFv are the only species with intact combining sitesthat are devoid of constant regions. Thus, they are suitable for reducednonspecific binding during in vivo use. sFv fusion proteins may beconstructed to yield fusion of an effector protein at either the aminoor the carboxy terminus of an sFv. See Antibody Engineering, ed.Borrebaeck, supra. The antibody fragment may also be a linear antibody,e.g., as described in U.S. Pat. No. 5,641,870 for example. Such linearantibody fragments may be monospecific or bispecific.

In particular embodiments, an antibody or antigen-binding fragmentthereof comprises the heavy chain complementary determining regions(CDRs) and light chain CDRs of PGT 121 LO6 (defined by any numberingscheme), wherein the antibody or antigen-binding fragment thereofcomprises one or more, two or more, three or more, or all four of thefollowing features:

(A) the heavy chain is an allotype other than IgG1m3 (e.g., Glm17, Glm1,nGlm1, Glm2, nGlm2, Glm17,1, Glm17,1,2 or Glm3,1), wherein in particularembodiments, the allotype is IgG1m17 allotype;

(B) the light chain is Lambda2;

(C) the heavy chain constant region (Fc) comprises one or more aminoacid substitutions as compared to the Fc of PGT-121 LO6 at one or moreof position 236, position 239, position 330, position 332, position 428,and position 434, wherein in particular embodiments, the one or moreamino acid substitutions are selected from: Ala at position 236, Asp atposition 239, Leu at position 330, Glu at position 332, Leu at position428, and Ser at position 434; and

(D) the heavy chain variable region (Fab) comprises one or more aminoacid substitutions of a glycosylation site present in the Fab of PGT-121LO6 or an immunogenic region in the Fab of PGT-121 L06, wherein inparticular embodiments, the glycosylation sites present in the Fab ofPGT-121 LO6 are located at positions 58-60, 68-70 and 105-107 and theimmunogenic region in the Fab of PGT-121 LO6 is located at positions82a-82c, and wherein in certain embodiments, the one or more amino acidsubstitutions is selected from: Ser-Ser-Val at positions 82a-82c,Thr-Gly-Val at positions 82a-82c, Gln at position 39, Asn at position60, His at position 68, Lys at position 105, Thr at position 105, andHis at position 105.

In particular embodiments, the antibody or antigen-binding fragmentthereof comprises any of the following combination of featuresidentified above: A and B; A and C; A and D; B and C; B and D; C and D;A, B and C; A, B and D; A, C and D; B, C and D; or A, B, C and D.

In particular embodiments of any of the antibodies or antigen-bindingfragments thereof described herein, the heavy chain is IgG1m17 allotype.

In particular embodiments of any of the antibodies or antigen-bindingfragments thereof described herein, the heavy chain constant region (Fc)comprises Ala at position 236, Asp at position 339, Leu at position 330,Glu at 332, Leu at 428, and Ser at position 434.

In particular embodiments of any of the antibodies or antigen-bindingfragments thereof described herein, the heavy chain constant region (Fc)comprises Lys at position 214, Glu at position 356, Met at position 358,and Ala at position 431.

In particular embodiments of any of the antibodies or antigen-bindingfragments thereof described herein, the heavy chain constant region (Fc)comprises the heavy chain sequence of PGT121.33.

In one embodiments of any of the antibodies or antigen-binding fragmentsthereof described herein, the heavy chain constant region (Fc) comprisesthe heavy chain sequence of PGT121.42, PGT121.43, PGT121.60, PGT121.61,PGT121.54, PGT121.55, PGT121.64, and PGT121.65. In other embodiments ofany of the antibodies or antigen-binding fragments thereof describedherein, the heavy chain constant region (Fc) is set forth in any of SEQID NOs: 252, 255, 266, 267, 268, 269, 272, and 273.

In particular embodiments of any of the antibodies or antigen-bindingfragments thereof described herein, the light chain is Lambda2. Inparticular embodiments of any of the antibodies or antigen-bindingfragments thereof described herein, the light chain comprises Ala atposition 6, Ser at position 8, Ile at position 30, Ser at position 46,Val at position 49, Ala at position 5, Thr at position 57, Arg atposition 83, Gln at position 88 and Thr at position 103. In particularembodiments of any of the antibodies or antigen-binding fragmentsthereof described herein, the light chain comprises any of the lightchain sequences or variable regions thereof shown in Table 1. In someembodiments of any of the antibodies or antigen-binding fragmentsthereof described herein, the light chain region comprises the lightchain sequence of PGT121.42, PGT121.43, PGT121.60, PGT121.61, PGT121.54,PGT121.55, PGT121.64, and PGT121.65. In certain embodiments of any ofthe antibodies or antigen-binding fragments thereof described herein,the light chain is set forth in any of SEQ ID NOs: 338, 341, 352, 353,354, 355, 358, and 359.

In particular embodiments of any of the antibodies or antigen-bindingfragments thereof described herein, the heavy chain variable region(Fab) comprises amino acid substitution at two or more or all threeglycosylation sites present in PGT-121 L06. In particular embodiments,the heavy chain variable region (Fab) comprises one or more of:Ser-Ser-Val at positions 82a-82c, Thr-Gly-Val at positions 82a-82c, Glnat position 39, Asn at position 60, His at position 68, Lys at position105, Thr at position 105 and His at position 105. In particularembodiments of any of the antibodies or antigen-binding fragmentsthereof described herein, the heavy chain variable region (Fab)comprises Ser-Ser-Val at positions 82a-82c or Thr-Gly-Val at positions82a-82c. In particular embodiments, the heavy chain variable region(Fab) comprises Asn at position 60, His at position 68, Lys at position105, Thr at position 105 and His at position 105. In particularembodiments, the heavy chain variable region (Fab) comprises:Ser-Ser-Val at positions 82a-82c, Thr-Gly-Val at positions 82a-82c, Glnat position 39, Asn at position 60, His at position 68, Lys at position105, Thr at position 105 and His at position 105. In particularembodiments of any of the antibodies or antigen-binding fragmentsthereof described herein, the heavy chain variable region comprises anyof the heavy chain variable regions shown in Table 1.

In particular embodiments, the antibody or antigen-binding fragmentthereof comprises a heavy chain (or fragment thereof) and/or a lightchain (or fragment thereof) having a sequence shown in Table 1. Inparticular embodiments, it has a combination of any heavy chain and anylight chain shown in Table 1. In particular embodiments, the antibody orantigen-binding fragment thereof comprises a heavy chain (or fragmentthereof) set forth in SEQ ID NOs: 404, 423, 425, 427, 429 and 449. Inparticular embodiments, the antibody or antigen-binding fragment thereofcomprises a light chain (or fragment thereof) set forth in SEQ ID NOs:415, 424, 426, 428, 430 and 450. In some embodiments, the disclosureprovides for an antibody, or an antigen-binding fragment thereof,comprising the heavy chain complementary determining regions 1-3 (CDRs1-3) set forth in SEQ ID NOs: 363, 405 and 406 and the light chain CDRs1-3 set forth in SEQ ID NOs: 416, 417 and 418. In some embodiments, thedisclosure provides for an antibody, or an antigen-binding fragmentthereof, comprising the heavy chain complementary determining regions1-3 (CDRs 1-3) set forth in SEQ ID NOs: 362, 364 and 367 and the lightchain CDRs 1-3 set forth in SEQ ID NOs: 395, 396 and 397. In someembodiments, the disclosure provides for an antibody, or anantigen-binding fragment thereof, comprising the heavy chaincomplementary determining regions 1-3 (CDRs 1-3) set forth in SEQ IDNOs: 362, 366 and 367 and the light chain CDRs 1-3 set forth in SEQ IDNOs: 395, 396 and 397. In some embodiments, the disclosure provides foran antibody, or an antigen-binding fragment thereof, comprising theheavy chain complementary determining regions 1-3 (CDRs 1-3) set forthin SEQ ID NOs: 431, 432 and 433 and the light chain CDRs 1-3 set forthin SEQ ID NOs: 442, 443 and 444.

The present invention also includes nucleic acid molecules encoding anantibody or antigen-binding fragment thereof of the present invention.In particular embodiments, the nucleic acid molecules encode an antibodylight chain (or a fragment thereof) or an antibody light chain (or afragment thereof), or both. In certain embodiments, the nucleic acidencodes a bivalent antibody or fragment thereof. In particularembodiments, the nucleic acid is a DNA, a cDNA or an mRNA. In particularembodiments, the nucleic acid molecule is codon-optimized to enhanceexpression in a host cell.

The invention further includes polypeptide variants of antibody andantigen-binding fragments thereof disclosed herein, including, e.g.,intact antibodies, scFvs, heavy chains, light chains, V_(H) regions, andV_(L) regions. In certain embodiments, the invention includes apolypeptide variant having at least 70%, at least 75%, at least 80%, atleast 85%, at least 90%, at least 95%, at least 98%, or at least 99%homology with a polypeptide described herein, including any of thoseshown in Table 1.

The invention further includes nucleic acid molecules that encodepolypeptide variants of antibody and antigen-binding fragments thereofdisclosed herein, as well as polynucleotide variants of nucleic acidmolecules encoding an antibody or antigen-binding fragment thereof ofthe present invention, such as, e.g., intact antibodies, scFvs, heavychains, light chains, V_(H) regions, and V_(L) regions. In certainembodiments, the invention includes a polynucleotide variant having atleast 70%, at least 75%, at least 80%, at least 85%, at least 90%, atleast 95%, at least 98%, or at least 99% homology with a polynucleotidedescribed herein.

In certain embodiments of the nucleic acid molecules, they (or parts orsubregions thereof) may be codon optimized. Codon optimization methodsare known in the art and may be used, e.g., to match codon frequenciesin target and host organisms, to ensure proper folding, bias GC contentto increase mRNA stability or reduce secondary structures, minimizetandem repeat codons or base runs that may impair gene construction orexpression, customize transcriptional and translational control regions,insert or remove protein trafficking sequences, modify ribosome bindingsites and mRNA degradation sites, to adjust translational rates to allowthe various domains of the protein to fold properly, or to reduce oreliminate problem secondary structures within the polynucleotide. Codonoptimization tools, algorithms and services are known in the art,non-limiting examples include services from GeneArt (Life Technologies),DNA2.0 (Menlo Park Calif.) and/or proprietary methods. In oneembodiment, the nucleic acid sequence is optimized using optimizationalgorithms. Examples of codon options for each amino acid are given inTable 3.

TABLE 3 Codon Options Single Letter Amino Acid Code Codon OptionsIsoleucine I ATT, ATC, ATA Leucine L CTT, CTC, CTA, CTG, TTA, TTG ValineV GTT, GTC, GTA, GTG Phenylalanine F TTT, TTC Methionine M ATG CysteineC TGT, TGC Alanine A GCT, GCC, GCA, GCG Glycine G GGT, GGC, GGA, GGGProline P CCT, CCC, CCA, CCG Threonine T ACT, ACC, ACA, ACG Serine STCT, TCC, TCA, TCG, AGT, AGC Tyrosine Y TAT, TAC Tryptophan W TGGGlutamine Q CAA, CAG Asparagine N AAT, AAC Histidine H CAT, CAC Glutamicacid E GAA, GAG Aspartic acid D GAT, GAC Lysine K AAA, AAG Arginine RCGT, CGC, CGA, CGG, AGA, AGG Selenocysteine Sec UGA in mRNA in presenceof Selenocystein insertion element (SECIS) Stop codons Stop TAA, TAG,TGA

The present invention also includes vectors comprising a nucleic acidmolecule of the invention. A vector can be of any type, for example, arecombinant vector such as an expression vector. Vectors include, butare not limited to, plasmids, cosmids, bacterial artificial chromosomes(BAC) and yeast artificial chromosomes (YAC) and vectors derived frombacteriophages or plant or animal (including human) viruses. Vectors cancomprise an origin of replication recognized by the proposed host celland in the case of expression vectors, promoter and other regulatoryregions recognized by the host cell. In particular embodiments, a vectorcomprises a polynucleotide encoding an antibody or antigen-bidingfragment thereof of the invention operably linked to a promoter andoptionally additional regulatory elements. Certain vectors are capableof autonomous replication in a host into which they are introduced(e.g., vectors having a bacterial origin of replication can replicate inbacteria). Other vectors can be integrated into the genome of a hostupon introduction into the host, and thereby are replicated along withthe host genome. Vectors include, but are not limited to, those suitablefor recombinant production of the antibodies and antigen-bindingfragments thereof of the invention, as well as those suitable forintroducing into a subject in need thereof, or a cell thereof, in orderto provide an antibody or antigen-binding fragment thereof of theinvention to the subject.

The choice of the vector is dependent on the recombinant proceduresfollowed and the host used. Introduction of vectors into host cells canbe effected by inter alia calcium phosphate transfection, virusinfection, DEAE-dextran-mediated transfection, lipofectamin transfectionor electroporation. Vectors may be autonomously replicating or mayreplicate together with the chromosome into which they have beenintegrated. In certain embodiments, the vectors contain one or moreselection markers. The choice of the markers may depend on the hostcells of choice. These include, but are not limited to, kanamycin,neomycin, puromycin, hygromycin, zeocin, thymidine kinase gene fromHerpes simplex virus (HSV-TK), and dihydrofolate reductase gene frommouse (dhfr). Vectors comprising one or more nucleic acid moleculesencoding the antibodies and antigen binding fragments thereof describedherein, operably linked to one or more nucleic acid molecules encodingproteins or peptides that can be used to isolate the antibodies andfragments thereof, are also covered by the disclosure. These proteins orpeptides include, but are not limited to, glutathione-S-transferase,maltose binding protein, metal-binding polyhistidine, green fluorescentprotein, luciferase and beta-galactosidase.

In particular embodiments, the vector is pcDNA™3.1+(ThermoFisher, MA),which has the following sequence:

(SEQ ID NO: 59) GACGGATCGGGAGATCTCCCGATCCCCTATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGTATCTGCTCCCTGCTTGTGTGTTGGAGGTCGCTGAGTAGTGCGCGAGCAAAATTTAAGCTACAACAAGGCAAGGCTTGACCGACAATTGCATGAAGAATCTGCTTAGGGTTAGGCGTTTTGCGCTGCTTCGCGATGTACGGGCCAGATATACGCGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCTCTGGCTAACTAGAGAACCCACTGCTTACTGGCTTATCGAAATTAATACGACTCACTATAGGGAGACCCAAGCTGGCTAGCGTTTAAACTTAAGCTTGGTACCGAGCTCGGATCCACTAGTCCAGTGTGGTGGAATTCTGCAGATATCCAGCACAGTGGCGGCCGCTCGAGTCTAGAGGGCCCGTTTAAACCCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGGCTTCTGAGGCGGAAAGAACCAGCTGGGGCTCTAGGGGGTATCCCCACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTAATTCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCTGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTCCCGGGAGCTTGTATATCCATTTTCGGATCTGATCAAGAGACAGGATGAGGATCGTTTCGCATGATTGAACAAGATGGATTGCACGCAGGTTCTCCGGCCGCTTGGGTGGAGAGGCTATTCGGCTATGACTGGGCACAACAGACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCTGTCAGCGCAGGGGCGCCCGGTTCTTTTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGAACTGCAGGACGAGGCAGCGCGGCTATCGTGGCTGGCCACGACGGGCGTTCCTTGCGCAGCTGTGCTCGACGTTGTCACTGAAGCGGGAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGGCAGGATCTCCTGTCATCTCACCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTGATGCAATGCGGCGGCTGCATACGCTTGATCCGGCTACCTGCCCATTCGACCACCAAGCGAAACATCGCATCGAGCGAGCACGTACTCGGATGGAAGCCGGTCTTGTCGATCAGGATGATCTGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAACTGTTCGCCAGGCTCAAGGCGCGCATGCCCGACGGCGAGGATCTCGTCGTGACCCATGGCGATGCCTGCTTGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGGATTCATCGACTGTGGCCGGCTGGGTGTGGCGGACCGCTATCAGGACATAGCGTTGGCTACCCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCGCTTCCTCGTGCTTTACGGTATCGCCGCTCCCGATTCGCAGCGCATCGCCTTCTATCGCCTTCTTGACGAGTTCTTCTGAGCGGGACTCTGGGGTTCGAAATGACCGACCAAGCGACGCCCAACCTGCCATCACGAGATTTCGATTCCACCGCCGCCTTCTATGAAAGGTTGGGCTTCGGAATCGTTTTCCGGGACGCCGGCTGGATGATCCTCCAGCGCGGGGATCTCATGCTGGAGTTCTTCGCCCACCCCAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGTATACCGTCGACCTCTAGCTAGAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTC.

In particular embodiments, the heavy and light chain coding sequence arecloned into the Nhel and EcoRI cut vector backbone. In certain case whenthe expressed antibody is histidine-tagged, the following codingsequence is appended to the 3′ end of the last codon of the heavy chainconstant region: -CAC CAT CAC CAT CAC CAT CAC CAT (SEQ ID NO: 60)—Stopcodon.

The invention also provides host cells comprising a nucleic acid or avector of the present invention. Any of a variety of host cells can beused. In one embodiment, a host cell is a prokaryotic cell, for example,E. coli. In another embodiment, a host cell is a eukaryotic cell, forexample, a mammalian cell, such as a Chinese Hamster Ovary (CHO) cell,COS cells, BHK cells, NSO cells or Bowes melanoma cells. Examples ofhuman host cells are, inter alia, HeLa, 911, AT1080, A549, 293 andHEK293T cells.

The present invention includes methods of producing antibodies andantigen-binding fragments thereof. In certain embodiments, they areproduced recombinantly or by chemical synthesis. For example, antibodiesand fragments thereof may be produced synthetically or by enzymatic orchemical cleavage of intact immunoglobulins or they may be geneticallyengineered by recombinant DNA techniques. Such methods of production arewell known in the art and are described, for example, in Antibodies: ALaboratory Manual, edited by E. Harlow and D. Lane (1988), Cold SpringHarbor Laboratory, Cold Spring Harbor, N.Y., which is incorporatedherein by reference. The antibodies and antigen-binding fragments may beproduced synthetically or by enzymatic or chemical cleavage of intactimmunoglobulins or they may be genetically engineered by recombinant DNAtechniques. Illustrative methods of production are well known in the artand are described, for example, in Antibodies: A Laboratory Manual,edited by E. Harlow and D. Lane (1988), Cold Spring Harbor Laboratory,Cold Spring Harbor, N.Y. Various techniques have been developed for theproduction of antibody fragments. Traditionally, these fragments werederived via proteolytic digestion of intact antibodies (see, e.g.,Morimoto et al., Journal of Biochemical and Biophysical Methods 24:107-117 (1992); and Brennan et al., Science, 229:81 (1985)). However,these fragments can now be produced directly by recombinant host cells.Fab, Fv and scFv antibody fragments can all be expressed in and secretedfrom E. coli, thus allowing the facile production of large amounts ofthese fragments. Fab′-SH fragments can be directly recovered from E.coli and chemically coupled to form F(ab′)₂ fragments (Carter et al.,Bio/Technology 10: 163-167 (1992)). According to another approach,F(ab′)₂ fragments can be isolated directly from recombinant host cellculture. Fab and F(ab′)₂ fragment with increased in vivo half-lifecomprising a salvage receptor binding epitope residues are described inU.S. Pat. No. 5,869,046. Other techniques for the production ofantibodies and antibody fragments will be apparent to the skilledpractitioner.

In one embodiment, an antibody or antigen-binding fragment thereof isproduced by isolating the antibody or antigen-binding fragment thereoffrom a host cell comprising an expression vector that encodes theantibody or antigen-binding fragment thereof. In certain embodiments,the method further comprises culturing the host cell under conditionssuitable for expression of the antibody or antigen-binding fragmentthereof and/or further comprises introducing an expression vectorencoding the antibody or antigen-binding fragment thereof into the hostcell.

Pharmaceutical Compositions

The present invention also includes pharmaceutical compositionscomprising an antibody or antigen-binding fragment thereof describedherein, or a polynucleotide encoding an antibody or antigen-bindingfragment thereof described herein, and a pharmaceutically acceptablediluent, carrier or excipient. In certain embodiments, thepharmaceutical composition comprises a therapeutically effective amountof the antibody, antigen-binding fragment thereof, or polynucleotide.

Various pharmaceutically acceptable diluents, carriers, and excipients,and techniques for the preparation and use of pharmaceuticalcompositions will be known to those of skill in the art in light of thepresent disclosure. Illustrative pharmaceutical compositions andpharmaceutically acceptable diluents, carriers, and excipients are alsodescribed in Remington: The Science and Practice of Pharmacy 20th Ed.(Lippincott, Williams & Wilkins 2003).

In particular embodiments, each carrier, diluent or excipient is“acceptable” in the sense of being compatible with the other ingredientsof the pharmaceutical composition and not injurious to the subject.Often, the pharmaceutically acceptable carrier is an aqueous pH-bufferedsolution. Some examples of materials which can serve aspharmaceutically-acceptable carriers, diluents or excipients include:water; buffers, e.g., phosphate-buffered saline; sugars, such aslactose, glucose and sucrose; starches, such as corn starch and potatostarch; cellulose, and its derivatives, such as sodium carboxymethylcellulose, ethyl cellulose and cellulose acetate; powdered tragacanth;malt; gelatin; talc; excipients, such as cocoa butter and suppositorywaxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesameoil, olive oil, corn oil and soybean oil; glycols, such as propyleneglycol; polyols, such as glycerin, sorbitol, mannitol and polyethyleneglycol; esters, such as ethyl oleate and ethyl laurate; agar; bufferingagents, such as magnesium hydroxide and aluminum hydroxide; alginicacid; pyrogen-free water; isotonic saline; Ringer's solution; ethylalcohol; phosphate buffer solutions; and other non-toxic compatiblesubstances employed in pharmaceutical formulations. Wetting agents,emulsifiers and lubricants, such as sodium lauryl sulfate and magnesiumstearate, as well as coloring agents, release agents, coating agents,sweetening, flavoring and perfuming agents, preservatives andantioxidants can also be present in the compositions.

In certain embodiments, pharmaceutical compositions are sterile. Incertain embodiments, the pharmaceutical composition has a pH in therange of 4.5 to 8.5, 4.5 to 6.5, 6.5 to 8.5, or a pH of about 5.0, about5.5, about 6.0, about 6.5, about 7.0, about 7.5, about 8.0 or about 8.5.In one embodiment, the pharmaceutical composition has an osmolarity inthe range of 240-260 or 250-330 mOsmol/L. In certain embodiments, thepharmaceutical composition is isotonic or near isotonic. In certainembodiments, the pharmaceutical composition is formulated forintravenous administration and has a concentration of antibody orfragment thereof of 10-100 mg/ml, 10-50 mg/ml, 20 to 40 mg/ml, or about30 mg/ml. In certain embodiments, the pharmaceutical composition isformulated for subcutaneous injection and has a concentration ofantibody or fragment thereof of 50-500 mg/ml, 50-250 mg/ml, or 100 to150 mg/ml, and a viscosity less than 50 cP, less than 30 cP, less than20 cP, or about 10 cP. In particular embodiments, the pharmaceuticalcompositions are liquids or solids. In particular embodiments, thepharmaceutical compositions are formulated for parenteral, e.g.,intravenous, subcutaneous, or oral administration.

The formulation of and delivery methods of pharmaceutical compositionswill generally be adapted according to the site and the disease to betreated. Exemplary formulations include, but are not limited to, thosesuitable for parenteral administration, e.g., intravenous,intra-arterial, intramuscular, or subcutaneous administration, includingformulations encapsulated in micelles, liposomes or drug-releasecapsules (active agents incorporated within a biocompatible coatingdesigned for slow-release); ingestible formulations; formulations fortopical use, such as creams, ointments and gels; and other formulationssuch as inhalants, aerosols and sprays.

Methods of Use

The present invention provides methods for treating and preventing anHIV infection or a related disease or disorder in a subject in needthereof, comprising providing to a subject in need thereof an effectiveamount of an antibody or antigen-binding fragment thereof describedherein, or a polynucleotide encoding the antibody or antigen-bindingfragment thereof. The polynucleotide may be present in a vector, e.g., aviral vector. In particular embodiments, the related disease or disorderis caused by infection with HIV. In particular embodiments, it isacquired immune deficiency syndrome (AIDS). In particular embodiments,the subject is a virologically suppressed HIV-infected mammal, while isother embodiments, the subject is a treatment-naïve HIV-infected mammal.In certain embodiments, a treatment-naïve subject has a viral loadbetween 10³ and 10⁵ copies/ml, and in certain embodiments, avirologically suppressed subject has a viral load <50 copies/ml. Inparticular embodiments, the subject is a mammal, e.g., a human. Incertain embodiments, the subject has been diagnosed with an HIV, e.g.,HIV-1 or HIV-2, infection or a related disease or disorder, e.g., AIDS,or is considered at risk for developing an HIV, e.g., HIV-1 or HIV-2,infection or a related disease or disorder, e.g., AIDS. Subjects at riskfor HIV-related diseases or disorders include patients who have comeinto contact with an infected person or who have been exposed to HIV insome other way. Administration of a prophylactic agent can occur priorto the manifestation of symptoms characteristic of HIV-related diseaseor disorder, such that a disease or disorder is prevented or,alternatively, delayed in its progression.

The present invention further provides methods for preventing orinhibiting an increase in HIV virus titer, virus replication, virusproliferation or an amount of an HIV viral DNA, HIV proviral DNA, or HIVviral protein in a subject. In one embodiment, the method comprisesproviding to the subject in need thereof an amount of an antibody orantigen-binding fragment thereof described herein, or a polynucleotideencoding the antibody or antigen-binding fragment thereof, effective toprevent an increase in HIV titer, virus replication or an amount of anHIV protein of one or more HIV strains or isolates in the subject. Incertain embodiments, the method further comprises measuring an amount ofHIV viral or proviral DNA or protein at one or more time points, e.g.,before and after the subject in provided with an antibody orantibody-binding fragment of the present invention. Methods andbiomarkers for determining an amount of HIV viral or proviral DNA orprotein in a subject are known and available in the art, and describedfor example, in Siliciano, J. D. et al., Curr Opin. HIV AIDS (2010)5(6):491-7 and Rouzioux, C. et al., Curr Opin HIV AIDS (2013)8(3):170-5, each of which are incorporated by reference in its entirety.

In certain aspect, the antibodies of the present disclosure may be usedin, for example, methods of inhibiting certain viruses such as HIVisolates described herein, prophylactic inhibiting or preventinginfections of certain viruses such as HIV isolates described herein,detection of certain viruses such as HIV isolates described herein in asample, inhibiting certain viruses such as HIV isolates describedherein, diagnosis of certain viruses such as HIV isolates describedherein.

For in vivo treatment of mammalian subject, e.g., humans, the subjectmay be administered or provided a pharmaceutical composition comprisingthe antibody or antigen-binding fragment thereof of the invention. Whenused for in vivo therapy, the antibodies and antigen-binding fragmentsthereof of the invention are typically administered or provided to thepatient in therapeutically effective amounts (i.e., amounts thateliminate or reduce the patient's viral burden and/or viral reservoir).The antibodies or antigen-binding fragments thereof are administered orprovided to a mammalian subject, e.g., a human, in accord with knownmethods, such as, but not limited to, intravenous administration, e.g.,as a bolus or by continuous infusion over a period of time, byintramuscular, intraperitoneal, intracerobrospinal, subcutaneous,intraarticular, intrasynovial, intrathecal, oral, topical, or inhalationroutes. The antibodies or antigen-binding fragments thereof may beadministered parenterally, when possible, at the target cell site, orintravenously. Intravenous or subcutaneous administration of theantibody or antigen-binding fragment thereof is preferred in certainembodiments. In particular embodiments, pharmaceutical compositions ofthe invention are administered to a patient or subject systemically,parenterally, or locally.

In particular embodiments, for parenteral administration, the antibodiesor antigen-binding fragments thereof are formulated in a unit dosageinjectable form (solution, suspension, emulsion) in association with apharmaceutically acceptable, parenteral vehicle. Examples of suchvehicles are water, saline, Ringer's solution, dextrose solution, and 5%human serum albumin. Nonaqueous vehicles such as fixed oils and ethyloleate may also be used. Liposomes may be used as carriers. The vehiclemay contain minor amounts of additives such as substances that enhanceisotonicity and chemical stability, e.g., buffers and preservatives. Incertain embodiments, the antibodies or antigen-binding fragments thereofare formulated in such vehicles at concentrations of about 1 mg/ml toabout 200 mg/ml, about 1 mg/ml to about 100 mg/ml, about 1 mg/ml toabout 50 mg/ml, about 1 mg/ml to about 25 mg/ml, about 1 mg/ml to about10 mg/ml, e.g., about 1 mg/ml, about 2 mg/ml, about 3 mg/ml, about 4mg/ml, about 5 mg/ml, about 6 mg/ml, about 7 mg/ml, about 8 mg/ml, about9 mg/ml, about 10 mg/ml about 25 mg/ml, about 50 mg/ml, about 100 mg/ml,about 150 mg/ml, or about 200 mg/ml.

The dose and dosage regimen depends upon a variety of factors readilydetermined by a physician, such as the nature of the infection, thecharacteristics of the subject, and the subject's history. In particularembodiments, the amount of antibody or antigen-binding fragment thereofadministered or provided to the subject is in the range of about 0.1mg/kg to about 50 mg/kg of the subject's body weight. Depending on thetype and severity of the infection, in certain embodiments, about 0.1mg/kg to about 50 mg/kg body weight (e.g., about 0.1-15 mg/kg/dose) ofantibody or antigen-binding fragment thereof may be provided as aninitial candidate dosage to the patient, whether, for example, by one ormore separate administrations, or by continuous infusion. The progressof the therapy is readily monitored by conventional methods and assaysand based on criteria known to the physician or other persons of skillin the art.

In particular embodiments, an antibody or fragment thereof of thepresent invention may be provided to a subject in an amount sufficientto achieve a C_(trough) level of ≤0.1 μg/mL, ≤0.5 μg/ml, ≤1 μg/ml, ≤10μg/ml, ≤20 μg/ml, ≤30 μg/ml, ≤40 μg/ml, ≤50 μg/ml, ≤75 μg/ml, <100μg/ml, ≤200 μg/ml, ≤300 μg/ml, or ≤500 μg/mL. In certain embodiments, anantibody or fragment thereof of the present invention may be provided toa subject in an amount sufficient to achieve a C_(trough) level of 1μg/ml to 100 μg/ml. In particular embodiments, an antibody or fragmentthereof of the present invention may be provided to a subject in anamount sufficient to achieve a C_(max) level of ≥1 μg/ml, ≥5 μg/ml, ≥10μg/ml, ≥50 μg/ml, ≥100 μg/ml, ≥200 μg/ml, ≥300 μg/ml, ≥400 μg/ml, ≥500μg/ml, or ≥1000 μg/mL. In certain embodiments, an antibody or fragmentthereof of the present invention may be provided to a subject in anamount sufficient to achieve a C_(max) level of 100 μg/ml to 1000 μg/ml.

In certain embodiments, the antibody or antigen-binding fragment thereofof the present invention is provided to the subject in combination withone or more additional therapeutic agent used to treat HIV infection ora related disease or disorder. In certain embodiments, a method fortreating or preventing an HIV infection in a mammal, e.g., a human,having or at risk of having the infection is provided, comprisingadministering to the human a therapeutically effective amount of anantibody or fragment thereof disclosed herein, or a pharmaceuticallyacceptable salt thereof, in combination with a therapeutically effectiveamount of one or more (e.g., one, two, three, one or two, or one tothree) additional therapeutic agents. In one embodiment, a method fortreating an HIV infection in a human having or at risk of having theinfection is provided, comprising administering to the human atherapeutically effective amount of an antibody or fragment thereofdisclosed herein, or a pharmaceutically acceptable salt thereof, incombination with a therapeutically effective amount of one or more(e.g., one, two, three, one or two, or one to three) additionaltherapeutic agents.

In certain embodiments, the present disclosure provides a method fortreating an HIV infection, comprising administering to a patient in needthereof a therapeutically effective amount of an antibody or fragmentthereof disclosed herein, or a pharmaceutically acceptable salt thereof,in combination with a therapeutically effective amount of one or moreadditional therapeutic agents which are suitable for treating an HIVinfection.

In certain embodiments, two or more antibodies or fragments thereofdisclosed herein, or pharmaceutically acceptable salts thereof, may beprovided to the subject. In particular embodiments, the two or moreantibodies or fragments thereof may have different specificities, e.g.,each may preferentially bind, inhibit, or neutralize a different HIVstrain or combination of strains, as compared to each other. In certainembodiments, the antibodies may comprise any of the following: PGT-121LO6 or one of its variants including somatic variants PGT122, PGT123,PGT124, 10-1074, PGT133, or PGT134 (or any of the variants describedherein); PGT145 or one of its variants; PG16 or one of its variants, PG9or one of its variants; PGT151 or one of its variants; or any othercombination of bNAbs that provide complementary binding, neutralizationor infected cell killing activity. In particular embodiments, the HIVstrains are Clade B strains.

An antibody or fragment thereof disclosed herein may be combined withone or more additional therapeutic agents in any dosage amount of theantibody or fragment thereof (e.g., from 50 mg to 1000 mg of compound).Also, an antibody or fragment thereof disclosed herein may be combinedwith one or more additional therapeutic agents in any dosage amount ofthe antibody or fragment thereof (e.g., about 0.1 mg/kg to about 50mg/kg of the subject's body weight or from 50 mg to 4000 mg ofcompound).

In one embodiment, pharmaceutical compositions comprising an antibody orfragment thereof disclosed herein, or a pharmaceutically acceptable saltthereof, in combination with one or more (e.g., one, two, three, one ortwo, or one to three) additional therapeutic agents, and apharmaceutically acceptable carrier, diluent or excipient are provided.

In one embodiment, kits comprising an antibody or fragment thereofdisclosed herein, or a pharmaceutically acceptable salt thereof, incombination with one or more (e.g., one, two, three, one or two, or oneto three) additional therapeutic agents are provided.

In the above embodiments, the additional therapeutic agent may be ananti-HIV agent. For example, in some embodiments, the additionaltherapeutic agent is selected from the group consisting of HIV proteaseinhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reversetranscriptase, HIV nucleoside or nucleotide inhibitors of reversetranscriptase, HIV integrase inhibitors, HIV non-catalytic site (orallosteric) integrase inhibitors, HIV entry inhibitors (e.g., CCR5inhibitors, gp41 inhibitors (i.e., fusion inhibitors) and CD4 attachmentinhibitors), CXCR4 inhibitors, gp120 inhibitors, G6PD and NADH-oxidaseinhibitors, HIV vaccines, HIV maturation inhibitors, latency reversingagents (e.g., histone deacetylase inhibitors, proteasome inhibitors,protein kinase C (PKC) activators, and BRD4 inhibitors), compounds thattarget the HIV capsid (“capsid inhibitors”; e.g., capsid polymerizationinhibitors or capsid disrupting compounds, HIV nucleocapsid p7 (NCp7)inhibitors, HIV p24 capsid protein inhibitors), pharmacokineticenhancers, immune-based therapies (e.g., Pd-1 modulators, Pd-L1modulators, toll like receptors modulators, IL-15 agonists), HIVantibodies, bispecific antibodies and “antibody-like” therapeuticproteins (e.g., dual-affinity re-targeting antibodies (DARTs®),bi-specific antibodies with two different arms that bind to twodifferent targets or different epitopes on the same target (DUOBODIES®),bi-specific T-cell engagers (BITES®), antibodies with enhanced Fcdomains (XMABS®), Tetravalent Bispecific Tandem Antibodies (TANDABS®),Fab derivatives) including those targeting HIV gp120 or gp41,combination drugs for HIV, HIV p17 matrix protein inhibitors, IL-13antagonists, Peptidyl-prolyl cis-trans isomerase A modulators, Proteindisulfide isomerase inhibitors, Complement C5a receptor antagonists, DNAmethyltransferase inhibitor, HIV vif gene modulators, Vif dimerizationantagonists, HIV-1 viral infectivity factor inhibitors, TAT proteininhibitors, HIV-1 Nef modulators, Hck tyrosine kinase modulators, mixedlineage kinase-3 (MLK-3) inhibitors, HIV-1 splicing inhibitors, Revprotein inhibitors, Integrin antagonists, Nucleoprotein inhibitors,Splicing factor modulators, COMM domain containing protein 1 modulators,HIV Ribonuclease H inhibitors, Retrocyclin modulators, CDK-9 inhibitors,Dendritic ICAM-3 grabbing nonintegrin 1 inhibitors, HIV GAG proteininhibitors, HIV POL protein inhibitors, Complement Factor H modulators,Ubiquitin ligase inhibitors, Deoxycytidine kinase inhibitors, Cyclindependent kinase inhibitors Proprotein convertase PC9 stimulators, ATPdependent RNA helicase DDX3× inhibitors, reverse transcriptase primingcomplex inhibitors, HIV gene therapy, PI3K inhibitors, compounds such asthose disclosed in WO 2013/006738 (Gilead Sciences), US 2013/0165489(University of Pennsylvania), WO 2013/091096A1 (Boehringer Ingelheim),WO 2009/062285 (Boehringer Ingelheim), US20140221380 (Japan Tobacco),US20140221378 (Japan Tobacco), WO 2010/130034 (Boehringer Ingelheim), WO2013/159064 (Gilead Sciences), WO 2012/145728 (Gilead Sciences),WO2012/003497 (Gilead Sciences), WO2014/100323 (Gilead Sciences),WO2012/145728 (Gilead Sciences), WO2013/159064 (Gilead Sciences) and WO2012/003498 (Gilead Sciences) and WO 2013/006792 (Pharma Resources), andother drugs for treating HIV, and combinations thereof.

In certain embodiments, the additional therapeutic is selected from thegroup consisting of HIV protease inhibitors, HIV non-nucleoside ornon-nucleotide inhibitors of reverse transcriptase, HIV nucleoside ornucleotide inhibitors of reverse transcriptase, HIV integraseinhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors,pharmacokinetic enhancers, and combinations thereof.

In particular embodiments, the additional therapeutic agent is a latencyreversing agent (LRA), e.g., a TLR7 agonist. In other embodiments, theadditional therapeutic agent is a latency reversing agent (LRA), e.g., aTLR8 agonist. Examples of TLR agonists include but are not limited toVesatolimod. Additional examples include but are not limited to thecompounds described in U.S. Pat. No. 8,367,670 and the compoundsdescribed in U.S. Patent Application Publication No. 2016-0289229. Inone embodiment, the antibody of the present invention may be combinedwith TLR7 agonist such as Vesatolimod. In another embodiment, theantibody of the present invention may be combined with TLR8 agonist. Inone embodiment, the additional therapeutic agent is a TLR modulator. TLRmodulators may include modulators of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6,TLR7, TLR8, TLR9, TLR10, TLR11, TLR12, and TLR13. Examples of TLR3modulators include rintatolimod, poly-ICLC, RIBOXXON®, Apoxxim,RIBOXXIM®, IPH-33, MCT-465, MCT-475, and ND-1.1. Examples of TLR7modulators include GS-9620, GSK-2245035, imiquimod, resiquimod,DSR-6434, DSP-3025, IMO-4200, MCT-465, MEDI-9197, 3M-051, SB-9922,3M-052, Limtop, TMX-30X, TMX-202, RG-7863, RG-7795, and the compoundsdisclosed in US20100143301 (Gilead Sciences), US20110098248 (GileadSciences), and US20090047249 (Gilead Sciences). Examples of TLR8modulators include motolimod, resiquimod, 3M-051, 3M-052, MCT-465,IMO-4200, VTX-763, VTX-1463, and the compounds disclosed inUS20140045849 (Janssen), US20140073642 (Janssen), WO2014/056953(Janssen), WO2014/076221 (Janssen), WO2014/128189 (Janssen),US20140350031 (Janssen), WO2014/023813 (Janssen), US20080234251 (ArrayBiopharma), US20080306050 (Array Biopharma), US20100029585 (VentirxPharma), US20110092485 (Ventirx Pharma), US20110118235 (Ventirx Pharma),US20120082658 (Ventirx Pharma), US20120219615 (Ventirx Pharma),US20140066432 (Ventirx Pharma), US20140088085 (Ventirx Pharma),US20140275167 (Novira Therapeutics), and US20130251673 (NoviraTherapeutics). Examples of TLR9 modulators include BB-001, BB-006,CYT-003, IMO-2055, IMO-2125, IMO-3100, IMO-8400, IR-103, IMO-9200,agatolimod, DIMS-9054, DV-1079, DV-1179, AZD-1419, leftolimod(MGN-1703), litenimod, and CYT-003-QbG10.

Without wishing to be bound by any particular theory, it is believedthat LRAs may increase cell surface Env expression, thus enhancinglatent cell killing via effector function enhanced by the antibodies ofthe present invention. In certain embodiments, the additionaltherapeutic agents comprise one or more antiretroviral therapies (ARTs).In particular embodiments, the ART is a combination ART (cART) such ashighly active ART (HAART). In particular embodiments, the ART comprisesone or more of a nucleoside reverse transcriptase inhibitor (NRTI), anon-nucleoside reverse transcriptase inhibitor (NNRTI), a proteaseinhibitor (PI), an entry inhibitor, or an HIV integrase inhibitor.Examples of NRTIs include but are not limited to: Zidovudine (Retrovir,AZT); Didanosine (Videx, Videx EC, ddl); Stavudine (Zerit, d4T);Lamivudine (Epivir, 3TC); Tenofovir, a nucleotide analog (Viread, TDF);Combivir (combination of zidovudine and lamivudine); Trizivir(combination of zidovudine, lamivudine and abacavir); Emtricitabine(Emtriva, FTC); Truvada (combination of emtricitabine and tenofovir);and Epzicom (combination of abacavir and lamivudine). Examples of NNRTIsinclude but are not limited to: Nevirapine (Viramune, NVP); Delavirdine(Rescriptor, DLV); Efavirenz (Sustiva or Stocrin, EFV, also part ofAtripla); Etravirine (Intelence, ETR); and Rilpivirine (Edurant, RPV,also part of Complera or Epivlera). Examples of PIs include but are notlimited to: Saquinavir (Invirase, SQV); Indinavir (Crixivan, IDV);Ritonavir (Norvir, RTV); Nelfinavir (Viracept, NFV); Amprenavir(Agenerase, APV); Lopinavir/ritonavir (Kaletra or Aluvia, LPV/RTV);Atazanavir (Reyataz, ATZ); Fosamprenavir (Lexiva, Telzir, FPV);Tipranavir (Aptivus, TPV); and Darunavir (Prezista, DRV). Examples ofentry inhibitors include but are not limited to: Enfuvirtide (Fuzeon,ENF, T-20) and Maraviroc (Selzentry or Celsentri, MVC). Examples of HIVintegras inhibitors include but are not limited to: Raltegravir(Isentress, RAL); Elvitegravir (EVG, part of the combination Stribild)and Dolutegravir (Tivicay, DTG).

In certain embodiments an antibody or fragment thereof disclosed hereinis formulated as a tablet, which may optionally contain one or moreother compounds useful for treating HIV. In certain embodiments, thetablet can contain another active ingredient for treating HIV, such asHIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitorsof reverse transcriptase, HIV nucleoside or nucleotide inhibitors ofreverse transcriptase, HIV integrase inhibitors, HIV non-catalytic site(or allosteric) integrase inhibitors, pharmacokinetic enhancers, andcombinations thereof.

In certain embodiments, such tablets are suitable for once daily dosing.In certain embodiments, the additional therapeutic agent is selectedfrom one or more of:

-   -   (1) Combination drugs selected from the group consisting of        ATRIPLA® (efavirenz+tenofovir disoproxil        fumarate+emtricitabine), COMPLERA® (EVIPLERA®,        rilpivirine+tenofovir disoproxil fumarate+emtricitabine),        STRIBILD® (elvitegravir+cobicistat+tenofovir disoproxil        fumarate+emtricitabine), dolutegravir+abacavir        sulfate+lamivudine, TRIUMEQ® (dolutegravir+abacavir+lamivudine),        lamivudine+nevirapine+zidovudine, dolutegravir+rilpivirine,        dolutegravir+rilpivirine hydrochloride, atazanavir        sulfate+cobicistat, atazanavir+cobicistat, darunavir+cobicistat,        efavirenz+lamivudine+tenofovir disoproxil fumarate, tenofovir        alafenamide hemifumarate+emtricitabine+cobicistat+elvitegravir,        tenofovir alafenamide hemifumarate+emtricitabine, tenofovir        alafenamide+emtricitabine, tenofovir alafenamide        hemifumarate+emtricitabine+rilpivirine, tenofovir        alafenamide+emtricitabine+rilpivirine, Vacc-4x+romidepsin,        darunavir+tenofovir alafenamide        hemifumarate+emtricitabine+cobicistat, APH-0812,        raltegravir+lamivudine, KALETRA® (ALUVIA®, lopinavir+ritonavir),        atazanavir sulfate+ritonavir, COMBIVIR® (zidovudine+lamivudine,        AZT+3TC), EPZICOM® (Livexa®, abacavir sulfate+lamivudine,        ABC+3TC), TRIZIVIR® (abacavir sulfate+zidovudine+lamivudine,        ABC+AZT+3TC), TRUVADA® (tenofovir disoproxil        fumarate+emtricitabine, TDF+FTC),        doravirine+lamivudine+tenofovir disoproxil fumarate,        doravirine+lamivudine+tenofovir disoproxil, tenofovir+lamivudine        and lamivudine+tenofovir disoproxil fumarate;    -   (2) HIV protease inhibitors selected from the group consisting        of amprenavir, atazanavir, fosamprenavir, fosamprenavir calcium,        indinavir, indinavir sulfate, lopinavir, ritonavir, nelfinavir,        nelfinavir mesylate, saquinavir, saquinavir mesylate,        tipranavir, brecanavir, darunavir, DG-17, TMB-657 (PPL-100) and        TMC-310911;    -   (3) HIV non-nucleoside or non-nucleotide inhibitors of reverse        transcriptase selected from the group consisting of delavirdine,        delavirdine mesylate, nevirapine, etravirine, dapivirine,        doravirine, rilpivirine, efavirenz, KM-023, VM-1500, lentinan        and AIC-292;    -   (4) HIV nucleoside or nucleotide inhibitors of reverse        transcriptase selected from the group consisting of VIDEX®        (didanosine) and VIDEX® EC (extended-release didanosine, ddl),        zidovudine, emtricitabine, didanosine, stavudine, zalcitabine,        lamivudine, censavudine, abacavir, abacavir sulfate,        elvucitabine, alovudine, phosphazid, fozivudine tidoxil,        apricitabine, KP-1461, fosalvudine tidoxil, tenofovir, tenofovir        disoproxil, tenofovir disoproxil fumarate, tenofovir disoproxil        hemifumarate, tenofovir alafenamide, tenofovir alafenamide        hemifumarate, tenofovir alafenamide fumarate, adefovir, adefovir        dipivoxil, and festinavir;    -   (5) HIV integrase inhibitors selected from the group consisting        of curcumin, derivatives of curcumin, chicoric acid, derivatives        of chicoric acid, 3,5-dicaffeoylquinic acid, derivatives of        3,5-dicaffeoylquinic acid, aurintricarboxylic acid, derivatives        of aurintricarboxylic acid, caffeic acid phenethyl ester,        derivatives of caffeic acid phenethyl ester, tyrphostin,        derivatives of tyrphostin, quercetin, derivatives of quercetin,        raltegravir, elvitegravir, dolutegravir and cab otegravir;    -   (6) HIV non-catalytic site, or allosteric, integrase inhibitors        (NCINI) selected from the group consisting of CX-05168, CX-05045        and CX-14442;    -   (7) HIV gp41 inhibitors selected from the group consisting of        enfuvirtide, sifuvirtide and albuvirtide;    -   (8) HIV entry inhibitors selected from the group consisting of        cenicriviroc;    -   (9) HIV gp120 inhibitors selected from the group consisting of        Radha-108 (Receptol) and BMS-663068;    -   (10) CCR5 inhibitors selected from the group consisting of        aplaviroc, vicriviroc, maraviroc, cenicriviroc, PRO-140,        Adaptavir (RAP-101), nifeviroc (TD-0232), TD-0680, and vMIP        (Haimipu);    -   (11) CD4 attachment inhibitors, e.g., Fostemsavir        (BMS-663068); (12) inhibitors of post-binding events required        for entry selected from the group consisting of ibalizumab;    -   (12) CXCR4 inhibitors selected from the group consisting of        plerixafor, ALT-1188, vMIP and Haimipu;    -   (13) Pharmacokinetic enhancers selected from the group        consisting of cobicistat and ritonavir;    -   (14) Immune-based therapies selected from the group consisting        of dermaVir, interleukin-7, plaquenil (hydroxychloroquine),        proleukin (aldesleukin, IL-2), interferon alfa, interferon        alfa-2b, interferon alfa-n3, pegylated interferon alfa,        interferon gamma, hydroxyurea, mycophenolate mofetil (MPA) and        its ester derivative mycophenolate mofetil (MMF), WF-10,        ribavirin, IL-2, IL-12, polymer polyethyleneimine (PEI), Gepon,        VGV-1, MOR-22, BMS-936559, toll-like receptors modulators (TLR1,        TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, TLR11,        TLR12 and TLR13), rintatolimod and IR-103;    -   (15) HIV vaccines selected from the group consisting of peptide        vaccines, recombinant subunit protein vaccines, live vector        vaccines, DNA vaccines, virus-like particle vaccines        (pseudovirion vaccine), CD4-derived peptide vaccines, vaccine        combinations, rgp120 (AIDSVAX), ALVAC HIV (vCP1521)/AIDSVAX B/E        (gp120) (RV144), monomeric gp120 HIV-1 subtype C vaccine        (Novartis), Remune, ITV-1, Contre Vir, Ad5-ENVA-48, DCVax-001        (CDX-2401), PEP-6409, Vacc-4x, Vacc-05, VAC-3S, multiclade DNA        recombinant adenovirus-5 (rAd5), Pennvax-G, VRC-HIV        MAB060-00-AB, AVX-101, AVX-201, HIV-LAMP-vax, Ad35, Ad35-GRIN,        NAcGM3/VSSP ISA-51, poly-ICLC adjuvanted vaccines, TatImmune,        GTU-multiHIV (FIT-06), AGS-004, gp140[delta]V2.TV1+MF-59, rVSVIN        HIV-1 gag vaccine, SeV-Gag vaccine, AT-20, DNK-4, Ad35-GRIN/ENV,        TBC-M4, HIVAX, HIVAX-2, NYVAC-HIV-PT1, NYVAC-HIV-PT4,        DNA-HIV-PT123, rAAV1-PG9DP, GOVX-B11, GOVX-B21, ThV-01, TUTI-16,        VGX-3300, TV1-HIV-1, Ad-4 (Ad4-env Clade C+Ad4-mGag),        EN41-UGR7C, EN41-FPA2, PreVaxTat, TL-01, SAV-001, AE-H,        MYM-V101, CombiHlVvac, ADVAX, MYM-V201, MVA-CMDR, MVATG-17401,        ETV-01, CDX-1401, rcAd26.MOS1.HIV-Env and DNA-Ad5        gag/pol/nef/nev (HVTN505);    -   (16) HIV antibodies, bispecific antibodies and “antibody-like”        therapeutic proteins (such as dual-affinity re-targeting        antibodies (DARTs®), bi-specific antibodies with two different        arms that bind to two different targets or different epitopes on        the same target (DUOBODIES®), bi-specific T-cell engagers        (BITES®), antibodies with enhanced Fc domains (XMABS®),        Tetravalent Bispecific Tandem Antibodies (TANDABS®), Fab        derivatives) including BMS-936559, TMB-360 and those targeting        HIV gp120 or gp41 selected from the group consisting of        bavituximab, UB-421, C2F5, C2G12, C4E10, C2F5+C2G12+C4E10,        3-BNC-117, PGT145, PGT121, MDX010 (ipilimumab), VRC01, A32, 7B2,        10E8, VRC-07-523 and VRC07;    -   (17) latency reversing agents selected from the group consisting        of Histone deacetylase inhibitors such as Romidepsin,        vorinostat, panobinostat; Proteasome inhibitors such as Velcade;        protein kinase C (PKC) activators such as Indolactam,        Prostratin, Ingenol B and DAG-lactones, Ionomycin, GSK-343, PMA,        SAHA, BRD4 inhibitors, IL-15, JQ1, disulfram, and amphotericin        B;    -   (18) HIV nucleocapsid p7 (NCp7) inhibitors selected from the        group consisting of azodicarbonamide;    -   (19) HIV maturation inhibitors selected from the group        consisting of BMS-955176 and GSK-2838232;    -   (20) PI3K inhibitors selected from the group consisting of        idelalisib, AZD-8186, buparlisib, CLR-457, pictilisib,        neratinib, rigosertib, rigosertib sodium, EN-3342, TGR-1202,        alpelisib, duvelisib, UCB-5857, taselisib, XL-765, gedatolisib,        VS-5584, copanlisib, CAI orotate, perifosine, RG-7666,        GSK-2636771, DS-7423, panulisib, GSK-2269557, GSK-2126458,        CUDC-907, PQR-309, INCB-040093, pilaralisib, BAY-1082439,        puquitinib mesylate, SAR-245409, AMG-319, RP-6530, ZSTK-474,        MLN-1117, SF-1126, RV-1729, sonolisib, LY-3023414, SAR-260301        and CLR-1401;    -   (21) the compounds disclosed in WO 2004/096286 (Gilead        Sciences), WO 2006/110157 (Gilead Sciences), WO 2006/015261        (Gilead Sciences), WO 2013/006738 (Gilead Sciences), US        2013/0165489 (University of Pennsylvania), US20140221380 (Japan        Tobacco), US20140221378 (Japan Tobacco), WO 2013/006792 (Pharma        Resources), WO 2009/062285 (Boehringer Ingelheim), WO        2010/130034 (Boehringer Ingelheim), WO 2013/091096A1 (Boehringer        Ingelheim), WO 2013/159064 (Gilead Sciences), WO 2012/145728        (Gilead Sciences), WO2012/003497 (Gilead Sciences),        WO2014/100323 (Gilead Sciences), WO2012/145728 (Gilead        Sciences), WO2013/159064 (Gilead Sciences) and WO 2012/003498        (Gilead Sciences); and    -   (22) other drugs for treating HIV selected from the group        consisting of BanLec, MK-8507, AG-1105, TR-452, MK-8591, REP 9,        CYT-107, alisporivir, NOV-205, IND-02, metenkefalin, PGN-007,        Acemannan, Gamimune, Prolastin, 1,5-dicaffeoylquinic acid,        BIT-225, RPI-MN, VSSP, Hlviral, IMO-3100, SB-728-T, RPI-MN,        VIR-576, HGTV-43, MK-1376, rHIV7-shl-TAR-CCR5RZ, MazF gene        therapy, BlockAide, ABX-464, SCY-635, naltrexone, AAV-eCD4-Ig        gene therapy, TEV-90110, TEV-90112, deferiprone, and PA-1050040        (PA-040).

In certain embodiments, an antibody or fragment thereof disclosedherein, or a pharmaceutically acceptable salt thereof, is combined withone, two, three, four or more additional therapeutic agents. In certainembodiments, a compound disclosed herein, or a pharmaceuticallyacceptable salt thereof, is combined with two additional therapeuticagents. In other embodiments, a compound disclosed herein, or apharmaceutically acceptable salt thereof, is combined with threeadditional therapeutic agents. In further embodiments, a compounddisclosed herein, or a pharmaceutically acceptable salt thereof, iscombined with four additional therapeutic agents. The one, two, three,four or more additional therapeutic agents can be different therapeuticagents selected from the same class of therapeutic agents, and/or theycan be selected from different classes of therapeutic agents. In aspecific embodiment, a compound disclosed herein, or a pharmaceuticallyacceptable salt thereof, is combined with an HIV nucleoside ornucleotide inhibitor of reverse transcriptase and an HIV non-nucleosideinhibitor of reverse transcriptase. In another specific embodiment, acompound disclosed herein, or a pharmaceutically acceptable saltthereof, is combined with an HIV nucleoside or nucleotide inhibitor ofreverse transcriptase, and an HIV protease inhibiting compound. In afurther embodiment, a compound disclosed herein, or a pharmaceuticallyacceptable salt thereof, is combined with an HIV nucleoside ornucleotide inhibitor of reverse transcriptase, an HIV non-nucleosideinhibitor of reverse transcriptase, and an HIV protease inhibitingcompound. In an additional embodiment, a compound disclosed herein, or apharmaceutically acceptable salt thereof, is combined with an HIVnucleoside or nucleotide inhibitor of reverse transcriptase, an HIVnon-nucleoside inhibitor of reverse transcriptase, and a pharmacokineticenhancer. In certain embodiments, a compound disclosed herein, or apharmaceutically acceptable salt thereof, is combined with at least oneHIV nucleoside inhibitor of reverse transcriptase, an integraseinhibitor, and a pharmacokinetic enhancer. In another embodiment, acompound disclosed herein, or a pharmaceutically acceptable saltthereof, is combined with two HIV nucleoside or nucleotide inhibitors ofreverse transcriptase.

In a particular embodiment, a compound disclosed herein, or apharmaceutically acceptable salt thereof, is combined with one, two,three, four or more additional therapeutic agents selected from Triumeq®(dolutegravir+abacavir+lamivudine), dolutegravir+abacavirsulfate+lamivudine, raltegravir, raltegravir+lamivudine, Truvada®(tenofovir disoproxil fumarate+emtricitabine, TDF+FTC), maraviroc,enfuvirtide, Epzicom® (Livexa®, abacavir sulfate+lamivudine, ABC+3 TC),Trizivir® (abacavir sulfate+zidovudine+lamivudine, ABC+AZT+3TC),adefovir, adefovir dipivoxil, Stribild®(elvitegravir+cobicistat+tenofovir disoproxil fumarate+emtricitabine),rilpivirine, rilpivirine hydrochloride, Complera® (Eviplera®,rilpivirine+tenofovir disoproxil fumarate+emtricitabine), Cobicistat,atazanavir sulfate+cobici stat, atazanavir+cobici stat, darunavir+cobicistat, Atripla® (efavirenz+tenofovir di soproxil fumarate+emtricitabine),atazanavir, atazanavir sulfate, dolutegravir, elvitegravir, Aluvia®(Kaletra®, lopinavir+ritonavir), ritonavir, emtricitabine,atazanavir_sulfate+ritonavir, darunavir, lamivudine, Prolastin,fosamprenavir, fosamprenavir calcium, efavirenz, Combivir®(zidovudine+lamivudine, AZT+3TC), etravirine, nelfinavir, nelfinavirmesylate, interferon, didanosine, stavudine, indinavir, indinavirsulfate, tenofovir+lamivudine, zidovudine, nevirapine, saquinavir,saquinavir mesylate, aldesleukin, zalcitabine, tipranavir, amprenavir,delavirdine, delavirdine mesylate, Radha-108 (Receptol), Hlviral,lamivudine+tenofovir disoproxil fumarate, efavirenz+lamivudine+tenofovirdisoproxil fumarate, phosphazid, lamivudine+nevirapine+zidovudine,abacavir, abacavir sulfate, tenofovir, tenofovir disoproxil, tenofovirdisoproxil fumarate, darunavir+cobicistat, atazanavirsulfate+cobicistat, atazanavir+cobicistat, tenofovir alafenamide andtenofovir alafenamide hemifumarate. In some embodiment, a compounddisclosed herein, or a pharmaceutically acceptable salt thereof, iscombined with one, two, three, four or more additional therapeuticagents selected from ATRIPLA® (efavirenz, tenofovir disoproxil fumarate,and emtricitabine); COMPLERA® (EVIPLERA®; rilpivirine, tenofovirdisoproxil fumarate, and emtricitabine); STRIBILD® (elvitegravir,cobicistat, tenofovir disoproxil fumarate, and emtricitabine); TRUVADA®(tenofovir disoproxil fumarate and emtricitabine; TDF+FTC); DESCOVY®(tenofovir alafenamide and emtricitabine); ODEFSEY® (tenofoviralafenamide, emtricitabine, and rilpivirine); GENVOYA® (tenofoviralafenamide, emtricitabine, cobicistat, and elvitegravir); adefovir;adefovir dipivoxil; cobicistat; emtricitabine; tenofovir; tenofovirdisoproxil; tenofovir disoproxil fumarate; tenofovir alafenamide;tenofovir alafenamide hemifumarate; TRIUIMEQ® (dolutegravir, abacavir,and lamivudine); dolutegravir, abacavir sulfate, and lamivudine;raltegravir; raltegravir and lamivudine; maraviroc; enfuvirtide; ALUVIA®(KALETRA®; lopinavir and ritonavir); COMBIVIR® (zidovudine andlamivudine; AZT+3TC); EPZICOM® (LIVEXA®; abacavir sulfate andlamivudine; ABC+3TC); TRIZIVIR® (abacavir sulfate, zidovudine, andlamivudine; ABC+AZT+3TC); rilpivirine; rilpivirine hydrochloride;atazanavir sulfate and cobicistat; atazanavir and cobicistat; darunavirand cobicistat; atazanavir; atazanavir sulfate; dolutegravir;elvitegravir; ritonavir; atazanavir sulfate and ritonavir; darunavir;lamivudine; prolastin; fosamprenavir; fosamprenavir calcium efavirenz;etravirine; nelfinavir; nelfinavir mesylate; interferon; didanosine;stavudine; indinavir; indinavir sulfate; tenofovir and lamivudine;zidovudine; nevirapine; saquinavir; saquinavir mesylate; aldesleukin;zalcitabine; tipranavir; amprenavir; delavirdine; delavirdine mesylate;Radha-108 (receptol); lamivudine and tenofovir disoproxil fumarate;efavirenz, lamivudine, and tenofovir disoproxil fumarate; phosphazid;lamivudine, nevirapine, and zidovudine; abacavir; and abacavir sulfate.It will be appreciated by one of skill in the art that the additionaltherapeutic agents listed above may be included in more than one of theclasses listed above. The particular classes are not intended to limitthe functionality of those compounds listed in those classes.

In a particular embodiment, a compound disclosed herein, or apharmaceutically acceptable salt thereof, is combined with abacavirsulfate, tenofovir, tenofovir disoproxil, tenofovir disoproxil fumarate,tenofovir disoproxil hemifumarate, tenofovir alafenamide or tenofoviralafenamide hemifumarate.

In a particular embodiment, a compound disclosed herein, or apharmaceutically acceptable salt thereof, is combined with tenofovir,tenofovir disoproxil, tenofovir disoproxil fumarate, tenofoviralafenamide, or tenofovir alafenamide hemifumarate.

In a particular embodiment, a compound disclosed herein, or apharmaceutically acceptable salt thereof, is combined with a firstadditional therapeutic agent selected from the group consisting of:abacavir sulfate, tenofovir, tenofovir disoproxil, tenofovir disoproxilfumarate, tenofovir alafenamide, and tenofovir alafenamide hemifumarateand a second additional therapeutic agent selected from the groupconsisting of emtricitabine and lamivudine.

In a particular embodiment, a compound disclosed herein, or apharmaceutically acceptable salt thereof, is combined with a firstadditional therapeutic agent selected from the group consisting of:tenofovir, tenofovir di soproxil, tenofovir di soproxil fumarate,tenofovir alafenamide, and tenofovir alafenamide hemifumarate and asecond additional therapeutic agent, wherein the second additionaltherapeutic agent is emtricitabine.

In certain embodiments, a compound disclosed herein, or apharmaceutically acceptable salt thereof, is combined with 5-30 mgtenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, ortenofovir alafenamide and 200 mg emtricitabine. In certain embodiments,a compound disclosed herein, or a pharmaceutically acceptable saltthereof, is combined with 5-10; 5-15; 5-20; 5-25; 25-30; 20-30; 15-30;or 10-30 mg tenofovir alafenamide fumarate, tenofovir alafenamidehemifumarate, or tenofovir alafenamide and 200 mg emtricitabine. Incertain embodiments, a compound disclosed herein, or a pharmaceuticallyacceptable salt thereof, is combined with 10 mg tenofovir alafenamidefumarate, tenofovir alafenamide hemifumarate, or tenofovir alafenamideand 200 mg emtricitabine. In certain embodiments, a compound disclosedherein, or a pharmaceutically acceptable salt thereof, is combined with25 mg tenofovir alafenamide fumarate, tenofovir alafenamidehemifumarate, or tenofovir alafenamide and 200 mg emtricitabine. Acompound as disclosed herein (e.g., a compound of formula (I)) may becombined with the agents provided herein in any dosage amount of thecompound (e.g., from 50 mg to 500 mg of compound) the same as if eachcombination of dosages were specifically and individually listed. Acompound as disclosed herein (e.g., a compound of formula (I)) may becombined with the agents provided herein in any dosage amount of thecompound (e.g., from 1 mg to 500 mg of compound) the same as if eachcombination of dosages were specifically and individually listed.

In certain embodiments, a compound disclosed herein, or apharmaceutically acceptable salt thereof, is combined with 200-400 mgtenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, ortenofovir disoproxil and 200 mg emtricitabine. In certain embodiments, acompound disclosed herein, or a pharmaceutically acceptable saltthereof, is combined with 200-250; 200-300; 200-350; 250-350; 250-400;350-400; 300-400; or 250-400 mg tenofovir disoproxil fumarate, tenofovirdisoproxil hemifumarate, or tenofovir disoproxil and 200 mgemtricitabine. In certain embodiments, a compound disclosed herein, or apharmaceutically acceptable salt thereof, is combined with 300 mgtenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, ortenofovir disoproxil and 200 mg emtricitabine. An antibody or fragmentthereof as disclosed herein may be combined with the agents providedherein in any dosage amount of the antibody or fragment thereof (e.g.,from 50 mg to 500 mg of antibody or fragment thereof) the same as ifeach combination of dosages were specifically and individually listed. Acompound as disclosed herein (e.g., a compound of formula (I)) may becombined with the agents provided herein in any dosage amount of thecompound (e.g., from 1 mg to 500 mg of compound) the same as if eachcombination of dosages were specifically and individually listed.

In certain embodiments, when an antibody or fragment thereof disclosedherein is combined with one or more additional therapeutic agents asdescribed above, the components of the composition are administered as asimultaneous or sequential regimen. When administered sequentially, thecombination may be administered in two or more administrations.

In certain embodiments, an antibody or fragment thereof disclosed hereinis combined with one or more additional therapeutic agents in a unitarydosage form for simultaneous administration to a patient, for example asa solid dosage form for oral administration.

In certain embodiments, an antibody or fragment thereof disclosed hereinis administered with one or more additional therapeutic agents.Co-administration of an antibody or fragment thereof disclosed hereinwith one or more additional therapeutic agents generally refers tosimultaneous or sequential administration of an antibody or fragmentthereof disclosed herein and one or more additional therapeutic agents,such that therapeutically effective amounts of the antibody or fragmentthereof disclosed herein and one or more additional therapeutic agentsare both present in the body of the patient.

Co-administration includes administration of unit dosages of theantibodies or fragments thereof disclosed herein before or afteradministration of unit dosages of one or more additional therapeuticagents, for example, administration of the antibody or fragment thereofdisclosed herein within seconds, minutes, or hours of the administrationof one or more additional therapeutic agents. For example, in someembodiments, a unit dose of an antibody or fragment thereof disclosedherein is administered first, followed within seconds or minutes byadministration of a unit dose of one or more additional therapeuticagents. Alternatively, in other embodiments, a unit dose of one or moreadditional therapeutic agents is administered first, followed byadministration of a unit dose of an antibody or fragment thereofdisclosed herein within seconds or minutes. In some embodiments, a unitdose of an antibody or fragment thereof disclosed herein is administeredfirst, followed, after a period of hours (e.g., 1-12 hours), byadministration of a unit dose of one or more additional therapeuticagents. In other embodiments, a unit dose of one or more additionaltherapeutic agents is administered first, followed, after a period ofhours (e.g., 1-12 hours), by administration of a unit dose of anantibody or fragment thereof disclosed herein.

The combined administration may be co-administration, using separatepharmaceutical compositions or a single pharmaceutical composition, orconsecutive administration in either order, wherein there is optionallya time period while both (or all) therapeutic agents simultaneouslyexert their biological activities. Such combined therapy may result in asynergistic therapeutic effect. In certain embodiments, it is desirableto combine administration of an antibody of the invention with anotherantibody or antigen-binding fragment thereof directed against anotherantigen associated with the infectious agent.

Aside from administration of the antibody or antigen-binding fragmentthereof protein to the subject, the invention also provides methods ofproviding the antibody by gene therapy. Such administration of nucleicacid encoding the antibody is encompassed by the expression“administering an effective amount of an antibody or antigen-bindingfragment thereof.” See, for example, PCT Patent Application PublicationWO96/07321 concerning the use of gene therapy to generate intracellularantibodies. In particular embodiments, the nucleic acid comprises one ormore polynucleotides encoding the antibody or antigen-binding fragmentthereof. In certain embodiments, the polynucleotide encodes an scFv. Inparticular embodiments, the polynucleotide comprises DNA, cDNA or RNA.In certain embodiments, the polynucleotide is present in a vector, e.g.,a viral vector

Examples

The application may be better understood by reference to the followingnon-limiting examples, which are provided as exemplary embodiments ofthe application. The following examples are presented in order to morefully illustrate embodiments of the invention and should in no way beconstrued, however, as limiting the broad scope of the application.While certain embodiments of the present application have been shown anddescribed herein, it will be obvious that such embodiments are providedby way of example only. Numerous variations, changes, and substitutionswill now occur to those skilled in the art without departing from theinvention. For example, some assays may be conducted at differentconditions and may generally produce results within a range of thereported values. It should be understood that various alternatives tothe embodiments described herein may be employed in practicing themethods described.

Example 1: Methods of Synthesizing Antibodies

For all antibodies described herein, the coding sequence of the variableregion of the variable heavy chain (VH) and variable light chain (VL),including the respective signal peptide and Kozak sequence, wascodon-optimized for Homo sapiens expression and de novo synthesized byGENEART™. The signal peptide of a mouse heavy chain (mewsrvfifllsvtagvhsq vqlqqsgael vrpgtsvkvs ckasgyaftn yliewvkqrp gqglewigvinpgsggtnyn ekfkgkatlt adkssstaym qlssltseds avyfcarsyy gydwfaywgqgtivtvsa (SEQ ID NO: 61); GenBank Accession no. AF045502.1) and that ofa mouse light chain (MRCLAEFLGLLVLWIPGAIGDIVMTQAAPSVPVTPGESVSISCRSSTSLLHS SGKHRLYW FLQRPGQSPQLLIYYMSNLASGVPDRFSGSGSGTDFTLRISRVEAEDFGVYYCMQSLEYP (SEQ ID NO: 62); GenBank Accession no.ADK97503.1) were used as the respective signal peptides for heavy chain(HC) and light chain (LC), respectively. The DNA fragments encoding VHand VL were cloned into a mammalian expression vector, pcDNA3.1, withits respective constant region by a ligation-independent cloning method(INFUSION® cloning).

For transient expression of the antibodies in 293 cell line-derivedEXPI293FTM cells, the manufacturer's protocol was followed. In brief,2.5×10⁹ cells in 1 liter of Expi293 medium were transfected with 0.6milligram of the light chain and 0.4 milligram of the heavy chainplasmid using 2.7 ml of Expifectamine transfection reagent. The culturewas incubated at 37° C. with 8% CO₂ in a humidified incubator for 5-6days post-transfection. The cell-free supernatant was harvested forpurification when the viability reached approximately 60%.

Purification of the expressed IgGs was performed by Protein A affinityfollowed by dialysis. PreSanitized GE mab select protein A (SURE®) resinwas equilibrated in PBS pH7.4, and the volume of resin used wasconsistent with 20 mg/ml capacity expected expression. The 0.2 umfiltered harvest conditioned media was passed through the resin at0.7×Col vol/min. When the load was complete, a wash step of 10× col volPBS pH7.4 was performed. This was followed by a pH3.6 elution step thatwas then immediately neutralized to pH5.5. This pool was dialyzed intoeither PBS pH 7.4 or 20 mM Sodium Acetate, 9% Sucrose and 0.02% Tween 20pH5.5 and 0.2 um filtered and stored at 4° C.

Other similar methods could also be used to generate the antibodiesdescribed herein, including those described in PCT ApplicationPublication No. WO2012/030904.

Example 2: In Vitro Characterization of Neutralizing Anti-HIV-1Antibodies

Antibodies were characterized using a variety of assays to determinetheir melting temperature, resistance to aggregation during low pH holdprocedures, target binding and HIV neutralization activity and breadth,their direct binding to FcRn and FcgRs, effector cell activation andkilling activity, and potential for immunogenicity.

Melting Temperature

The thermal stability of PGT-121 LO6 and antibodies of the presentinvention was determined using either Differential Scanning Fluorimetry(DSF) or Differential Scanning calorimetry (DSC) (Niesen F H et al.2007, Nature Protocol 2:2212-2221, Garber E and Demarest S J. 2007.Biochem and Biophys Res Commun 355: 751-757). In both assays, changes inthe Fab domain unfolding transition were monitored to determine theeffects of various point mutations introduced into PGT121 WT.

DSF measures the temperature of thermal unfolding transition of aprotein (Tm) based on the change in fluorescence intensity of theenvironmentally sensitive dye SYPRO Orange. DSF was carried in 96-wellsMicroAmp Fast reaction plate using ViiA7 Real-Time PCR machine (LifeTechnologies, Grand Island, N.Y.) in formulation buffer containing PBS,pH 7.4 or 20 sodium acetate, 9% sucrose, pH 5.5. Antibody at 1 mg/mLconcentration was combined with 1:1000 diluted Sypro Orange fluorescentprobe (all concentration are final after mixing) in 25 μL volume perwell. Thermal denaturation was carried out within 5-10 min of dyeaddition by increasing the temperature from 20° C. to 95° C. with rateof 1° C./minute. Fluorescence intensity data were collected at 0.07° C.interval (excitation at 490 nm and emission with the use of a ROX filterat 600 to 630 nm) and were analyzed with Protein Thermal Shift Software(Invitrogen) using first derivative approach to calculate the Tm. Inthis method, Tm is a temperature corresponding to the maximum value ofthe first derivative of the DSF melting curve. For antibodies withmultiple melting transitions, Tm1 and Tm2 referred to the meltingtemperature for the first and the second discrete melting transition,respectively. The results of DSF analysis are shown in FIGS. 2 and 3.

DSC experiments were performed using a MicroCal VP-Capillary DSC (GEHealthcare, Piscataway, N.J.). The samples were buffer exchanged into a20 mM sodium acetate, 9% sucrose pH 5.5 formulation buffer and dilutedto the final concentration of 1 mg/mL. The formulation buffer was usedas the reference solution for each measurement. Thermal denaturation ofsamples was achieved by increasing the temperature of protein solutionfrom 25° C. to 95° C. at the scan rate of 1° C. per minute. Data wasanalyzed after subtraction of reference buffer and linear baselinesubtraction. The three transition melting temperatures for each samplewere obtained after fitting each the thermogram to a Non-2 state modelwith three transitions using Origin 7 software (OriginLab v7.0552). FIG.4 shows the Tm of the Fab domains as determined by DSC for selectedPGT121 variants.

Table 4 summarizes illustrative mutations that increase the thermalstability of PGT121 antibodies of the present invention.

TABLE 4 Mutations that increase the thermal stability of PGT121 Mutation(Kabat Numbering) Mean increase in Tm (° C.) V82aS, A82bS, A82cV 1.1R39Q 1.0 S60N 2.2Post-Translational Modifications of PGT121 and Variants

PGT121 LO6 has three consensus glycosylation sites in the heavy chainvariable region. While the presence of glycosylation at the third site(N105 linked, Kabat numbering) has been previously confirmed (Mouquet etal. 2012. PNAS 109: E3268-E3277), the glycosylation status of the othersites was unknown. Glycosylation, including that on the Fc or Fabdomains can be heterogeneous and have impacts on PK, drug safety andimmunogenicity (Jones et al. 2007. Glycobiology 17: 529-540, Alessandriet al. 2012. mAbs 4: 509-520, Goetze et al. 2011. Glycobiology 21:949-959, Chung et al. 2008. NEJM 358:1109-1117). The Fab glycan contentin PGT121 and selected variants was analyzed in a mass spectrometrypeptide mapping assay similar to those described (Zhang Z. 2009. Anal.Chem. 81: 8354-8364, Shah et al. 2014. J. Am. Soc. Mass Spectrom.25:999-1011). The results of this assay revealed detectable andheterogeneous glycosylation at both N68 (5.5% glycosylated) and N105(92.4% glycosylated), as indicated in Tables 5 and 6. Peptide mappinganalysis of N68 glycosylation for PGT121 WT showed that N68 wasapproximately 3.7% glycosylated, with multiple glyco-forms present asshown (naming consistent with IMGT conventions, —N=loss of GlcNAc;bN=bisecting GlcNAc), as shown in Table 6. Peptide mapping analysis ofN105 glycosylation for PGT121 WT showed that N105 was 100% glycosylated,with multiple glyco-forms present as shown (naming consistent with IMGTconventions, —N=loss of GlcNAc; bN=bisecting GlcNAc). ManS containingglycans that have been implicated in poor pharmacokinetic properties areshaded (Goetze et al. 2011. Glycobiology 21: 949-959).

TABLE 5 Glycosylation of N68 of PGT121 LO6 Molecule PGT121 WT G1F bN0.30% G1F + NANA 0.40% G1F bN + NANA 1.00% G2F2 + NANA 0.60% G2F + NANA0.80% G1F2 + NANA 0.30% G2F + 2 NANA 0.40% Total Glycosylation 3.70%

TABLE 6 Glycosylation of N105 of PGT121 LO6 Molecule PGT121 WT Man525.80% G1F − N 2.10% G0F 3.90% G1F 15.40% G0F bN 12.40% G2F 9.10% G1F bN3.40% G1F + NANA 27.90% Total Glycosylated 100.00%Binding to Gp120 Antigen and Fc Receptors

The in vitro binding characteristics of antibodies for both the antigen(HIV gp120) and Fc binding receptors (FcγRs, FcRn) were determined usingan Enzyme-Linked Immunosorbant Assay (ELISA). For the gp120/gp140 ELISAassay, 25 μL of recombinant gp120 protein was coated on 384 well NUNCMaxisorp plates at 1 μg/mL in PBS pH 7.4 overnight at 4° C. with gentlerocking, the plate was blocked with 5% BSA in PBS pH 7.4 for 1 hour, theplate was washed 4 times with PBS pH 7.4+0.05% Tween 20 (PBST), 25 μL ofa three-fold dilution series of antibody in PBS pH 7.4+1% BSA with amaximum antibody concentration of 300 nM was incubated in the wells for1 hour with shaking at 600 RPM at room temperature, the plate was washed4 times with PBST, 25 μL of HRP conjugated Thermo goat-anti-human IgG(H+L) polyclonal diluted 1:10,000 in PBS was incubated with the wellsfor 1 hour with shaking at 600 RPM at room temperature, the plate waswashed 4 times with PBST, 25 μL of TMB substrate was added to the wells,the plate was incubated at room temperature for 120 seconds, 25 μL of 1MHCl as added to the wells, absorbance at 450 nM was read on a Spectramaxplate reader, and the resulting points were fit using non-linearregression to determine an ELISA EC50 value.

Multiple Env sequences were used to assess binding in either gp120and/or gp140 formats, including BaL, TRO, SHIV, SF162 P3, pRHPA4259,qh0692, 6535, pCAAN5342, pWITO4160, and AC10.0. The apparent EC50 valuesfrom these assays are shown below for PGT121 LO6 WT, as well as selectedPGT121 variants described herein, and indicate their relative bindingaffinities (see Tables 7 and 8). FIGS. 5 and 6 demonstrate that some ofthe single site PGT121 variants made for other reasons, e.g., to improvelow pH stability, improve immunogenicity, remove glycosylation sites,etc.) resulted in reduced target binding affinity, while others improvedit. FIG. 7 shows the gp120 of selected PGT121 variants. These resultsdemonstrate that only certain mutations do not negatively impact gp120binding affinity.

TABLE 7 ELISA EC50 values for PGT121 WT and selected variants againstgp120 BaL and gp120 TRO Variant Name EC50 TRO (nM) EC50 BaL (nM)PGT121.30 1.142 5.694 PGT121.26 1.342 5.981 PGT121.32 1.713 6.066PGT121.28 1.306 6.706 PGT121.31 1.090 7.057 PGT121.29 1.388 6.914PGT121.19 1.497 7.111 PGT121.25 1.366 7.434 PGT121.11 1.137 7.805PGT121.20 1.498 7.560 PGT121.27 1.090 7.970 PGT121.12 1.106 8.221PGT121.17 1.178 8.243 PGT121.21 1.877 7.881 PGT121 WT 1.327 8.512PGT121.2 1.260 9.143 PGT121.8 1.654 8.780 PGT121.7 1.396 9.093 PGT121.232.089 8.583 PGT121.4 1.859 9.090 PGT121.1 1.282 9.799 PGT121.18 1.4899.832 PGT121.15 1.127 10.240 PGT121.10 1.297 10.150 PGT121.16 1.26310.780 PGT121.9 1.399 13.080 PGT121.3 5.582 11.860 PGT121.22 4.12013.700 PGT121.5 1.927 16.370 PGT121.14 2.429 21.710 PGT121.13 5.80230.660

TABLE 8 ELISA EC50 values for PGT121 WT and selected variants againstgp140 BaL and gp140 SHIV SF162P3 EC50 (nM) EC50 (nM) Variant Name gp140BaL gp140 SHIV SF162P3 PGT121.46 0.52 0.43 PGT121.39 0.50 0.40 PGT121.520.50 0.39 PGT121.36 0.48 0.41 PGT121.48 0.55 0.50 PGT121.44 0.60 0.42PGT121.33 0.46 0.34 PGT121.45 0.52 0.42 PGT121.57 0.54 0.46 PGT121.400.50 0.41 PGT121.35 0.58 0.49 PGT121.49 0.55 0.41 PGT121 WT 0.60 0.45PGT121.51 0.53 0.41 PGT121.56 0.59 0.48 PGT121.37 0.50 0.42 PGT121.380.55 0.37 PGT121.50 0.57 0.47 PGT121.42 0.52 0.45 PGT121.47 0.64 0.49PGT121.54 0.63 0.55 PGT121.43 0.60 0.50 PGT121.34 0.54 0.42 PGT121.410.56 0.51 PGT121.55 0.58 0.49 PGT121.53 0.64 0.53 PGT121.13 1.32 0.94

For the FcγR ELISA assay, the antigen used was the extracellular domainof a human FcγR containing a C-terminal peptide tag (AVITAG™), with asingle biotin conjugated by the bacterial BirA protein. To conduct theassay, 25 μL of 0.5 μg/mL FcγR diluted in PBS pH 7.4+1% bovine serumalbumin (BSA) was incubated the wells of a 384 well deglycosylatedavidin (NEUTRAVIDIN™) coated ELISA plate (PIERCE™) for 1 hour at roomtemperature with shaking at 600 RPM, the plate was washed 5 times withPBST, 25 μL of a 3.5-fold dilution series of antibody in PBS pH 7.4+1%BSA with a maximum antibody concentration of 5000 nM as incubated in thewells for 1 hour with shaking at 600 RPM at room temperature, the platewas washed 5 times with PBS pH 7.4+0.05% Tween 20 (PBST), 25 μL ofhorseradish peroxidase (HRP) conjugated goat F(ab′)₂ anti-human F(ab′)₂polyclonal (Jackson ImmunoResearch) diluted 1:5,000 in PBS pH 7.4+1% BSAwas incubated with the wells for 30 minutes with shaking at 600 RPM atroom temperature, the plates was washed 5 times with PBST, 25 μL of TMBsubstrate was added to the wells, the plate was incubated at roomtemperature for 120 seconds, 25 μL of 1M HCl was added to the wells,absorbance at 450 nM was read on a Spectramax plate reader, and theresulting points were fit using non-linear regression to determine anELISA EC50 value using methods known in the art. The EC50 values asdetermined in these assays for PGT121 WT and variants are shown in FIG.8A. Similar experiments were performed to determine the EC50 of PGT121WT and variants comprising various point mutations using otherrecombinant human FcγRs, and the results are shown in FIG. 8B-8H.

Binding to Recombinant HIV Env in Transfected Human Cell Lines

The binding of the antibodies to recombinant HIV Env expressed on thesurface of transfected HEK293 cell lines was assessed using flowcytometry. Three Env sequences were employed for the binding studiesincluding BaL, US92HT593 and U92US657. For the binding assay, therecombinant HIV Env constructs were transfected in HEK293T cells. Thecells were harvested 48 hours post transfection and incubated with theantibodies in a serial dilution at 4 degree for 1 hour. The cells werethen washed and incubated with a secondary goat anti-human IgG Alexa488conjugated antibody. The binding was then detected and quantified byflow cytometry. The measured MFI values were fitted to non-linearregression dose-response curve to determine EC50 values. The apparentEC50 values from these assays for PGT121 LO6 WT and representativePGT121 variants described herein are shown in FIG. 9, while FIG. 10indicates the relative binding affinities.

Low pH Induced Aggregation

In order to screen for low pH induced protein aggregation, such as thatinduced by industrial viral inactivation procedures during antibodyproduction, antibodies were held for 1 hour at pH 3.5 using twodifferent procedures. In the first procedure, protein was first dialyzedinto 25 mM NaOAc, with or without 10 mM NaCl pH 5, concentrated to 16mg/mL, and then samples titrated to pH 3.5 with 0.5 M acetic acid withor without 10 mM NaCl and targeting a final protein concentration of 10mg/mL. The sample was then incubated for 1 hour at room temp,neutralized to pH 5 with 2M Tris, held for an additional 2 hours at roomtemp and then analyzed by size exclusion chromatography (SEC). Theresults of the first procedure conducted on selected PGT121 mutants inthe presence or absence or NaCl are shown in FIG. 11. In the secondprocedure, duplicate samples of antibody solution at 9 mg/mL in 20 mMSodium Acetate pH 5.5, 9% sucrose are titrated to either 0 or 40 mM NaClby addition of 10% v/v of 20 mM NaOAc, 9% Sucrose, 0.44M NaCl. Next,0.5M acetic acid was added in the presence or absence of 40 mM NaCluntil the target pH is 3.5, samples are incubated for 1 hour at roomtemperature, neutralized with 20% v/v 2M Tris base, held for anadditional 2 hour at room temp and then analyzed by SEC. The percentageof monomer peak on SEC was analyzed before and after the low pH holdprocedure and the change in monomer content is analyzed to identifyantibody variants with increased aggregation/reduced monomer content.The results of the second procedure are shown in FIG. 12.

Antibody-Dependent Effector Cell Activation

The ability of the antibodies to activate Jurkat cells expressing humanFcγRIIIA coupled to a NFAT luciferase reporter was determined using Envexpressing HEK293 cells. Three Env sequences were employed for thereporter assays including 92HT593, 92US657 and BaL. The transfectedcells were harvested 48 hours post transfection, and incubated with theantibodies and the described effector cells at 37 degree for 6 hours.The activation of the effector cells was represented and measured asluciferase signal. The collected data were fitted to non-linearregression dose-response curves, and the activity was quantified by areaunder the curve (AUC). The results are shown in FIG. 13-16. The activityof certain antibodies of the present invention was 10-fold enhanced overthat of the PGT-121 antibody when quantified by area under the curve(AUC).

NK-Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC)

Antibody-dependent killing by natural killer (NK) cells was assessedusing a primary cell-based assay system with infected primary CD4+ Tcells and purified autologous effector NK cells obtained from healthydonors. NK cells express the activating FcγR IIIA and mediateantibody-dependent killing of infected cells via granzyme- andperforin-mediated cytotoxicity (ADCC). To mimic the latent CD4+ T cellreservoirs, where cell surface antigen expression is predicted to bevery low, target cells were generated by infecting quiescent primaryCD4+ T cells by spinfection. In addition, to reproduce physiologicalconditions, ADCC was assessed in the presence of 10 mg/ml nonspecifichuman serum IgG which would compete with the effector Abs for FcγRbinding. Antibody-dependent killing by NK cells was measured by thereduction in % p24 expressing CD4^(low) T cells using flow cytometry.

PGT-121 mediated killing of infected CD4+ T cells in the absence ofcompeting nonspecific serum IgG, but its overall magnitude of killingwas substantially reduced by the presence of competing nonspecific serumIgG. In contrast, antibodies of the present invention mediated killingof US657-infected target cells in the presence of competing nonspecificIgGs. ADCC activity of certain antibodies was greater than 10-foldimproved over that of PGT-121 as quantitated by calculated area underthe curve (AUC) for the ADCC dose response. Similar levels ofenhancement were observed when BaL-infected target cells were used. Inthe presence of competing nonspecific human serum IgG, antibodies of thepresent invention were more active than PGT121 due to their enhancedbinding to the FcγRIIIs on the effector cells. These results are shownin FIG. 17 and Tables 9-11. In Table 9-11, the assays were performed inthe presence of 10 mg/mL nonspecific human serum IgG. 1 μg/mL effectormAb=6.7 nM. Additional results are shown in FIGS. 26, 27, and 28 andTables 20-21.

TABLE 9 Primary NK cell-mediated ADCC activity of PTG121.42 and PGT121against CD4⁺ T cells infected with HIV-1 strain US657. PGT121.42 PGT121EC₅₀ E_(max) EC₅₀ E_(max) Virus Donor (nM) (%) AUC (nM) (%) AUC US657A4595 0.57 68 211 42.6 9 13 A4588 4.3 68 154 96.3 20 17 A4589 1.5 78 2013.0 5 13 A4838 0.94 45 114 A4839 0.54 47 140 A4813 1.4 72 222 Geomean1.2 62 169 23 10 14 Range 0.5-4 45-72 114-222 3-96 5-20 13-17

TABLE 10 Primary NK cell-mediated ADCC activity of PTG121.42 and PGT121against CD4⁺ T cells infected with HIV-1 strain BaL PGT121.42 PGT121EC₅₀ E_(max) EC₅₀ E_(max) Virus Donor (nM) (%) AUC (nM) (%) AUC BaLA4590 1.2 71 273 1.2 16 53 A4591 0.02 58 281 239 27 57 A4838 0.5 59 174A4839 3.9 60 140 A4813 4.4 75 216 Geomean 0.7 64 210 16.9 21 55 Range0.02-4.4 58-75 140-281

TABLE 11 Primary NK cell-mediated ADCC activity of PTG121.42 and PGT121against CD4⁺ T cells infected with HIV-1 strain HT593. PTG121.42 PGT121EC₅₀ E_(max) EC₅₀ E_(max) Virus Donor (nM) (%) AUC (nM) (%) AUC HT593 10.024 75 391 0.24 40 217 X 0.014 77 362 0.0001 48 289 A4588 0.176 70 2531.36 18 48 A4589 0.18 70 264 0.93 18 46 A4838 0.62 44 125 A4839 5.2 58.5114 A4813 4.9 71 191 Geomean 0.3 65.5 221.0 0.1 28.1 108.5 Range0.01-5.2 44-77 114-391 0.00012-1.4 18-48 45-290Monocyte- and PBMC-Mediated Antibody-Dependent Cell Killing

The ability of antibodies to mediate antibody-dependent cell killing wasinvestigated in vitro using HIV-1-infected primary resting CD4⁺ T cellsas target cells, and primary autologous PBMCs or isolated monocytes aseffector cells. PBMCs, in particular CD14⁺ monocytes and CD56⁺ NK cells,express the activating FcγRs I, IIA and IIIA and can mediateantibody-dependent killing of infected cells via phagocytosis(antibody-dependent cellular phagocytosis; ADCP) and granzyme- andperforin-mediated cytotoxicity (ADCC). The target CD4⁺ T cells, primaryCD14⁺ monocyte effector cells and PBMCs used in the assays were obtainedfrom healthy donors.

Antibodies of the invention exhibited significantly improvedmonocyte-mediated killing of HIV-1-infected CD4 T cells compared toPGT-121 in two donors infected in vitro with two independent viralisolates, and was significantly more effective than PGT-121. They alsoexhibited significantly improved potency and maximum killing ofHIV-1-infected cells compared to PGT-121 in the PBMC effector assay infour donors examined using the viral isolate, US657. For two donors,they exhibited killing where PGT-121 was inactive. In the other twodonors, they showed a higher Emax that PGT-121. The improvement inpotency observed ranged from about 2- to 25-fold for the donors in whichPGT-121 was active to >2000 for the donors in whom PGT-121 was inactive.Data is shown in FIG. 18 and Tables 12, 24 and 25.

TABLE 12 Parameters for monocyte- and PBMC-mediated PGT121.42-dependentcell killing Effector EC₅₀ (nM) E_(max) (%) cells Donor Virus PGT121PGT121.42 PGT121 PGT121.42 Monocytes A4169 US657 15.2 1.2 56.5 72.0A4169 HT593 10.2 1.5 49.5 64.2 A4168 US657 11.8 1.2 52.2 70.9 A4168HT593 8.8 0.6 51.2 65.4 PBMCs A4614 US657 >134 0.3 8.3 82.5 A4615US657 >134 0.1 5.9 82.8 A4616 US657 1.9 0.8 48.1 76.1 A4617 US657 5.40.2 58.3 75.4Virus Neutralization Activity

PGT121 is a highly potent neutralizing antibody with broad coverage ofHIV subtype B isolates (IC50 0.03 μg/ml, 80% breadth). The Env-basedbinding studies described herein demonstrated comparable activity ofPGT-121 and antibodies of the present invention. The potency (measuredas IC50 or IC95) and breadth (% of isolates neutralized from the paneltested) of neutralization of PGT121 and its variants was examined usingtwo different published assay formats: i) the CEM-NKr-CCR5-Luc reportercell-line based assay (Li et al. 2005. J Vir 79(16): 10108-10125), whichis compatible for screening antibodies against pseudotyped as well asreplication competent HIV isolates; and ii) the Monogram HIV PhenoSenseNeutralization Assay (Monogram Biosciences) which uses a luciferasereporter virus pseudotyped with HIV Env variants of interest (Richman etal. 2003. PNAS 100(7): 4144-4149). In the reporter cell-line-basedCEM-NKr-CCR5-LucR neutralization assay, a multicycle viral replicationassay (Spenlehauer et al. 2001. Virology, doi:10.1006/viro.2000.0780),antibodies were screened against a panel of five replication competentclinical isolates including the lab adapted HIV-1 BaL strain and subtypeB isolates 93HT593, 92US657, 92US712 and 92US727 amplified from patientplasma samples (NIH AIDS Reagent Program).

Neutralization potency of the antibodies of the invention was observedto be comparable to that of PGT-121 for the five viruses tested,suggesting that the modification present in these antibodies as compareto PGT-121 had minimal impact on the determinants of antigen recognitionand binding (Table 13 below with the CEM-NKr-CCR5-Luc cells). Othervariants (e.g. PGT121.60, PGT121.61) exhibited a 2-3 fold increase inneutralization potency against this limited virus panel compared toPGT121.

TABLE 13 Neutralization activity of PGT121, and select variants againstHIV-1 strains BaL, HT593, US657, US712 and US727, as observed using theCEM.NKr.CCR5.Luc based assay. Data represents mean of 2 to 3 repeatsNeutralization Potency, IC₅₀ (μg/mL) PGT121 IC₅₀/Variant IC₅₀ mAb BaLHT593 US657 US712 US727 BaL HT593 US657 US712 US727 PGT121 0.020 0.2160.111 0.017 0.013 1 1 1 1 1 PGT121.42 0.015 0.155 0.096 0.020 0.015 1.31.4 1.2 0.9 0.9 PGT121.43 0.013 0.127 0.092 0.016 0.012 1.5 1.7 1.2 1.11.1 PGT121.56 0.02 0.164 0.142 0.019 0.011 1.0 1.3 0.8 0.9 1.2 PGT121.600.007 0.141 0.062 0.008 0.007 2.9 1.5 1.8 2.1 1.9 PGT121.61 0.008 0.3430.072 0.008 0.005 2.5 0.6 1.5 2.1 2.6

In the Monogram neutralization assay, the Env (gp160) coding region isamplified from plasma viral RNA isolated from HIV+ART naïve viremicpatients and cloned into an expression vector, such that the virusquasispecies distribution present in the patient plasma samples ismaintained. The expression vectors are then used to generate HIV-1pseudovirus swarms expressing the patient-derived Env proteins. Twopanels of clade B clinical isolates were generated for the Monogramneutralization assay: Panel 1 (Monogram clinical isolates panel)comprised 63 isolates from the Monogram library collection, and included33 or more CCR5-tropic viruses, 15 or more CXCR4-tropic (X4) and 15 ormore viruses of dual-mixed (DM) tropism; and Panel 2 (Gilead clinicalisolates panel) comprised 142 subtype B viruses isolated from pre-ARTbaseline plasma samples from ART naïve HIV patients enrolled in clinicaltrials and included 113 CCR5-tropic (R5) viruses, 28 viruses of dual ormixed-tropism (DM) and one CXCR4 tropic (X4) virus. Given that HIV-1 Envexhibits significant diversity among patient isolates, between clades,as well as within a clade, neutralization activity of PGT121 andvariants was also profiled against viruses representing non-B cladesusing a panel of viruses from Monogram's library collection. TheMonogram HIV PhenoSense Neutralization Assay was utilized to profilelarge collections of patient isolates, thereby enabling a more rigorousprofiling of both breadth and potency of PGT121 and the variantsgenerated. The results are shown in FIGS. 19-21, 29-30 and Tables 22-25.Results showed that variants of PGT121 such as PGT121.60 showed enhancedneutralization activity against select viruses.

These experiments demonstrated an unexpected improvement in X4-tropicHIV neutralization by Fc enhanced PGT121. HIV can utilize twoco-receptors in addition to CD4 for entry into T cells—either CXCR4 orCCR5. The co-receptor binding is mediated by Env, the target of thebroadly neutralizing antibodies described herein. Different strains ofHIV with different sequences thus preferentially use CXCR4 (known asX4-tropic), CCR5 (known as R5-tropic) or both (known as X4/R5 ordual-tropic). Virus pools showing both R5 and X4 tropism (referred to asDual-Mixed or DM) may contain mixtures of R5, X4 and or dual tropicstrains. PGT121 generally shows poor sensitivity (low potency andbreadth) against X4 isolates, preferentially neutralizing R5 tropicviruses. Addition of the Fc mutations DEAL+LS into PGT121 (PGT121.56)specifically enhanced its neutralization activity against DM and X4tropic viruses (median IC50 enhancement of 2-fold and up to about20-fold enhancement for at least one isolate. While some PGT121 Fabvariants (e.g. PGT121.13 and PGT121.22) exhibited reduced neutralizationpotency against R5 DM and X4 viruses, several of the engineered PGT121Fab variants carrying the DEAL+LS Fc mutations, including PGT121.56 withthe WT Fab were more potent at neutralizing DM and X4 viruses comparedto R5 viruses (P<0.0001) (FIG. 29A-29B). This is highly unexpected asHIV neutralization is thought to be mediated exclusively by the Fabdomain rather than the Fc domain. Among R5 isolates, a 2- to 3-foldenhancement in neutralization was observed in about 46% of isolatestested. The DEAL+LS mutation is present in certain antibodies andfragments thereof of the present invention. Additional modificationsintroduced to PGT121.56 further improved neutralization activity ofselect variants (PGT121.42, PGT121.60, etc.) but not necessarily all.

Breadth of coverage was calculated as the percentage of virusesneutralized at an IC95<15 μg/ml. Potency was determined by calculatingmedian IC95 values across viruses with IC95<15 μg/ml (FIG. 20 and Table24). When tested against both panels of HIV-1 isolates, comprising 89clade B isolates in total, antibodies of the present invention exhibitedno loss in neutralization activity compared to PGT121 (data not shown).Potency of certain antibodies was near identical to PGT121, with aslightly improved neutralization breadth. The neutralization profilingalso served as a surrogate assessment of the ability of the antibodiesrelative to PGT-121 to recognize and bind diverse Env antigens from awide range of HIV-1 clinical isolates. Data from profiling of variousantibodies showed that antibodies with reduced neutralization potencyalso exhibited reduced ADCC activity (data not shown), suggesting apositive correlation between the neutralization activity and ADCCactivity of the antibodies, and supporting the use of neutralizationbreadth as a surrogate for the assessment of ADCC breadth.

Immunogenicity

Three methods were used to assess immunogenicity and guide engineeringto remove immunogenic motifs in PGT121. In silico prediction tools wereused to identify sites of potential risk of immunogenicity in the PGT121antibody, and also to guide engineering efforts to improvemanufacturability (e.g. removal of glycosylation sites, improvement oflow pH hold stability) while preventing introduction of novel T cellepitopes. Based on this analysis, modification of the framework regionswere made in antibodies of the present invention to reduceimmunogenicity which had a low risk of impacting functional activity. Inaddition, to further identify potentially immunogenic motifs within thevariable domain of one antibody of the present invention, an ex vivohuman T cell activation assay, the (EPISCREEN™. Antitope, Ltd.,Cambridge, UK) was employed. CD4⁺ T cells responses induced in 50healthy donors, representing a variety of HLA haplotypes, in response tooverlapping 15 amino acid peptides derived from the antibody, and KLH(keyhole limpet hemocyanin, positive control) were assessed usingH-thymidine incorporation assay to measure T-cell proliferation. Theassay enabled the localization of specific T cell epitopes in theprimary antibody sequence to guide antibody engineering. It alsoprovided a ranking of the relative immunogenicity of T cell epitopeswith tested antibodies. The predicted or actual immunogenic epitopesidentified in these assays are shown in Tables 14-16 (in silicoprediction of T-cell epitopes is shown in grey and amino acid variantsdesigned to reduce T-cell epitope is shown in white). The data usingdonor cells shows that certain mutations reduce immunogenicity in theseassays, while others do not.

TABLE 14 In silico prediction of T-cell epitopes in  PGT-121 LO6 HC and amino acid variants de-  signed to reduce T-cell epitope content in   the PGT-121 LO6 HC #HLAAlleles Pre- dicted #HLA to Alleles Bind Pre- with dicted High to Af-Bind finity TCED Anti- (out of (out of Data- tope SEQ 34 34 base iTopeID Epitope Epitope total total Blast Risk NO # Sequence tested) tested)Hit? Level  63 121-HC-1 MQLQESGPG 25 14 No mod- erate  64 121-HC-1.1VQLQESGPG 25 14 No low  65 121-HC-1.2 VHLQESGPG 21  8 No mod- erate  66121-HC-1.3 LHLQESGPG 21  8 No mod- erate  67 121-HC-2 VSGASISDS 21  3 Nomod- erate  68 121-HC-2.1 VSGGSISDS 11  8 No low  69 121-HC-2.2VSGASISDA  7  0 No low  70 121-HC-2.3 VSGGSISDA  7  1 No low  71 121-VSGTLVRON  5  1 No low HC--2.4  72 121-HC-2.5 VSGASINDA 14  0 No low  73121-HC-2.6 VSGGSISNY  6  1 No low  74 121-HC-2.7 VSNGSVSGR 10  5 No low 75 121-HC-3 IRRSPGKGLL 23 13 No mod- erate  76 121-HC-3.1 IRQSPGKGL 17 4 No low  77 121-HC-3.2 IRQPLGKQP  2  1 No low  78 121-HC-3.3 IRQSPGKRP 9  2 No low  79 121-HC-3.4 IRQSPGRGL 17  8 No low  80 121-HC-4IGYVHKSGD 17  6 No mod- erate  81 121-HC-4.1 IGYVHDSGD  2  2 No low  82121-HC-4.2 VGYVHHSGD  5  4 No low  83 121-HC-4.3 IGYISDRET  4  1 No low 84 121-HC-4.4 IGYFSDTDR  7  0 No low  85 121-HC--5 LKSRVNLSL 23 14 Nomod- erate  86 121-HC-5.1 LKSRVTLSL 29 22 No high  87 121-HC-5.2LKSRVHLSL 21 16 No mod- erate  88 121-HC-5.3 LKSRVSLSL 23 19 No high  89121-HC-5.4 LKSRVALSL 23 20 No high  90 121-HC-5.5 LKRRVTFSL 30 21 Nohigh  91 121-HC-5.6 LNSRAVISR 20 14 No mod- erate  92 121-HC-5.7LRSRLTLSV 33 31 No high  93 121-HC-6 VSLSLVAAT 22  4 No mod- erate  94121-HC-6.1 VSLKLVAAT 17 13 No mod- erate  95 121-HC-6.2 VSLSLTSVT 14  5No low  96 121-HC-6.3 VSLSLSSVT 21  9 No mod- erate  97 121-HC-6.7VSLSLKSVT 20 12 No mod- erate  98 121-HC-6.4 VSLSLNSVT 26 12 No mod-erate  99 121-HC-6.8 VSLKLTSVT 15  6 No low 100 121-HC-6.9 VSLRLTGVT  9 5 No low 101 121- VSLKLVOLT  8  4 No low HC-6.10 102 121- LSLQLRSVT  8 1 No low HC-6.11 103 121- LSLRLKSVT  9  6 No low HC-6.12 104 121-LSLKLKSVT 12  8 No low HC-6.13 105 121-HC-7 LVAATAADS 32 31 No high 106121-HC-7.1 LTSVTAADS 23 13 No mod- erate 107 121-HC-7.2 LTGVTAADS 23 13No mod- erate 108 121-HC-7.3 LRSVTAADS 34 31 No high 109 121-HC-7.4LKSVTAADS 31 24 No high 110 121-HC-7.5 LNSVTAADS 31 21 No high 111121-HC-7.6 LSSVTAADS 19  9 No mod- erate 112 121-HC-7.7 LVDLTAADS 31 24No high 113 121-HC-7.8 LRSVTTADT 34 30 No high 114 121-HC-7.9 LKSVTAADS31 24 No high 115 121-HC-8 YYCARTLHG 20 15 No mod- erate 116 121-HC-8.1YYCATTKHG 16 12 No low 117 121-HC-8.2 YFCARALHG 19 11 No mod- erate 118121-HC-8.3 YFCATARRG 11  7 No low 119 121-HC-8.4 YYCARAQQG 12  3 No low120 121-HC-9 LHGRRIYGI 23 15 No mod- erate 121 121-HC-9.1 KHGRRIYGV  0 0 No low 122 121-HC-9.2 LHGKRIYGI 21 15 No mod- erate 123 121-HC-9.3RRGQRIYGV  0  0 No low 124 121-HC-9.4 QQGKRIYGI  0  0 No low 125121-HC-10 IYGIVAFNE 21 12 No mod- erate 126 121- IYGVVAFKE 16 11 No lowHC-10.1 127 121- IYGIVALGE 23 17 No high HC-10.2 128 121- IYGVVSFGE 1710 No mod- HC-10.3 erate 129 121- IYGIVSFGE 22 14 No mod- HC-10.4 erate130 121-HC-11 YFYMDVWGN 19 15 No mod- erate 131 121- YFYMDVWGK 18 17 Yeshigh HC-11.1 132 121- YFYMDVWDQ 19 17 Yes high HC-11.2 133 121-YFYMDVWGA 20 19 No high HC-11.3 134 121- YFYMDVWGH 20 17 No high HC-11.4135 121- YFYMDVWGR 20 17 Yes high HC-11.5 136 121- YFYMDVWGT 20 18 Nohigh HC-11.6 137 121- YYYMDVWGK 18 17 Yes high HC-11.7 138 121-YYYMDAWGK 17 13 Yes mod- HC-11.8 erate

TABLE 15 In silico prediction of T-cell epitopes inPGT-121 LO6 LC and amino acid variants de-signed to reduce T-cell epitope content in the PGT-121 LO6 LC. #HLAAlleles Pre- dicted #HLA to Alleles Bind Pre- with dicted High to  Af-Bind finity TCED Anti- (out of (out of Data- tope SEQ 34 34 base iTopeID Epitope Epitope total total Blast Risk NO # Sequence tested} tested)Hit? Level 139 121-LC-1 VAPGETARI 19 11 No mod- erate 140 121-LC-1.1VAPGQTARI 19 11 No low 141 121-LC-1.2 VSPGETAKI 15  6 No low 142121-LC-1.3 VSPLSVALG 25 17 No high 143 121-LC-1.4 LAPGATAKI 13 11 Nomod- erate 144 121-LC-2 LIIYNNQDR 27 20 No high 145 121-LC-2.1 LIIYNNNDR28 22 No high 146 121-LC-2.2 LLIYNNQDR 26 19 No high 147 121-LC-3FGTTATLTI 17 12 No mod- erate 148 121-LC-3.1 PGTTATLTI  0  0 No low 149121-LC-3.2 IGVTATLTI 31 20 No high 150 121-LC-4 FGGGTTLTV 17 12 No mod-erate 151 121-LC-4.1 FGEGTTLIV  7  2 No low 152 121-LC-4.2 FDRGTTLTV  7 2 No low 153 121-LC-4.3 FGGATRLTV 15 14 No low 154 121-LC-4.4 FGGGTQLTV10  3 No low 155 121-LC-4.5 FAGGTGLTV  6  2 No low

TABLE 16 Ex vivo T-cell epitope mapping screen resultsfor PGT-121 LO6 HC and LC and variants de-signed to reduce immunogenicity. % Donor Contains Response Mean In- (50Stimu- silico donors, lation SEQ Epitopes except * Index ID (coreEpitope 37 (>2 is NO 9-mer) Sequence donors) positive) 156 121-HC-2VSGASISDSYWSWIR 30 2.34 157 121-HC-3 SYWSWIRRSPGKGLE 20 2.39 158121-HC-6, QVSLSLVAATAADSG 54* 3.65 121-HC-7 159 121-HC-6.2,QVSLSLTSVTAADSG 30 4.03 121-HC-7.1 160 121-HC-6.3, QVSLSLSSVTAADSG  22.31 121-HC-7.6 161 121-HC-7.2 QVSLSLTGVTAADSG  4 2.18 162 121-HC-10IYGIVAFNEWFTYFY  8 2.29 163 121-HC-11 FNEWFTYFYMDVWGN 12 2.05 164121-HC-11.1 FNEWFTYFYMDVWGK  8 1.97 165 121-HC-11.4 FNEWFTYFYMDVWGH 222.28 166 121-HC-11.3 FNEWFTYFYMDVWGA  6 2.08 167 121-HC-11.6FNEWFTYFYMDVWGT 20 2.17 168 121-HC-11 WFTYFYMDVWGNGTQ 34 2.45 169121-HC-11.1 WFTYFYMDVWGKGTQ 22 2.27 170 121-HC-11.4 WFTYFYMDVWGHGTQ  82.48 171 121-HC-11.3 WFTYFYMDVWGAGTQ  0 0 172 121-HC-11.6WFTYFYMDVWGTGTQ  2 2.82 173 121-HC-11 YFYMDVWGNGTQVTV 30 2.35 174121-HC-11.1 YFYMDVWGKGTQVTV 38 3 175 121-HC-11.4 YFYMDVWGHGTQVTV 20 2.24176 121-HC-11.3 YFYMDVWGAGTQVTV  4 2.27 177 121-HC-11.6 YFYMDVWGTGTQVTV 0 0 178 121-LC-3 FGTTATLTITSVEAG 18 2.18 179 121-LC-3 SPFGTTATLTITSVE60 2.31 180 121-LC-3 SPDSPFGTTATLTIT 28 2.22 181 121-LC-4PTKWVFGGGTTLTVL 18 2.43

To assess clinical immunogenicity risk of selected antibody variants,the ex vivo time course T-cell assay (EPISCREEN™, Antitope, Ltd.,Cambridge, UK) was used to measure T-cell activation induced by intactantibodies. The whole molecule assay was conducted as described (Bakerand Jones 2007. Curr. Opin. Drug Discov. Devel. 10: 219-227). Thus, thisassay takes into account not just T-cell epitope content, but also theprocessing of the native IgG. Unlike the in silico and peptide scanningassays, the whole molecule ex vivo T-cell activation assay can providean assessment of the relative clinical risk of a given antibody, and incertain cases may be used to predict clinical immunogenicity rates asdescribed (Baker and Jones 2007 Curr. Opin. Drug Discov. Devel.10:219-227).

Many clinical stage antibodies have been run in this assay, andantibodies showing little to no clinical immunogenicity have scores nearor below 10% (dotted line) in this assay while antibodies showing highclinical immunogenicity such as Alemtuzumab and Infliximab show scoresin the 25-40% range (Baker and Jones 2007. Curr. Opin. Drug Discov.Devel. 10:219-227). PGT121.42, PGT121.60, PGT121.61 and PGT121.65 showedreduced donor response rates when compared to PGT121 WT, supporting areduced risk of clinical immunogenicity for these variants (FIG. 22).

FcRn Binding

The neonatal Fc receptor (FcRn) is an Fc receptor that has been shown toplay a major role in regulating the pharmacokinetic s of IgG moleculesin human and preclinical species. Following endocytosis, at acidic pH(<6.5), FcRn binds to the Fc portion of IgG with high affinity. FcRnbound IgG is recycled back to the extracellular space, where atphysiological pH IgG binding affinity is reduced and IgG is releasedback into the circulation. Free IgG that is not salvaged by the FcRnpathway is degraded in the lysosome to endogenous amino acids. Therelative binding affinity characteristics of IgG to FcRn at pH 6.0/7.0has become a well-established correlate for ranking the half-life ofIgGs in vivo and a design feature for pharmacokinetic optimization.

The binding of antibodies to FcRn of various species at different pHswas determined. A 96-well Maxisorp plate was coated with 100 ul of 5μg/mlFcRn. The plate was incubated overnight at 4° C., and then blockedwith 4% skim milk for 2 hr at room temperature after washing 3 timeswith 0.05% Tween 20 washing buffer. The plate was incubated with 3 foldserial dilution of primary antibody for 1 hr at room temperature. Theplate was then washed 3 times and 100 μL of Fab-anti-human Fab-HRP orGoat anti-human IgG-HRP secondary antibody diluted in 4% skimmed milkwas added. Plates were then incubated 50 min at room temperature, washedthree times, and 100 μL fresh TMB substrate was added. Plates weredeveloped for 3 minutes on bench with gentle shaking. Plate was quenchedwith 100 μL 1M HCl, shaken briefly, read at A450 on a spectramax m5plate reader.

Relative to PGT-121, antibodies of the present invention comprising LSmutations in the Fc portion of IgG that interacts with FcRn showed asignificant improvement in FcRn binding at pH 6.0 with lesser impact onbinding at neutral pH of 7.0, as represented by the ratio of pH 7.0/6.0for Human FcRn. The improved binding was attributed to the presence ofthe LS mutations and is predicted to provide for a prolonged half-lifein humans relative to PGT-121. Data is shown in Table 17 and FIGS. 23Aand 23B.

TABLE 17 Human FcRn binding data for PGT121 and variants PGT121 pH 6.0EC₅₀ pH 7.0 EC₅₀ Ratio pH Variants (nM) (nM) 7.0/6.0 Fold vs PGT121PGT121 10.9 358 33 1 121.42 0.41 69.8 170 5 121.56 0.47 102.2 217 7121.60 0.22 78 355 11 121.61 0.13 139.5 1073 33 121.64 1.59 125.1 79 2121.65 0.57 103.6 182 6

This data shows significant improvement of PGT121.60 and 61 overPGT121.56 or PGT121.42. PGT121.56 is the WT Fab with DEAL+LS Fc. Thissuggests that the Fab mutations in PGT121.60 and 61 improve FcRnbinding. PGT121.64 and PGT121.65 do not show this improvement,suggesting that the Fab modifications in these two variants may actuallyreduce FcRn binding.

In Vivo Profiling

PGT121 and several antibodies from the present application were assayedto characterize their basic pharmacokinetic profiles to ensure that theFab/Fc modifications present in the antibodies of the present inventionenhanced, and did not significantly perturb, the PGT121 intrinsicpharmacokinetic behavior. The in vivo disposition of PGT121 and severalother antibodies of invention were characterized after a singleintravenous (IV) 1.0 mg/kg dose in two male naïve cynomolgus monkeys(n=2). Serum samples were collected from monkeys and analyzed using abioanalytical method (described herein) to determine serumconcentration-time profiles and mean serum pharmacokinetic parameters bynon-compartmental pharmacokinetic analysis (NCA). The pharmacokineticconcentration-time profiles for PGT121 compared to PGT121.42, anillustrative antibody of the invention, are depicted in FIG. 24.

In a separate study, the intrinsic pharmacokinetic behavior of PGT121,PGT121 LS, and new lots of PGT121.42 and PGT121.60 were characterizedafter a single IV 10.0 mg/kg dose in three male naïve cynomolgus monkeys(n=3). Serum samples were collected and analyzed using a bioanalyticalmethod (described herein) to determine serum concentration-time profilesand mean serum pharmacokinetic parameters by non-compartmentalpharmacokinetic analysis (NCA). The pharmacokinetic concentration-timeprofiles for a 10 mg/kg IV dose of PGT121, PGT121 LS, PGT121.42 andPGT121.60 are depicted in FIG. 25.

The mean serum pharmacokinetic parameters of PGT121, PGT121.42,PGT121.43, PGT121.60, and PGT121.61 were determined from thenon-compartmental pharmacokinetic analysis of the concentration-timeprofiles and are depicted in Table 18. All antibodies of the inventionthat were tested in vivo had comparable or improved pharmacokinetics (asdefined herein) relative to PGT121.

TABLE 18 Pharmacokinetic parameters of PGT121 and variants after IVadministration (1 mg/kg) in naïve cynomolgus monkeys (n = 2) AUC_(0-∞)Cl V_(d) t_(1/2) mAb Variant (day * ug/mL) (mL/day/kg) (mL/kg) (day)PGT121 120 8.38 89.9 7.5 PGT121.42 217 4.63 77.9 11.8 PGT121.43 191 5.2570.0 9.1 PGT121.60 127 7.95 113 9.9 PGT121.61 117 8.76 127 10.5

The mean serum pharmacokinetic parameters of PGT121, PGT121 LS,PGT121.42, and PGT121.60 were determined from the non-compartmentalpharmacokinetic analysis of the concentration-time profiles and aredepicted in Table 19. All antibodies of the invention that were testedin vivo had comparable or improved pharmacokinetics (as defined herein)relative to PGT121. Results of additional characterizations were shownin Tables 20-27. Table 23 indicates that PGT121.60 showed increasedpotency against the tested viruses, compared to PGT121. Table 24 showsthat some the PGT121 variants such as PGT121.60, PGT121.64 and PGT121.65exhibited improved potency across all viral isolates tested (also seeFIG. 20). This suggests that the modifications made (likely themodifications made to the antigen contact residues outside the CDRs)improved neutralization potency. Table 25 illustrates that PGT121.60showed about increased naturalizing activities against the virusesrepresenting B and non-B subtypes, compared to PGT121.

TABLE 19 Pharmacokinetic parameters of PGT121, PGT121 LS, PGT121.42, andPGT121.60 after IV administration (10 mg/kg) in naïve cynomolgus monkeys(n = 3) AUC_(0-∞) Cl V_(d) t_(1/2) Test Article (day * μg/mL)(mL/day/kg) (mL/kg) (day) PGT121 1510 7.0 111 11.4 PGT121 LS 3670 2.895.1 24.3 PGT121.42 1240 8.2 97.9 8.2 PGT121.60 1490 7.0 96.4 9.7

TABLE 20 Primary NK cell-mediated ADCC activity of a select set ofPGT121 variants against primary CD4⁺ T cells infected with 2 HIV-1strains, US657 or HT539 Donor A4813 Emax (%) EC₅₀ (nM) AUC mAb VariantUS657 HT593 US657 HT593 US657 HT593 PGT121.56 71 72 1.5 6.3 219 161PGT121.42 72 71 1.4 4.9 222 191 PGT121.60 72 67 1.2 0.7 220 185PGT121.61 72 70 1.3 2.2 190 169 PGT121.64 70 66 1.6 1.4 188 167PGT121.65 75 71 3.2 2.6 190 158

TABLE 21 Primary NK cell-mediated ADCC activity of PGT121and PGT121.60,against CEM.NKr.CCR5.Luc cells infected with 3 HIV-1 isolates US727HT593 US657 mAb NK Emax EC₅₀ Emax EC₅₀ Emax EC₅₀ Variant Donor (%) (nM)AUC (%) (nM) AUC (%) (nM) AUC PGT121 A5277 23 7.1 45 7 2.4 35 nd nd 3A5278 31 1.1 106 6 4.9 16 nd nd 2 PGT121.60 A5277 60 0.5 195 62 1.1 17867 6.9 153 A5278 58 0.2 212 59 1.0 189 58 3.5 139 PGT121.60 A5277 60 0.9174 57 2.3 147 63 5.8 147 A5278 60 0.5 189 61 2.1 157 66 10.9 128

TABLE 22 Neutralization activity (IC₅₀) of PGT121 and PGT121.60 againstsubtype B viruses PGT121.60 PGT121 IC50/ PGT121 IC50 IC50 PGT121.60Isolate Tropism (μg/mL) (μg/mL) IC50 MGRM-B-106 DM 0.0041 0.0010 4.1MGRM-B-112 DM 0.0145 0.0058 2.5 MGRM-B-136 X4 0.0087 0.0071 1.2MGRM-B-105 DM 0.0219 0.0076 2.9 MGRM-B-132 X4 0.0092 0.0077 1.2MGRM-B-110 DM 0.0373 0.0113 3.3 MGRM-B-115 DM 0.2362 0.1412 1.7MGRM-B-111 DM 2.1336 0.9549 2.2 MGRM-B-118 DM 2.4658 3.3142 0.7

TABLE 23 Neutralization potency of PGT121 and PGT121.60 against subtypeB viruses PGT121 PGT121 IC50 PGT121.60 IC50 IC50/PGT121.60 Virus ID(μg/mL) (μg/mL) IC50 X15-124986 0.0048 0.0015 3.2 15-124918 0.00540.0018 3.0 15-124914 0.0059 0.0020 3.0 15-124964 0.0092 0.0026 3.515-124906 0.0550 0.0103 5.3 15-124904 0.0375 0.0121 3.1 15-102514 0.04500.0128 3.5 15-101757 0.0621 0.0132 4.7 15-124987 0.0510 0.0163 3.115-124962 0.0955 0.0277 3.4 15-124970 0.1101 0.0285 3.9 15-124950 0.29960.0995 3.0 15-124975 0.5775 0.1052 5.5 15-124934 9.6415 0.7973 12.115-101608 6.7016 1.8392 3.6 15-124963 16.8855 2.0546 8.2

TABLE 24 Neutralization potency and coverage of PGT121 and selectvariants against 92 subtype B viruses Median IC95 PGT121 mAb (μg/mL)IC50/Variant IC50 Coverage (%) PGT121 0.329 1.0 57.6 PGT121.13 0.629 0.551.1 PGT121.42 0.277 1.2 63.0 PGT121.43 0.266 1.2 62.0 PGT121.54 0.2831.2 63.0 PGT121.55 0.275 1.2 63.0 PGT121.56 0.265 1.2 62.0 PGT121.580.244 1.3 58.7 PGT121.59 0.253 1.3 60.9 PGT121.60 0.177 1.9 59.8PGT121.61 0.327 1.0 58.7 PGT121.62 0.254 1.3 63.0 PGT121.63 0.379 0.960.9 PGT121.64 0.129 2.6 59.8 PGT121.65 0.165 2.0 59.8

TABLE 25 Neutralization activity of PGT121 and PGT121.60 againstmulticlade viruses PGT121.60 PGT121 IC50/ PGT121 IC50 IC50 PGT121.60Virus ID (μg/mL) (μg/mL) IC50 MGRM-Chronic-B-004 0.0078 0.0013 6.0MGRM-Acute-B-005 0.0043 0.0014 3.1 MGRM-Acute-B-009 0.0037 0.0016 2.3MGRM-Chronic-B-020 0.0038 0.0018 2.1 MGRM-Chronic-B-006 0.0056 0.00202.8 MGRM-Chronic-B-023 0.0043 0.0034 1.3 MGRM-Chronic-B-008 0.01110.0056 2.0 MGRM-Chronic-B-010 0.0154 0.0074 2.1 MGRM-Chronic-B-0030.0080 0.0079 1.0 MGRM-Chronic-B-009 0.0224 0.0112 2.0 MGRM-Acute-B-0030.0361 0.0179 2.0 MGRM-Acute-B-007 0.0466 0.0255 1.8 MGRM-Chronic-B-0160.0583 0.0283 2.1 MGRM-Acute-B-001 0.0739 0.0313 2.4 MGRM-Acute-B-0100.0466 0.0328 1.4 MGRM-Chronic-B-012 0.0914 0.0409 2.2 MGRM-Acute-B-0040.0933 0.0497 1.9 MGRM-Chronic-B-002 0.1010 0.0649 1.6MGRM-Chronic-B-005 0.0866 0.0720 1.2 MGRM-Acute-B-006 0.1307 0.0966 1.4MGRM-Chronic-B-001 0.1257 0.0985 1.3 MGRM-Chronic-B-014 0.2879 0.13342.2 MGRM-Chronic-B-015 0.2736 0.1855 1.5 MGRM-Chronic-B-019 0.34620.1993 1.7 MGRM-Chronic-B-007 2.1241 2.5544 0.8 MGRM-Chronic-B-022 >5011.4677 MGRM-C-026 0.0016 0.0004 4.0 MGRM-C-011 0.0028 0.0012 2.3MGRM-C-006 0.0091 0.0030 3.0 MGRM-C-027 0.0054 0.0038 1.4 MGRM-C-0220.0101 0.0038 2.7 MGRM-C-023 0.0179 0.0044 4.1 MGRM-C-008 0.0075 0.00441.7 MGRM-C-017 0.0087 0.0058 1.5 MGRM-C-004 0.0118 0.0064 1.8 MGRM-C-0050.0145 0.0078 1.9 MGRM-C-002 0.0219 0.0095 2.3 MGRM-C-016 0.0083 0.01370.6 MGRM-C-012 0.1060 0.0338 3.1 MGRM-C-024 0.1703 0.0826 2.1 MGRM-C-0070.2868 0.1993 1.4 MGRM-C-028 1.3581 0.7440 1.8 MGRM-C-018 28.161910.3254 2.7 MGRM-C-013 36.4162 12.2616 3.0 MGRM-C-020 >50 14.8835MGRM-A-014 0.0032 0.0010 3.2 MGRM-A-002 0.0199 0.0047 4.2 MGRM-A-0090.0072 0.0074 1.0 MGRM-A-012 0.1364 0.0397 3.4 MGRM-A-013 0.6126 0.056110.9 MGRM-A-003 0.2001 0.0865 2.3 MGRM-A-010 1.1108 0.7452 1.5MGRM-A-006 1.0250 4.0544 0.3 MGRM-AG-006 0.0242 0.0106 2.3 MGRM-AG-0090.1000 0.0868 1.2 MGRM-AG-007 0.1649 0.1082 1.5 MGRM-AG-005 1.58760.2029 7.8 MGRM-AG-001 4.6658 1.4409 3.2 MGRM-AG-008 1.7322 1.7064 1.0MGRM-D-002 0.0049 0.0015 3.3 MGRM-D-014 0.0068 0.0019 3.6 MGRM-D-0110.0122 0.0043 2.8 MGRM-D-001 0.7988 0.4310 1.9 MGRM-F1-010 0.0092 0.01250.7 MGRM-F1-018 0.0244 0.0201 1.2 MGRM-F1-020 0.0603 0.0410 1.5MGRM-F1-014 0.0551 0.0509 1.1 MGRM-F1-013 0.0547 0.0871 0.6 MGRM-F1-0160.9707 0.5219 1.9 MGRM-F1-004 4.7363 0.5474 8.7 MGRM-F1-012 2.33401.1877 2.0 MGRM-F1-006 8.8384 2.3278 3.8 MGRM-F1-015 32.6175 11.5867 2.8MGRM-G-014 0.0035 0.0034 1.0 MGRM-G-001 0.0022 0.0050 0.4 MGRM-G-0190.0079 0.0091 0.9 MGRM-G-024 0.0240 0.0119 2.0 MGRM-G-017 0.0258 0.02551.0 MGRM-G-004 0.3741 0.0460 8.1 MGRM-G-013 1.8198 1.4978 1.2 MGRM-G-0112.1778 1.9067 1.1

TABLE 26 Killing of HIV-infected primary CD4 T cells against 6 HIV-1strains EC₅₀ (μg/mL) Emax (%) Donor Virus PGT121 PGT121.60 PGT121PGT121.60 9089 7552 0.263 0.002 54 73 CH058 3.956 0.006 72 84 92US7120.307 0.008 47 70 8176 0.567 0.023 44 64 93HT593 0.871 0.119 46 68 8320nc 11.26 3 64 9090 7552 0.227 0.002 57 76 CH058 2.080 0.025 48 7992US712 0.368 0.026 53 77 8176 1.0  0.062 47 72 93HT593 0.998 0.637 4067 8320 nc 61.4 7 64 nc: not calculable

TABLE 27 Killing of HIV-infected primary CD4 T cells against HIV-1strain 92US657 EC50 (μg/mL) Emax (%) Donor PGT121 PGT121.60 PGT121PGT121.60 4737 2.53 0.12 22 50 4736 50.9 1.0 10 52 4739 >100 0.45 0 51

All of the above U.S. patents, U.S. patent application publications,U.S. patent applications, foreign patents, foreign patent applicationsand non-patent publications referred to in this specification and/orlisted in the Application Data Sheet, are incorporated herein byreference, in their entirety.

The present invention may be embodied in other specific forms withoutdeparting from its structures, methods, or other essentialcharacteristics as broadly described herein and claimed hereinafter. Thedescribed embodiments are to be considered in all respects only asillustrative, and not restrictive. The scope of the invention is,therefore, indicated by the appended claims, rather than by theforegoing description. All changes that come within the meaning andrange of equivalency of the claims are to be embraced within theirscope.

TABLE 1 Clone Designation PGT121 LO6 Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 190) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 276)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO:401) PGT121 hG1 (EFTEA)/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVEFEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVTNKALPAPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 191) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 277)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121 hG1 (DEA)/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 192) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 278)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121 hG1 (DEL)/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 193) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 279)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121-FES/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 194) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 280)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121-FEAQS hG1 Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 195) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 281)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121-DEAR hG1 Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPEEKTISKAKGQPRRPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 196) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 282)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121-LPLIL hG1 Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLLPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPPEEQYNSTLRVVSILTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPLVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 197) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 283)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121-FTEA hG1 Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSFEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVTNKALPAPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 198) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 284)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121-FTDE hG1 Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSFEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVTNKALPAPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 199) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 285)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121-AAA hG1 Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNATYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIAATISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 200) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 286)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121 hIgG1 (VLPLL)/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELVGGPSVFLLPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPPEEQYNSTLRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPLVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 201) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 287)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121 hIgG1 (DE)/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 202) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 288)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121 hIgG1 (DEA2)/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNATYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 203) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 289)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121 hIgG1 (DEALS)/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 204) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 290)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121 hIgG1 (LS)/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 205) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 291)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121 hIgG1 (DEA2G)/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNATYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHGALHNHYTQKSLSLSPGK (SEQ ID NO: 206) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 292)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121 hIgG1 (DEAG)/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHGALHNHYTQKSLSLSPGK (SEQ ID NO: 207) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 293)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121 hIgG1 (DEG)/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHGALHNHYTQKSLSLSPGK (SEQ ID NO: 208) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 294)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121 hIgG1 (DEAL)/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 209) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 295)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121 hIgG1 (AE)/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 210) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 296)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.23 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYNPSLKSRVTLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGKGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 211) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYNPSLKS (SEQ ID NO: 366) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYNPSLKSR (SEQ ID NO: 390) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSYVLTQPSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 297)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.22 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDAYWSWIRRSPGKGLEWIGYVHKSGDTNYNPSLKSRVTLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGKGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 212) Heavy CDR1 Kabat DAYWS (SEQ ID NO: 363)Heavy CDR2 Kabat YVHKSGDTNYNPSLKS (SEQ ID NO: 366) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDAY (SEQ ID NO: 372) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDA (SEQ ID NO: 380) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDAY (SEQ ID NO: 386) Heavy CDR2 HoneggerVHKSGDTNYNPSLKSR (SEQ ID NO: 390) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 298)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.21 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYNPSLKSRVTLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGKGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 213) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYNPSLKS (SEQ ID NO: 366) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYNPSLKSR (SEQ ID NO: 390) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 299)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.20 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 214) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTNWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 300)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTNWV (SEQ ID NO: 398)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTNWV (SEQ ID NO: 398) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTNW (SEQ ID NO: 402) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTNW (SEQ ID NO: 402) PGT121.19 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 215) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPTLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 301)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.18 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 216) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSSVTSYVSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 302)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.17 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 217) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSYVLTQPSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 303)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.16 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGQGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 218) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 304)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.15 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGKGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 219) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 305)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.14 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNELFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 220) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNELFTYFYMDV (SEQ ID NO: 369) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNELFTYFYMDV (SEQ ID NO: 378)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNELFTYFYMD (SEQ ID NO: 383)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNELFTYFYMD (SEQ ID NO: 392) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 306)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.13 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEAFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 221) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEAFTYFYMDV (SEQ ID NO: 369) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEAFTYFYMDV (SEQ ID NO: 377)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEAFTYFYMD (SEQ ID NO: 383)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEAFTYFYMD (SEQ ID NO: 392) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 307)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.12 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGTYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 222) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 308)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.11 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLTSVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 223) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 309)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.10 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLKLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 224) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 310)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.9 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVHLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 225) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 311)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.8 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVTLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 226) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 312)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.7 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYNPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 227) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYNPSLKS (SEQ ID NO: 366) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYNPSLKSR (SEQ ID NO: 390) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 313)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.6 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRQSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 228) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQQRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 314)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.5 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDAYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 229) Heavy CDR1 Kabat DAYWS (SEQ ID NO: 363)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDAY (SEQ ID NO: 372) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDA (SEQ ID NO: 380) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDAY (SEQ ID NO: 386) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 315)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.4 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGGSISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 230) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGGSISDSY (SEQ ID NO: 373) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GGSISDS (SEQ ID NO: 381) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGGSISDSY (SEQ ID NO: 387) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 316)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.3 hIgG1/hLambda Heavy ChainQVQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 231) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 317)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.2 hIgG1/hLambda Heavy ChainEMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 232) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO:382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 318)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.32 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGTGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 233) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 319)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.31 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGHGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 234) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 320)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.30 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGAGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 235) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 321)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.29 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVALSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 236) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 322)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.28 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLTGVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 237) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 323)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.27 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLSSVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 238) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 324)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.26 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYAPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 239) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYAPSLKS (SEQ ID NO: 365) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYAPSLKSR (SEQ ID NO: 389) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 325)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.25 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRQSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 240) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 326)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.57 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLSSVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 241) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 327)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.56 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 242) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 328)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.33 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLSSVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGKGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 243) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 329)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.34 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLSSVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGHGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 244) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 330)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.35 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVHLSLDTSKNQVSLSLSSVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 245) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 331)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.36 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVHLSLDTSKNQVSLSLSSVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGKGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 246) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 332)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.37 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVHLSLDTSKNQVSLSLSSVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGHGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 247) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 333)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.38 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYNPSLKSRVNLSLDTSKNQVSLSLSSVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 248) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYNPSLKS (SEQ ID NO: 366) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYNPSLKSR (SEQ ID NO: 390) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 334)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.39 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYNPSLKSRVNLSLDTSKNQVSLSLSSVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGKGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 249) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYNPSLKS (SEQ ID NO: 366) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYNPSLKSR (SEQ ID NO: 390) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 335)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.40 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYNPSLKSRVNLSLDTSKNQVSLSLSSVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGHGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 250) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYNPSLKS (SEQ ID NO: 366) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYNPSLKSR (SEQ ID NO: 390) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 336)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.41 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYNPSLKSRVHLSLDTSKNQVSLSLSSVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 251) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYNPSLKS (SEQ ID NO: 366) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYNPSLKSR (SEQ ID NO: 390) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 337)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.42 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYNPSLKSRVHLSLDTSKNQVSLSLSSVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGKGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 252) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYNPSLKS (SEQ ID NO: 366) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYNPSLKSR (SEQ ID NO: 390) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 338)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.42 hIgG1 (FEAQS)/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYNPSLKSRVHLSLDTSKNQVSLSLSSVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGKGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 253) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYNPSLKS (SEQ ID NO: 366) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYNPSLKSR (SEQ ID NO: 390) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 339)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.42 hIgG1 (WT Fc)/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYNPSLKSRVHLSLDTSKNQVSLSLSSVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGKGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNVVYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 254) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYNPSLKS (SEQ ID NO: 366) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYNPSLKSR (SEQ ID NO: 390) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 340)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.43 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYNPSLKSRVHLSLDTSKNQVSLSLSSVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGHGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 255) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYNPSLKS (SEQ ID NO: 366) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYNPSLKSR (SEQ ID NO: 390) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 341)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.44 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRQSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLSSVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 256) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 342)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.45 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRQSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLSSVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGKGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 257) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 343)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.46 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRQSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLSSVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGHGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 258) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 344)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.47 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRQSPGKGLEWIGYVHKSGDTNYSPSLKSRVHLSLDTSKNQVSLSLSSVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 259) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 345)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.48 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRQSPGKGLEWIGYVHKSGDTNYSPSLKSRVHLSLDTSKNQVSLSLSSVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGKGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 260) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 346)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.49 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRQSPGKGLEWIGYVHKSGDTNYSPSLKSRVHLSLDTSKNQVSLSLSSVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGHGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 261) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 347)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.50 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRQSPGKGLEWIGYVHKSGDTNYNPSLKSRVNLSLDTSKNQVSLSLSSVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 262) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYNPSLKS (SEQ ID NO: 366) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYNPSLKSR (SEQ ID NO: 390) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 348)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.51 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRQSPGKGLEWIGYVHKSGDTNYNPSLKSRVNLSLDTSKNQVSLSLSSVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGKGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 263) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYNPSLKS (SEQ ID NO: 366) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYNPSLKSR (SEQ ID NO: 390) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 349)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.52 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRQSPGKGLEWIGYVHKSGDTNYNPSLKSRVNLSLDTSKNQVSLSLSSVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGHGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 264) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYNPSLKS (SEQ ID NO: 366) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYNPSLKSR (SEQ ID NO: 390) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 350)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.53 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRQSPGKGLEWIGYVHKSGDTNYNPSLKSRVHLSLDTSKNQVSLSLSSVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 265) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYNPSLKS (SEQ ID NO: 366) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYNPSLKSR (SEQ ID NO: 390) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 351)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.54 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRQSPGKGLEWIGYVHKSGDTNYNPSLKSRVHLSLDTSKNQVSLSLSSVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGKGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 266) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYNPSLK (SEQ ID NO: 366) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYNPSLKSR (SEQ ID NO: 390) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 352)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.55 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRQSPGKGLEWIGYVHKSGDTNYNPSLKSRVHLSLDTSKNQVSLSLSSVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGHGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 267) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYNPSLKS (SEQ ID NO: 366) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYNPSLKSR (SEQ ID NO: 390) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 353)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.65 hIgG1/hLambda Heavy ChainQLQLQESGPGLVKPSETLSLTCSVSGASISDAYWSWIRRSPGKGLEWIGYVHKSGDTNYNPSLKSRVHLSLDTSKNQVSLSLTGVTAADSGKYYCARALHGRRIYGIVAFNEWFTYFYMDVWGTGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 268) Heavy CDR1 Kabat DAYWS (SEQ ID NO: 363)Heavy CDR2 Kabat YVHKSGDTNYNPSLKS (SEQ ID NO: 366) Heavy CDR3 KabatALHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 368) Heavy CDR1 IMGTGASISDAY (SEQ ID NO: 372) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARALHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 376)Heavy CDR1 Chothia GASISDA (SEQ ID NO: 380) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDAY (SEQ ID NO: 386) Heavy CDR2 HoneggerVHKSGDTNYNPSLKSR (SEQ ID NO: 390) Heavy CDR3 HoneggerALHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 392) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSRPGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 354)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.64 hIgG1/hLambda Heavy ChainQLQLQESGPGLVKPSETLSLTCSVSGASISDAYWSWIRRSPGKGLEWIGYVHKSGDTNYNPSLKSRVHLSLDTSKNQVSLSLTGVTAADSGKYYCARALHGRRIYGIVAFNEWFTYFYMDVWGTGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 269) Heavy CDR1 Kabat DAYWS (SEQ ID NO: 363)Heavy CDR2 Kabat YVHKSGDTNYNPSLKS (SEQ ID NO: 366) Heavy CDR3 KabatALHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 368) Heavy CDR1 IMGTGASISDAY (SEQ ID NO: 372) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARALHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 376)Heavy CDR1 Chothia GASISDA (SEQ ID NO: 380) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDAY (SEQ ID NO: 386) Heavy CDR2 HoneggerVHKSGDTNYNPSLKSR (SEQ ID NO: 390) Heavy CDR3 HoneggerALHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 392) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSRPGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 355)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.63 hIgG1/hLambda Heavy ChainQLQLQESGPGLVKPSETLSLTCSVSGASISDAYWSWIRRSPGKGLEWIGYVHKSGDTNYNPSLKSRVHLSLDTSKNQVSLSLTGVTAADSGKYYCARALHGRRIYGIVAFNEWFTYFYMDVWGTGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 270) Heavy CDR1 Kabat DAYWS (SEQ ID NO: 363)Heavy CDR2 Kabat YVHKSGDTNYNPSLKS (SEQ ID NO: 366) Heavy CDR3 KabatALHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 368) Heavy CDR1 IMGTGASISDAY (SEQ ID NO: 372) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARALHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 376)Heavy CDR1 Chothia GASISDA (SEQ ID NO: 380) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDAY (SEQ ID NO: 386) Heavy CDR2 HoneggerVHKSGDTNYNPSLKSR (SEQ ID NO: 390) Heavy CDR3 HoneggerALHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 392) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 356)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.62 hIgG1/hLambda Heavy ChainQLQLQESGPGLVKPSETLSLTCSVSGASISDAYWSWIRRSPGKGLEWIGYVHKSGDTNYNPSLKSRVHLSLDTSKNQVSLSLTGVTAADSGKYYCARALHGRRIYGIVAFNEWFTYFYMDVWGTGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 271) Heavy CDR1 Kabat DAYWS (SEQ ID NO: 363)Heavy CDR2 Kabat YVHKSGDTNYNPSLKS (SEQ ID NO: 366) Heavy CDR3 KabatALHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 368) Heavy CDR1 IMGTGASISDAY (SEQ ID NO: 372) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARALHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 376)Heavy CDR1 Chothia GASISDA (SEQ ID NO: 380) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDAY (SEQ ID NO: 386) Heavy CDR2 HoneggerVHKSGDTNYNPSLKSR (SEQ ID NO: 390) Heavy CDR3 HoneggerALHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 392) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 357)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.61 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYNPSLKSRVHLSLDTSKNQVSLSLTGVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGTGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 272) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYNPSLKS (SEQ ID NO: 366) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYNPSLKSR (SEQ ID NO: 390) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSRPGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 358)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.60 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYNPSLKSRVHLSLDTSKNQVSLSLTGVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGTGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 273) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYNPSLKS (SEQ ID NO: 366) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYNPSLKSR (SEQ ID NO: 390) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSRPGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 359)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.59 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYNPSLKSRVHLSLDTSKNQVSLSLTGVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGTGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 274) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYNPSLKS (SEQ ID NO: 366) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYNPSLKSR (SEQ ID NO: 390) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 360)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.58 hIgG1/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYNPSLKSRVHLSLDTSKNQVSLSLTGVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGTGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 275) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYNPSLKS (SEQ ID NO: 366) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYNPSLKSR (SEQ ID NO: 390) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 361)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT123 hIgG1/hLambda Heavy ChainQLHLQESGPGLVKPPETLSLTCSVSGASINDAYWSWIRQSPGKRPEWVGYVHHSGDTNYNPSLKRRVTFSLDTAKNEVSLKLVDLTAADSATYFCARALHGKRIYGIVALGELFTYFYMDVWGKGTAVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 404) Heavy CDR1 Kabat DAYWS (SEQ ID NO: 363)Heavy CDR2 Kabat YVHKSGDTNYNPSLKS (SEQ ID NO: 405) Heavy CDR3 KabatALHGKRIYGIVALGELFTYFYMDV (SEQ ID NO: 406) Heavy CDR1 IMGTGASINDAY (SEQ ID NO: 407) Heavy CDR2 IMGT VHHSGDT (SEQ ID NO: 408)Heavy CDR3 IMGT ARALHGKRIYGIVALGELFTYFYMDV (SEQ ID NO: 409)Heavy CDR1 Chothia GASINDA (SEQ ID NO: 410) Heavy CDR2 Chothia HSGHeavy CDR3 Chothia LHGKRIYGIVALGELFTYFYMD (SEQ ID NO: 411)Heavy CDR1 Honegger VSGASINDAY (SEQ ID NO: 412) Heavy CDR2 HoneggerVHHSGDTNYNPSLKRR (SEQ ID NO: 413) Heavy CDR3 HoneggerALHGKRIYGIVALGELFTYFYMD (SEQ ID NO: 414) Light ChainSSMSVSPGETAKISCGKESIGSRAVQWYQQKPGQPPSLIIYNNQDRPAGVPERFSASPDFRPGTTATLTITNVDAEDEADYYCHIYDARGGTNWVFDRGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 415)Light CDR1 Kabat GKESIGSRAVQ (SEQ ID NO: 416) Light CDR2 KabatNNQDRPA (SEQ ID NO: 417) Light CDR3 Kabat HIYDARGGTNWV (SEQ ID NO: 418)Light CDR1 IMGT SIGSRA (SEQ ID NO: 419) Light CDR2 IMGT NNQLight CDR3 IMGT HIYDARGGTNWV (SEQ ID NO: 418) Light CDR1 ChothiaKESIGSRA (SEQ ID NO: 420) Light CDR2 Chothia NNQ Light CDR3 ChothiaYDARGGTNW (SEQ ID NO: 421) Light CDR1 Honegger KESIGSRA (SEQ ID NO: 420)Light CDR2 Honegger NNQDRPAGVPER (SEQ ID NO: 422) Light CDR3 HoneggerYDARGGTNW (SEQ ID NO: 421) PGT121 hIgG1 (Avi)/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGSGGLNDIFEAQKIEWHE (SEQ ID NO: 423) Heavy CDR1 KabatDSYWS (SEQ ID NO: 362) Heavy CDR2 KabatYVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 424)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT121.42 hIgG1 (Avi)/hLambda Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYNPSLKSRVHLSLDTSKNQVSLSLSSVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGKGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGKGGSGGLNDIFEAQKIEWHE (SEQ ID NO: 425) Heavy CDR1 KabatDSYWS (SEQ ID NO: 362) Heavy CDR2 KabatYVHKSGDTNYNPSLKS (SEQ ID NO: 366) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYNPSLKSR (SEQ ID NO: 390) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 426)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401) PGT123 hIgG1/hLambda(TC) Heavy ChainQLHLQESGPGLVKPPETLSLTCSVSGASINDAYWSWIRQSPGKRPEWVGYVHHSGDTNYNPSLKRRVTFSLDTAKNEVSLKLVDLTAADSATYFCARALHGKRIYGIVALGELFTYFYMDVWGKGTAVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 427) Heavy CDR1 Kabat DAYWS (SEQ ID NO: 363)Heavy CDR2 Kabat YVHKSGDTNYNPSLKS (SEQ ID NO: 405) Heavy CDR3 KabatALHGKRIYGIVALGELFTYFYMDV (SEQ ID NO: 406) Heavy CDR1 IMGTGASINDAY (SEQ ID NO: 407) Heavy CDR2 IMGT VHHSGDT (SEQ ID NO: 408)Heavy CDR3 IMGT ARALHGKRIYGIVALGELFTYFYMDV (SEQ ID NO: 409)Heavy CDR1 Chothia GASINDA (SEQ ID NO: 410) Heavy CDR2 Chothia HSGHeavy CDR3 Chothia LHGKRIYGIVALGELFTYFYMD (SEQ ID NO: 411)Heavy CDR1 Honegger VSGASINDAY (SEQ ID NO: 412) Heavy CDR2 HoneggerVHHSGDTNYNPSLKRR (SEQ ID NO: 413) Heavy CDR3 HoneggerALHGKRIYGIVALGELFTYFYMD (SEQ ID NO: 414) Light ChainSSMSVSPGETAKISCGKESIGSRAVQWYQQKPGQPPSLIIYNNQDRPAGVPERFSASPDFRPGTTATLTITNVDAEDEADYYCHIYDARGGTNWVFDRGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 428)Light CDR1 Kabat GKESIGSRAVQ (SEQ ID NO: 416) Light CDR2 KabatNNQDRPA (SEQ ID NO: 417) Light CDR3 Kabat HIYDARGGTNWV (SEQ ID NO: 418)Light CDR1 IMGT SIGSRA (SEQ ID NO: 419) Light CDR2 IMGT NNQLight CDR3 IMGT HIYDARGGTNWV (SEQ ID NO: 418) Light CDR1 ChothiaKESIGSRA (SEQ ID NO: 420) Light CDR2 Chothia NNQ Light CDR3 ChothiaYDARGGTNW (SEQ ID NO: 421) Light CDR1 Honegger KESIGSRA (SEQ ID NO: 420)Light CDR2 Honegger NNQDRPAGVPER (SEQ ID NO: 422) Light CDR3 HoneggerYDARGGTNW (SEQ ID NO: 421) PGT122 hIgG1/hLambda(TC) Heavy ChainQVHLQESGPGLVKPSETLSLTCNVSGTLVRDNYWSWIRQPLGKQPEWIGYVHDSGDTNYNPSLKSRVHLSLDKSKNLVSLRLTGVTAADSAIYYCATTKHGRRIYGVVAFKEWFTYFYMDVWGKGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 429) Heavy CDR1 Kabat DNYWS (SEQ ID NO: 431)Heavy CDR2 Kabat YVHDSGDTNYNPSLKS (SEQ ID NO: 432) Heavy CDR3 KabatTKHGRRIYGVVAFKEWFTYFYMDV (SEQ ID NO: 433) Heavy CDR1 IMGTGTLVRDNY (SEQ ID NO: 434) Heavy CDR2 IMGT VHDSGDT (SEQ ID NO: 435)Heavy CDR3 IMGT ATTKHGRRIYGVVAFKEWFTYFYMDV (SEQ ID NO: 436)Heavy CDR1 Chothia GTLVRDN (SEQ ID NO: 437) Heavy CDR2 Chothia DSGHeavy CDR3 Chothia KHGRRIYGVVAFKEWFTYFYMD (SEQ ID NO: 438)Heavy CDR1 Honegger VSGTLVRDNY (SEQ ID NO: 439) Heavy CDR2 HoneggerVHDSGDTNYNPSLKSR (SEQ ID NO: 440) Heavy CDR3 HoneggerTKHGRRIYGVVAFKEWFTYFYMD (SEQ ID NO: 441) Light ChainTFVSVAPGQTARITCGEESLGSRSVIWYQQRPGQAPSLIIYNNNDRPSGIPDRFSGSPGSTFGTTATLTITSVEAGDEADYYCHIWDSRRPTNWVFGEGTTLIVLSQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 430) Light CDR1 KabatGEESLGSRSVI (SEQ ID NO: 442) Light CDR2 Kabat NNNDRPS (SEQ ID NO: 443)Light CDR3 Kabat HIWDSRRPTNWV (SEQ ID NO: 444) Light CDR1 IMGTSLGSRS (SEQ ID NO: 445) Light CDR2 IMGT NNN Light CDR3 IMGTHIWDSRRPTNWV (SEQ ID NO: 444) Light CDR1 ChothiaEESLGSRS (SEQ ID NO: 446) Light CDR2 Chothia NNN Light CDR3 ChothiaWDSRRPTNW (SEQ ID NO: 447) Light CDR1 Honegger EESLGSRS (SEQ ID NO: 446)Light CDR2 Honegger NNNDRPSGIPDR (SEQ ID NO: 448) Light CDR3 HoneggerWDSRRPTNW (SEQ ID NO: 447) PGT121 hIgG1/hLambda(TC) Heavy ChainQMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 449) Heavy CDR1 Kabat DSYWS (SEQ ID NO: 362)Heavy CDR2 Kabat YVHKSGDTNYSPSLKS (SEQ ID NO: 364) Heavy CDR3 KabatTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 367) Heavy CDR1 IMGTGASISDSY (SEQ ID NO: 371) Heavy CDR2 IMGT VHKSGDT (SEQ ID NO: 374)Heavy CDR3 IMGT ARTLHGRRIYGIVAFNEWFTYFYMDV (SEQ ID NO: 375)Heavy CDR1 Chothia GASISDS (SEQ ID NO: 379) Heavy CDR2 Chothia KSGHeavy CDR3 Chothia LHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 382)Heavy CDR1 Honegger VSGASISDSY (SEQ ID NO: 385) Heavy CDR2 HoneggerVHKSGDTNYSPSLKSR (SEQ ID NO: 388) Heavy CDR3 HoneggerTLHGRRIYGIVAFNEWFTYFYMD (SEQ ID NO: 391) Light ChainSDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 450)Light CDR1 Kabat GEKSLGSRAVQ (SEQ ID NO: 395) Light CDR2 KabatNNQDRPS (SEQ ID NO: 396) Light CDR3 Kabat HIWDSRVPTKWV (SEQ ID NO: 397)Light CDR1 IMGT SLGSRA (SEQ ID NO: 399) Light CDR2 IMGT NNQLight CDR3 IMGT HIWDSRVPTKWV (SEQ ID NO: 397) Light CDR1 ChothiaEKSLGSRA (SEQ ID NO: 400) Light CDR2 Chothia NNQ Light CDR3 ChothiaWDSRVPTKW (SEQ ID NO: 401) Light CDR1 Honegger EKSLGSRA (SEQ ID NO: 400)Light CDR2 Honegger NNQDRPSGIPER (SEQ ID NO: 403) Light CDR3 HoneggerWDSRVPTKW (SEQ ID NO: 401)

The invention claimed is:
 1. One or more polynucleotides encoding anantibody or an antigen-binding fragment thereof that binds to humanimmunodeficiency virus-1 (HIV-1) Envelope glycoprotein gp120, theantibody or antigen-binding fragment thereof comprising heavy chainvariable region complementary determining regions 1-3 (CDRs 1-3) setforth in SEQ ID NOs:362, 366 and 367, respectively, and light chainvariable region CDRs 1-3 set forth in SEQ ID NOs:395, 396 and 397,respectively.
 2. The one or more polynucleotides of claim 1, wherein theantibody or antigen-binding fragment thereof comprises the heavy chainvariable region sequence set forth in amino acids 1-132 of SEQ ID NO:211, 213, 227, 248, 249, 250, 251, 252, 255, 262, 263, 264, 265, 266,267, 272, 273, 274 or
 275. 3. The one or more polynucleotides of claim1, wherein the antibody or antigen-binding fragment thereof comprisesthe light chain variable region sequence set forth in amino acids 1-105of SEQ ID NO:297, 299, 313, 334, 335, 336, 337, 338, 341, 348, 349, 350,351, 352, 353, 358, 359, 360 or
 361. 4. The one or more polynucleotidesof claim 1, wherein the antibody or antigen-binding fragment thereofcomprises the heavy chain variable region sequence set forth in aminoacids 1-132 of SEQ ID NO: 211, 213, 227, 248, 249, 250, 251, 252, 255,262, 263, 264, 265, 266, 267, 272, 273, 274 or 275; and the light chainvariable region sequence set forth in amino acids 1-105 of SEQ IDNO:297, 299, 313, 334, 335, 336, 337, 338, 341, 348, 349, 350, 351, 352,353, 358, 359, 360 or
 361. 5. One or more polynucleotides encoding anantibody or an antigen-binding fragment thereof, the antibody orantigen-binding fragment thereof comprising a heavy chain variableregion and a light chain variable region, wherein: the heavy chainvariable region comprises the amino acid sequence set forth in aminoacids 1-132 of SEQ ID NO:211 and the light chain variable regioncomprises the amino acid sequence set forth in amino acids 1-105 of SEQID NO:297; the heavy chain variable region comprises the amino acidsequence set forth in amino acids 1-132 of SEQ ID NO:213 and the lightchain variable region comprises the amino acid sequence set forth inamino acids 1-105 of SEQ ID NO:299; the heavy chain variable regioncomprises the amino acid sequence set forth in amino acids 1-132 of SEQID NO:227 and the light chain variable region comprises the amino acidsequence set forth in amino acids 1-105 of SEQ ID NO:313; the heavychain variable region comprises the amino acid sequence set forth inamino acids 1-132 of SEQ ID NO:248 and the light chain variable regioncomprises the amino acid sequence set forth in amino acids 1-105 of SEQID NO:334; the heavy chain variable region comprises the amino acidsequence set forth in amino acids 1-132 of SEQ ID NO:249 and the lightchain variable region comprises the amino acid sequence set forth inamino acids 1-105 of SEQ ID NO:335; the heavy chain variable regioncomprises the amino acid sequence set forth in amino acids 1-132 of SEQID NO:250 and the light chain variable region comprises the amino acidsequence set forth in amino acids 1-105 of SEQ ID NO:336; the heavychain variable region comprises the amino acid sequence set forth inamino acids 1-132 of SEQ ID NO:251 and the light chain variable regioncomprises the amino acid sequence set forth in amino acids 1-105 of SEQID NO:337; the heavy chain variable region comprises the amino acidsequence set forth in amino acids 1-132 of SEQ ID NO:252 and the lightchain variable region comprises the amino acid sequence set forth inamino acids 1-105 of SEQ ID NO:338; the heavy chain variable regioncomprises the amino acid sequence set forth in amino acids 1-132 of SEQID NO:255 and the light chain variable region comprises the amino acidsequence set forth in amino acids 1-105 of SEQ ID NO:341; the heavychain variable region comprises the amino acid sequence set forth inamino acids 1-132 of SEQ ID NO:262 and the light chain variable regioncomprises the amino acid sequence set forth in amino acids 1-105 of SEQID NO:348; the heavy chain variable region comprises the amino acidsequence set forth in amino acids 1-132 of SEQ ID NO:263 and the lightchain variable region comprises the amino acid sequence set forth inamino acids 1-105 of SEQ ID NO:349; the heavy chain variable regioncomprises the amino acid sequence set forth in amino acids 1-132 of SEQID NO:264 and the light chain variable region comprises the amino acidsequence set forth in amino acids 1-105 of SEQ ID NO:350; the heavychain variable region comprises the amino acid sequence set forth inamino acids 1-132 of SEQ ID NO:265 and the light chain variable regioncomprises the amino acid sequence set forth in amino acids 1-105 of SEQID NO:351; the heavy chain variable region comprises the amino acidsequence set forth in amino acids 1-132 of SEQ ID NO:266 and the lightchain variable region comprises the amino acid sequence set forth inamino acids 1-105 of SEQ ID NO:352; the heavy chain variable regioncomprises the amino acid sequence set forth in amino acids 1-132 of SEQID NO:267 and the light chain variable region comprises the amino acidsequence set forth in amino acids 1-105 of SEQ ID NO:353; the heavychain variable region comprises the amino acid sequence set forth inamino acids 1-132 of SEQ ID NO:272 and the light chain variable regioncomprises the amino acid sequence set forth in amino acids 1-105 of SEQID NO:358; the heavy chain variable region comprises the amino acidsequence set forth in amino acids 1-132 of SEQ ID NO:273 and the lightchain variable region comprises the amino acid sequence set forth inamino acids 1-105 of SEQ ID NO:359; the heavy chain variable regioncomprises the amino acid sequence set forth in amino acids 1-132 of SEQID NO:274 and the light chain variable region comprises the amino acidsequence set forth in amino acids 1-105 of SEQ ID NO:360; or the heavychain variable region comprises the amino acid sequence set forth inamino acids 1-132 of SEQ ID NO:275 and the light chain variable regioncomprises the amino acid sequence set forth in amino acids 1-105 of SEQID NO:361.
 6. The one or more polynucleotides of claim 5, wherein theheavy chain variable region comprises the amino acid sequence set forthin amino acids 1-132 of SEQ ID NO:211 and the light chain variableregion comprises the amino acid sequence set forth in amino acids 1-105of SEQ ID NO:297.
 7. The one or more polynucleotides of claim 5, whereinthe heavy chain variable region comprises the amino acid sequence setforth in amino acids 1-132 of SEQ ID NO:213 and the light chain variableregion comprises the amino acid sequence set forth in amino acids 1-105of SEQ ID NO:299.
 8. The one or more polynucleotides of claim 5, whereinthe heavy chain variable region comprises the amino acid sequence setforth in amino acids 1-132 of SEQ ID NO:227 and the light chain variableregion comprises the amino acid sequence set forth in amino acids 1-105of SEQ ID NO:313.
 9. The one or more polynucleotides of claim 5, whereinthe heavy chain variable region comprises the amino acid sequence setforth in amino acids 1-132 of SEQ ID NO:248 and the light chain variableregion comprises the amino acid sequence set forth in amino acids 1-105of SEQ ID NO:334.
 10. The one or more polynucleotides of claim 5,wherein the heavy chain variable region comprises the amino acidsequence set forth in amino acids 1-132 of SEQ ID NO:249 and the lightchain variable region comprises the amino acid sequence set forth inamino acids 1-105 of SEQ ID NO:335.
 11. The one or more polynucleotidesof claim 5, wherein the heavy chain variable region comprises the aminoacid sequence set forth in amino acids 1-132 of SEQ ID NO:250 and thelight chain variable region comprises the amino acid sequence set forthin amino acids 1-105 of SEQ ID NO:336.
 12. The one or morepolynucleotides of claim 5, wherein the heavy chain variable regioncomprises the amino acid sequence set forth in amino acids 1-132 of SEQID NO:251 and the light chain variable region comprises the amino acidsequence set forth in amino acids 1-105 of SEQ ID NO:337.
 13. The one ormore polynucleotides of claim 5, wherein the heavy chain variable regioncomprises the amino acid sequence set forth in amino acids 1-132 of SEQID NO:252 and the light chain variable region comprises the amino acidsequence set forth in amino acids 1-105 of SEQ ID NO:338.
 14. The one ormore polynucleotides of claim 5, wherein the heavy chain variable regioncomprises the amino acid sequence set forth in amino acids 1-132 of SEQID NO:255 and the light chain variable region comprises the amino acidsequence set forth in amino acids 1-105 of SEQ ID NO:341.
 15. The one ormore polynucleotides of claim 5, wherein the heavy chain variable regioncomprises the amino acid sequence set forth in amino acids 1-132 of SEQID NO:262 and the light chain variable region comprises the amino acidsequence set forth in amino acids 1-105 of SEQ ID NO:348.
 16. The one ormore polynucleotides of claim 5, wherein the heavy chain variable regioncomprises the amino acid sequence set forth in amino acids 1-132 of SEQID NO:263 and the light chain variable region comprises the amino acidsequence set forth in amino acids 1-105 of SEQ ID NO:349.
 17. The one ormore polynucleotides of claim 5, wherein the heavy chain variable regioncomprises the amino acid sequence set forth in amino acids 1-132 of SEQID NO:264 and the light chain variable region comprises the amino acidsequence set forth in amino acids 1-105 of SEQ ID NO:350.
 18. The one ormore polynucleotides of claim 5, wherein the heavy chain variable regioncomprises the amino acid sequence set forth in amino acids 1-132 of SEQID NO:265 and the light chain variable region comprises the amino acidsequence set forth in amino acids 1-105 of SEQ ID NO:351.
 19. The one ormore polynucleotides of claim 5, wherein the heavy chain variable regioncomprises the amino acid sequence set forth in amino acids 1-132 of SEQID NO:266 and the light chain variable region comprises the amino acidsequence set forth in amino acids 1-105 of SEQ ID NO:352.
 20. The one ormore polynucleotides of claim 5, wherein the heavy chain variable regioncomprises the amino acid sequence set forth in amino acids 1-132 of SEQID NO:267 and the light chain variable region comprises the amino acidsequence set forth in amino acids 1-105 of SEQ ID NO:353.
 21. The one ormore polynucleotides of claim 5, wherein the heavy chain variable regioncomprises the amino acid sequence set forth in amino acids 1-132 of SEQID NO:272 and the light chain variable region comprises the amino acidsequence set forth in amino acids 1-105 of SEQ ID NO:358.
 22. The one ormore polynucleotides of claim 5, wherein the heavy chain variable regioncomprises the amino acid sequence set forth in amino acids 1-132 of SEQID NO:273 and the light chain variable region comprises the amino acidsequence set forth in amino acids 1-105 of SEQ ID NO:359.
 23. The one ormore polynucleotides of claim 5, wherein the heavy chain variable regioncomprises the amino acid sequence set forth in amino acids 1-132 of SEQID NO:274 and the light chain variable region comprises the amino acidsequence set forth in amino acids 1-105 of SEQ ID NO:360.
 24. The one ormore polynucleotides of claim 5, wherein the heavy chain variable regioncomprises the amino acid sequence set forth in amino acids 1-132 of SEQID NO:275 and the light chain variable region comprises the amino acidsequence set forth in amino acids 1-105 of SEQ ID NO:361.
 25. The one ormore polynucleotides of claim 5, comprising a heavy chain comprising theamino acid sequence set forth in SEQ ID NO:211 and a light chaincomprising the amino acid sequence set forth in SEQ ID NO:297.
 26. Theone or more polynucleotides of claim 5, comprising a heavy chaincomprising the amino acid sequence set forth in SEQ ID NO:213 and alight chain comprising the amino acid sequence set forth in SEQ IDNO:299.
 27. The one or more polynucleotides of claim 5, comprising aheavy chain comprising the amino acid sequence set forth in SEQ IDNO:227 and a light chain comprising the amino acid sequence set forth inSEQ ID NO:313.
 28. The one or more polynucleotides of claim 5,comprising a heavy chain comprising the amino acid sequence set forth inSEQ ID NO:248 and a light chain comprising the amino acid sequence setforth in SEQ ID NO:334.
 29. The one or more polynucleotides of claim 5,comprising a heavy chain comprising the amino acid sequence set forth inSEQ ID NO:249 and a light chain comprising the amino acid sequence setforth in SEQ ID NO:335.
 30. The one or more polynucleotides of claim 5,comprising a heavy chain comprising the amino acid sequence set forth inSEQ ID NO:250 and a light chain comprising the amino acid sequence setforth in SEQ ID NO:336.
 31. The one or more polynucleotides of claim 5,comprising a heavy chain comprising the amino acid sequence set forth inSEQ ID NO:251 and a light chain comprising the amino acid sequence setforth in SEQ ID NO:337.
 32. The one or more polynucleotides of claim 5,comprising a heavy chain comprising the amino acid sequence set forth inSEQ ID NO:252 and a light chain comprising the amino acid sequence setforth in SEQ ID NO:338.
 33. The one or more polynucleotides of claim 5,comprising a heavy chain comprising the amino acid sequence set forth inSEQ ID NO:253 and a light chain comprising the amino acid sequence setforth in SEQ ID NO:339.
 34. The one or more polynucleotides of claim 5,comprising a heavy chain comprising the amino acid sequence set forth inSEQ ID NO:254 and a light chain comprising the amino acid sequence setforth in SEQ ID NO:340.
 35. The one or more polynucleotides of claim 5,comprising a heavy chain comprising the amino acid sequence set forth inSEQ ID NO:255 and a light chain comprising the amino acid sequence setforth in SEQ ID NO:341.
 36. The one or more polynucleotides of claim 5,comprising a heavy chain comprising the amino acid sequence set forth inSEQ ID NO:262 and a light chain comprising the amino acid sequence setforth in SEQ ID NO:348.
 37. The one or more polynucleotides of claim 5,comprising a heavy chain comprising the amino acid sequence set forth inSEQ ID NO:263 and a light chain comprising the amino acid sequence setforth in SEQ ID NO:349.
 38. The one or more polynucleotides of claim 5,comprising a heavy chain comprising the amino acid sequence set forth inSEQ ID NO:264 and a light chain comprising the amino acid sequence setforth in SEQ ID NO:350.
 39. The one or more polynucleotides of claim 5,comprising a heavy chain comprising the amino acid sequence set forth inSEQ ID NO:265 and a light chain comprising the amino acid sequence setforth in SEQ ID NO:351.
 40. The one or more polynucleotides of claim 5,comprising a heavy chain comprising the amino acid sequence set forth inSEQ ID NO:266 and a light chain comprising the amino acid sequence setforth in SEQ ID NO:352.
 41. The one or more polynucleotides of claim 5,comprising a heavy chain comprising the amino acid sequence set forth inSEQ ID NO:267 and a light chain comprising the amino acid sequence setforth in SEQ ID NO:353.
 42. The one or more polynucleotides of claim 5,comprising a heavy chain comprising the amino acid sequence set forth inSEQ ID NO:272 and a light chain comprising the amino acid sequence setforth in SEQ ID NO:358.
 43. The one or more polynucleotides of claim 5,comprising a heavy chain comprising the amino acid sequence set forth inSEQ ID NO:273 and a light chain comprising the amino acid sequence setforth in SEQ ID NO:359.
 44. The one or more polynucleotides of claim 5,comprising a heavy chain comprising the amino acid sequence set forth inSEQ ID NO:274 and a light chain comprising the amino acid sequence setforth in SEQ ID NO:360.
 45. The one or more polynucleotides of claim 5,comprising a heavy chain comprising the amino acid sequence set forth inSEQ ID NO:275 and a light chain comprising the amino acid sequence setforth in SEQ ID NO:361.
 46. The one or more polynucleotides of claim 5,comprising a heavy chain comprising the amino acid sequence set forth inSEQ ID NO:425 and a light chain comprising the amino acid sequence setforth in SEQ ID NO:426.
 47. The one or more polynucleotides of claim 1,wherein the antibody or antigen-binding fragment thereof comprises alight chain variable region comprising a proline at position 66,aspartic acid at position 67, serine at position 67a, and phenylalanineat position 67c (position numbering according to Kabat).
 48. The one ormore polynucleotides of claim 1, wherein the antibody or antigen-bindingfragment thereof comprises a light chain variable region comprising aproline at position 66, aspartic acid at position 67, serine at position67a, and proline at position 67c (position numbering according toKabat).
 49. The one or more polynucleotides of claim 1, wherein theantibody or antigen-binding fragment thereof comprises a light chainvariable region comprising a proline or arginine at position 67b(position numbering according to Kabat).
 50. The one or morepolynucleotides of claim 1, wherein the antibody or antigen-bindingfragment thereof comprises an IgG 1m17 allotype heavy chain.
 51. The oneor more polynucleotides of claim 1, wherein the antibody orantigen-binding fragment thereof comprises a Lambda2 light chain. 52.The one or more polynucleotides of claim 1, wherein the antibody orantigen-binding fragment thereof comprises a heavy chain constant regioncomprising one or more of Ala at position 236, Asp at position 239, Leuat position 330, Glu at position 332, Leu at position 428, and Ser atposition 434 (numbering according to EU).
 53. The one or morepolynucleotides of claim 1, wherein the antibody or antigen-bindingfragment thereof comprises a heavy chain constant region comprising Leuat position 428 and Ser at position 434 (numbering according to EU). 54.The one or more polynucleotides of claim 1, wherein the antibody orantigen-binding fragment thereof comprises a heavy chain variable regioncomprising one or more of Ser-Ser-Val or Thr-Gly-Val at positions82a-82c, Gln at position 39, Asn at position 60, His at position 68, anyone of Lys, His or Thr at position 105, Leu at position 2, Ala atposition 32, and Ala at position 95 (numbering according to Kabat). 55.The one or more polynucleotides of claim 1, wherein the antibody orantigen-binding fragment thereof comprises a heavy chain constant regioncomprising Lys at position 214, Glu at position 356, Met at position358, and Ala at position 431 (numbering according to EU).
 56. The one ormore polynucleotides of claim 1, wherein the antibody or antigen-bindingfragment thereof comprises a light chain comprising one or more of Argat position 67b, Pro at position 67c, and Lys at position 103 (numberingaccording to Kabat).
 57. The one or more polynucleotides of claim 1,wherein the antibody or antigen-binding fragment thereof comprises aheavy chain constant region comprising Ala at position 236, Asp atposition 239, Leu at position 330, and Glu at position 332 (numberingaccording to EU).
 58. The one or more polynucleotides of claim 1,wherein the one or more polynucleotides are comprised of cDNA or mRNA.59. The one or more polynucleotides of claim 5, wherein the one or morepolynucleotides are comprised of cDNA or mRNA.
 60. A pharmaceuticalcomposition comprising the one or more polynucleotides of claim 1 and apharmaceutically acceptable carrier, excipient or diluent.
 61. Thepharmaceutical composition of claim 60, further comprising a secondagent for treating an HIV infection.
 62. The pharmaceutical compositionof claim 60, further comprising a TLR7 agonist.
 63. The pharmaceuticalcomposition of claim 62, wherein the TLR7 agonist is selected from thegroup consisting of vesatolimod, imiquimod, and resiquimod.
 64. Thepharmaceutical composition of claim 60, further comprising an antibodyor antigen-binding fragment thereof that binds, inhibits or neutralizesHIV.
 65. A pharmaceutical composition comprising the one or morepolynucleotides of claim 5 and a pharmaceutically acceptable carrier,excipient or diluent.
 66. The pharmaceutical composition of claim 65,further comprising a second agent for treating an HIV infection.
 67. Thepharmaceutical composition of claim 65, further comprising a TLR7agonist.
 68. The pharmaceutical composition of claim 67, wherein theTLR7 agonist is selected from the group consisting of vesatolimod,imiquimod, and resiquimod.
 69. The pharmaceutical composition of claim65, further comprising an antibody or antigen-binding fragment thereofthat binds, inhibits or neutralizes HIV.
 70. A method of treating HIV ina human subject in need thereof, the method comprising administering tothe subject an effective amount of the antibody or antigen-bindingfragment thereof of claim
 1. 71. A method of treating HIV in a humansubject in need thereof, the method comprising administering to thesubject an effective amount of the antibody or antigen-binding fragmentthereof of claim
 5. 72. The method of claim 70, further comprisingadministering to the subject a second agent for treating an HIVinfection.
 73. The method of claim 70, further comprising administeringto the subject a TLR7 agonist.
 74. The method of claim 73, wherein theTLR7 agonist is selected from the group consisting of vesatolimod,imiquimod, and resiquimod.
 75. The method of claim 70, furthercomprising administering to the subject an antibody or antigen-bindingfragment thereof that binds, inhibits or neutralizes HIV.
 76. A methodof inhibiting HIV in a human subject in need thereof, the methodcomprising administering to the subject an effective amount of theantibody or antigen-binding fragment thereof of claim
 1. 77. A method ofinhibiting HIV in a human subject in need thereof, the method comprisingadministering to the subject an effective amount of the antibody orantigen-binding fragment thereof of claim 5.